

Aus dem Lehrstuhl für Physiologie  
der Technischen Universität München  
(Betreuer: Prof. Dr. Dieter Schams)

vorgelegt über  
Prof. Fred Sinowatz,  
Lehrstuhl für Tieranatomie II  
Ludwig-Maximilians-Universität München

**Investigations of extracellular matrix proteases, apoptotic and anti-apoptotic  
factors in the bovine corpus luteum**

**Inaugural-Dissertation**

zur Erlangung der tiermedizinischen Doktorwürde  
der Tierärztlichen Fakultät  
der Ludwig-Maximilians-Universität München

von

Heike Susanne Kliem

aus

Friedberg / Hessen

München 2006

Gedruckt mit Genehmigung der Tierärztlichen Fakultät der  
Ludwig-Maximilians-Universität München

Dekan:	Univ.-Prof. Dr. E. P. Märtlbauer
1. Referent:	Univ.-Prof. Dr. Dr. F. Sinowatz
1. Korreferent:	Univ.-Prof. Dr. H. Zerbe
2. Korreferent:	Univ.-Prof. Dr. W. Schmahl
3. Korreferent:	Univ.-Prof. Dr. M. Förster
4. Korreferentin:	Priv.-Doz. Dr. B. Schalch

Tag der Promotion: 28. Juli 2006



**Für  
meine Eltern  
Enrique  
und  
Frieda**

## CONTENTS

## LIST OF ABBREVIATIONS

<b>1</b>	<b>INTRODUCTION AND AIM OF THE STUDY</b> .....	<b>12</b>
<b>2</b>	<b>LITERATURE</b> .....	<b>14</b>
<b>2.1</b>	<b>REGULATION OF THE OESTROUS CYCLE IN CATTLE</b> .....	<b>14</b>
2.1.1	<i>Folliculogenesis</i> .....	14
2.1.2	<i>Regulation of the oestrous cycle</i> .....	14
2.1.3	<i>Corpus luteum (CL) formation, function and regression (luteolysis)</i> ....	15
<b>2.2</b>	<b>EARLY PREGNANCY IN CATTLE</b> .....	<b>16</b>
<b>2.3</b>	<b>ENDOCRINE REGULATORY FACTORS</b> .....	<b>17</b>
2.3.1	<i>Progesterone</i> .....	17
2.3.2	<i>Oestradiol-17<math>\beta</math></i> .....	17
2.3.3	<i>Prostaglandin F<math>2\alpha</math> (PGF<math>2\alpha</math>)</i> .....	18
<b>2.4</b>	<b>LOCALLY PRODUCED FACTORS</b> .....	<b>18</b>
2.4.1	<i>Vascular endothelial growth factors (VEGFs)</i> .....	18
2.4.2	<i>Housekeeping Genes</i> .....	19
2.4.3	<i>Extracellular matrix proteases</i> .....	20
2.4.3.1	General aspects.....	20
2.4.3.2	Matrix metalloproteases (MMPs) .....	21
2.4.3.3	Tissue inhibitors of metalloproteases (TIMPs).....	22
2.4.3.4	Plasminogen activator (PA) system.....	23
2.4.3.5	Monocyte chemoattractant protein-1 (MCP-1).....	23
2.4.4	<i>Apoptosis</i> .....	24
2.4.4.1	General aspects.....	24
2.4.4.2	Extrinsic pathway.....	25
2.4.4.2.1	<i>Tumor necrosis factor family (TNF<math>\alpha</math>, TNFR1, TNFR2)</i> .....	25
2.4.4.2.2	<i>Fas and Fas-Ligand (FasL)</i> .....	27
2.4.4.3	Intrinsic pathway .....	28
2.4.4.3.1	<i>Tumor suppressor p53</i> .....	28
2.4.4.3.2	<i>Bax and Bcl-X<sub>L</sub></i> .....	29
2.4.4.3.3	<i>Second mitochondria derived activator of caspases (Smac)</i> .....	30
2.4.4.3.4	<i>Survivin</i> .....	30
2.4.4.4	Caspase3, -6, -7 .....	31
<b>3</b>	<b>MATERIAL</b> .....	<b>32</b>
<b>3.1</b>	<b>DEVELOPMENT OF A METHOD TO GAIN UTERUS MILK <i>IN VIVO</i></b> .....	<b>32</b>
3.1.1	<i>Equipment</i> .....	32
3.1.2	<i>Medicaments</i> .....	32
3.1.3	<i>Biochemicals</i> .....	33
3.1.4	<i>Reagents</i> .....	33
<b>3.2</b>	<b>EXPRESSION OF HOUSEKEEPING GENES, PROTEASES, APOPTOTIC AND ANTI-APOPTOTIC FACTORS IN THE CL DURING OESTROUS CYCLE AND INDUCED LUTEOLYSIS</b> .....	<b>35</b>
3.2.1	<i>Tissue collection</i> .....	35
3.2.1.1	Follicles 20 hours after GnRH application.....	35
3.2.1.2	CL during oestrous cycle .....	35
3.2.1.3	CL during induced luteolysis .....	36
3.2.2	<i>Equipment</i> .....	36
3.2.3	<i>Surgical instruments</i> .....	37

3.2.4	<b>Medicaments</b> .....	37
3.2.5	<b>Laboratory equipment</b> .....	37
3.2.6	<b>Biochemicals</b> .....	39
3.2.7	<b>Reagents</b> .....	40
3.2.8	<b>Kits</b> .....	40
3.2.9	<b>Enzymes</b> .....	40
3.2.10	<b>Markers</b> .....	41
3.2.11	<b>Buffers and solutions</b> .....	41
3.2.12	<b>Primersequences and polymerase chain reaction (PCR) products</b> .....	42
<b>4</b>	<b>METHODS</b> .....	<b>46</b>
4.1	<b>DEVELOPMENT OF A METHOD TO GAIN UTERUS MILK <i>IN VIVO</i></b> .....	<b>46</b>
4.1.1	<b>Enzyme immuno assay (EIA) of progesterone, oestradiol-17<math>\beta</math> and PGF2<math>\alpha</math></b> .....	48
4.1.2	<b>Radio immuno assay (RIA) of VEGF</b> .....	50
4.2	<b>EXPRESSION OF HOUSEKEEPING GENES, PROTEASES, APOPTOTIC AND ANTI- APOPTOTIC FACTORS IN THE CL DURING OESTROUS CYCLE AND INDUCED LUTEOLYSIS</b> .....	<b>50</b>
4.2.1	<b>Transvaginal ovariectomy</b> .....	50
4.2.2	<b>Immunohistochemistry</b> .....	50
4.2.2.1	Fixation and Paraffin embedding .....	50
4.2.3	<b>Molecular techniques</b> .....	51
4.2.3.1	Enzyme immuno assay (EIA).....	51
4.2.3.2	RNA extraction.....	51
4.2.3.3	DNA digestion .....	52
4.2.3.4	Control of the RNA quantity and quality.....	52
4.2.3.4.1	Quantity.....	52
4.2.3.4.2	Quality.....	53
4.2.3.5	Reverse transcription .....	55
4.2.3.6	Polymerase chain reaction (PCR) methods.....	56
4.2.3.6.1	Block PCR.....	56
4.2.3.6.2	Gradient PCR:.....	58
4.2.3.6.3	Quantitativ real time PCR (qPCR) .....	58
4.2.3.7	Primer design and optimation .....	63
4.2.3.8	Analysis of the PCR-product.....	64
4.2.4	<b>Data processing</b> .....	64
<b>5</b>	<b>RESULTS</b> .....	<b>66</b>
5.1	<b>DEVELOPMENT OF A METHOD TO GAIN UTERUS MILK <i>IN VIVO</i></b> .....	<b>66</b>
5.1.1	<b>Flushing of the uterus horns</b> .....	66
5.1.2	<b>Progesterone analysis</b> .....	66
5.1.2.1	Blood plasma: .....	66
5.1.2.2	Uterus milk .....	67
5.1.3	<b>Oestradiol-17<math>\beta</math> analysis in the uterus milk</b> .....	67
5.1.4	<b>VEGF analysis in the uterus milk</b> .....	67
5.1.5	<b>PGF2<math>\alpha</math> analysis in the uterus milk</b> .....	67
5.1.6	<b>Recapitulating comment to 5.1.</b> .....	68
5.2	<b>EXPRESSION OF HOUSEKEEPING GENES, PROTEASES, APOPTOTIC AND ANTI- APOPTOTIC FACTORS IN THE CL DURING OESTROUS CYCLE AND INDUCED LUTEOLYSIS</b> .....	<b>69</b>
5.2.1	<b>Enzyme immuno assay (EIA) of progesterone</b> .....	69
5.2.2	<b>RNA quality control by the Bioanalyzer</b> .....	69
5.2.3	<b>Sequencing of PCR-products</b> .....	69
5.2.4	<b>Quantitative real time PCR (qPCR)</b> .....	70

5.2.4.1	Housekeeping genes .....	70
5.2.4.1.1	<i>Follicle phase and CL during oestrous cycle</i> .....	70
5.2.4.1.2	<i>CL during induced luteolysis</i> .....	71
5.2.4.2	Extracellular matrix proteases .....	72
5.2.4.2.1	<i>MMPs and TIMPs during follicle phase and CL during oestrous cycle</i> .....	72
5.2.4.2.2	<i>PA system during follicle phase and CL during oestrous cycle</i> .....	75
5.2.4.2.3	<i>MMPs and TIMPs during induced luteolysis</i> .....	78
5.2.4.2.4	<i>PA system during induced luteolysis</i> .....	81
5.2.4.3	Monocyte chemoattractant protein-1 (MCP-1) .....	84
5.2.4.3.1	<i>CL during oestrous cycle</i> .....	84
5.2.4.3.2	<i>CL during induced luteolysis</i> .....	85
5.2.4.4	Apoptosis .....	86
5.2.4.4.1	<i>Extrinsic pathway during oestrous cycle in the CL</i> .....	86
5.2.4.4.2	<i>Intrinsic pathway during oestrous cycle in the CL</i> .....	88
5.2.4.4.3	<i>Caspase3, -6, -7 during oestrous cycle in the CL</i> .....	90
5.2.4.4.4	<i>Extrinsic pathway during induced luteolysis in the CL</i> .....	92
5.2.4.4.5	<i>Intrinsic pathway during induced luteolysis in the CL</i> .....	94
5.2.4.4.6	<i>Caspase3, -6, -7 during induced luteolysis in the CL</i> .....	96
<b>6</b>	<b>DISCUSSION</b> .....	<b>98</b>
<b>6.1</b>	<b>DEVELOPMENT OF A METHOD TO GAIN UTERUS MILK <i>IN VIVO</i></b> .....	<b>98</b>
6.1.1	<b>Method</b> .....	98
6.1.2	<b>Results</b> .....	99
<b>6.2</b>	<b>EXPRESSION OF HOUSEKEEPING GENES, PROTEASES, APOPTOTIC AND ANTI-APOPTOTIC FACTORS IN THE CL DURING OESTROUS CYCLE AND INDUCED LUTEOLYSIS</b> .....	<b>100</b>
6.2.1	<b>Housekeeping Genes (HKGs)</b> .....	100
6.2.2	<b>Extracellular matrix proteases in the CL during oestrous cycle and induced luteolysis</b> .....	102
6.2.2.1	CL during oestrous cycle .....	102
6.2.2.1.1	<i>Matrix metalloproteases (MMPs)</i> .....	102
6.2.2.1.2	<i>Tissue inhibitors of matrix metalloproteases (TIMPs)</i> .....	103
6.2.2.1.3	<i>Plasminogen activator system (PAs)</i> .....	104
6.2.2.2	CL during induced luteolysis .....	106
6.2.2.2.1	<i>Matrix metalloproteases (MMPs) and tissue inhibitors of matrix metalloproteases (TIMPs):</i> .....	106
6.2.2.2.2	<i>Plasminogen (PA) activator system</i> .....	109
6.2.3	<b>Apoptosis in the CL during oestrous cycle and induced luteolysis</b> ....	110
6.2.3.1	CL during oestrous cycle .....	110
6.2.3.1.1	<i>Fas antigen (Fas) and Fas-Ligand (FasL)</i> .....	110
6.2.3.1.2	<i>Tumor necrosis factor alpha (TNF<math>\alpha</math>), TNF receptor 1 and 2 (TNFR1, TNFR2)</i> .....	110
6.2.3.1.3	<i>p53, Bax and Bcl-X<sub>L</sub></i> .....	112
6.2.3.1.4	<i>Smac and Survivin</i> .....	113
6.2.3.1.5	<i>Caspase3, -6 and -7</i> .....	114
6.2.3.2	CL during induced luteolysis .....	114
6.2.3.2.1	<i>Extrinsic pathway</i> .....	115
6.2.3.2.2	<i>Intrinsic pathway</i> .....	117
6.2.3.2.3	<i>Caspase3, -6 and -7:</i> .....	118
6.2.4	<b>Conclusion</b> .....	120
<b>7</b>	<b>SUMMARY</b> .....	<b>123</b>
<b>8</b>	<b>ZUSAMMENFASSUNG</b> .....	<b>127</b>

---

<b>9</b>	<b>REFERENCE LIST .....</b>	<b>131</b>
<b>10</b>	<b>DANKSAGUNG .....</b>	<b>152</b>
<b>11</b>	<b>CURRICULUM VITAE .....</b>	<b>153</b>
<b>12</b>	<b>PUBLICATIONS, ABSTRACTS, POSTERS, PRESENTATIONS .....</b>	<b>154</b>



---

**List of abbreviations**

ADP	adenosine diphosphate
acc. no.	access number
Apaf-1	apoptotic protease activating factor
Apo-1	Fas antigen
bFGF	basic fibroblast growth factor
BIR	baculoviral IAP repeat
CAD	caspase activated DNase
CCR	c-chemokine receptor
CD95	Fas antigen
CHO	chinese hamster ovary
CL	corpus luteum
CP	crossing point
DCNP	2,6-dichloro-4-nitrophenol
DNA	deoxyribonucleic acid
DNase	deoxyribonuclease
dsDNA	double stranded deoxyribonucleic acid
ECM	extracellular matrix
EDTA	ethylenediaminetetraacetat
EIA	enzyme immuno assay
FADD	Fas-associated protein with death domain
Fas	Fas antigen
FasL	Fas Ligand
FSH	follicle-stimulating hormon
GAPDH	Glyceraldehyd-3-phosphat-Dehydrogenase
GM-CSF	granulocyte-macrophage-colony-stimulating factor
GnRH	gonadotropin releasing hormone
HKG	housekeeping gene
3 $\beta$ -HSD	3 $\beta$ -hydroxysteroid dehydrogenase
IAP	inhibitor of apoptosis
ICAD	inhibitor of caspase activated DNase
INF $\gamma$	interferon $\gamma$

## List of abbreviations

IGF	insulin like growth factor
IL	interleukin
LH	luteinizing hormone
MCP-1	monocyte chemoattractant protein-1
MDM2	Murine double minute 2
MMP	matrix metalloprotease
MT-MMP	membran-type matrix metalloprotease
NADPH	nicotinamid-adenosine-dinucleotid-phosphat-hydrogen
NF $\kappa$ B	nuclear factor kappa B
OP	onapristone
PA	plasminogen activator
PAI	plasminogen activator inhibitor
PARP	poly ADP-ribose polymerase
PBS	phosphate buffered solution
PCD	programmed cell death
PCR	polymerase chain reaction
PGF $_{2\alpha}$	prostaglandin F $_{2\alpha}$
P4	progesterone
qRT/PCR	quantitative reverse transcription polymerase chain reaction
RIN	RNA integrity number
RNA	ribonucleic acid
RNase	ribonuclease
rRNA	ribosomal ribonucleic acid
RIA	radioimmunoassay
RING	really interesting new gene
ROS	reactive oxygen species
RT	reverse transcription
Smac	second mitochondrial derived activator of caspases
TAE	tris base / acetic acid / EDTA buffer
TIMP	tissue inhibitor of matrix metalloprotease
TNF $\alpha$	tumor necrosis factor alpha
TNFR	tumor necrosis factor alpha receptor
TRAIL	tumor necrosis factor-related apoptosis-inducing ligand

---

**List of abbreviations**

TRAF2	tumor necrosis factor receptor-associated factor-2
tPA	tissue plasminogen activator
uPA	urokinase plasminogen activator
uPAR	urokinase plasminogen activator receptor
UV	ultraviolet
VEGF	vascular endothelial growth factor
XIAP	X-linked inhibitor of apoptosis

## **1 Introduction and aim of the study**

The corpus luteum (CL) is a transient endocrine gland, which plays an essential role in the reproductive process of the bovine species. Its main function is to produce progesterone, a steroidal hormone, which is necessary for the establishment and maintenance of pregnancy. The development of the CL begins with the ovulation of a Graafian follicle. This happens normally every 21 days in the cow if no implantation of an embryo occurs. After ovulation an active endocrine gland is formed in best time to produce progesterone, which can reach more than 10 ng/ml in the blood plasma (Döcke 1994). During formation of the CL, 50% of the cells are mitotic, primary to form new blood vessels (angiogenesis), which are necessary to assure an optimal support of the steroidal cells. Some researchers compare the angiogenesis in the corpus luteum with angiogenesis in a malignant tumor, but even in a highly malignant and fast growing Glioblastoma multiforme only 9% of all cells are mitotic. In malignant mammary gland tumors or prostata carcinomas even only 2%. During development the CL grows from 200 mg tissue to a several grams swaying endocrine gland with a diameter of 1-3 cm (Augustin and Kuhn 1999). The adult CL is highly vasculated und consists of 53% of endothelial cells. The steroidal cells represent with 19% (small luteal cells) and 4% (large luteal cells) only a small contingent of the cellular composition. The CL consists more than 17% of fibroblast and 7% of plasma cells, lymphocytes and leukocytes (McCracken *et al.* 1999). If no embryo gives a signal to maintain pregnancy the luteolytic PGF<sub>2</sub>α released from the uterus reaches the CL and luteolysis occurs. This happens through a counter-current mechanism from the vena uteri to the arteria ovarica, which supports the ovary. Within 24 hours after PGF<sub>2</sub>α induced luteolysis the blood plasma level of progesterone drops to basal values of under 1 ng/ml (Schallenberger *et al.* 1984). This decline of progesterone is characteristic for the so called functional luteolysis. After 2-3 days the corpus luteum has only half of its original volume and after a few weeks only a small, avascular scar remains (Augustin and Kuhn 1999). These degeneration of the tissue is called structural luteolysis.

The CL with its high rate of angiogenesis and its normally smooth degradation is an unique formation in the adult organism. The smooth process of CL development and degradation needs a fine balanced interaction between numerous endocrine and locally acting factors. At the endocrine level it is thought that luteolysis in the cow occurs as follows: Progesterone inhibits the PGF<sub>2</sub>α synthesis in the endometrium of the uterus. Through the decline of its progesterone sensitivity and the stimulation through oxytocin occurs an increased release of PGF<sub>2</sub>α in the endometrium. This leads to secretion of luteal oxytocin and PGF<sub>2</sub>α, which increases in turn the endometrial production of PGF<sub>2</sub>α

inducing a positive feedback between CL and endometrium. If the concentration of PGF<sub>2</sub> $\alpha$  reaches a certain level, luteolysis occurs (Schams and Berisha 2002; Döcke 1994). The role and interaction of the locally acting factors are not totally known today.

The maintenance of the CL function is dependent on the presence of an embryo that prevents the signal cascade released from the endometrium to induce luteolysis. To ensure the survival of the conceptus not only the secretion of progesterone from the CL is necessary, but although provision of an optimal environment and nutrition in the uterus. Up to 40% of the embryonic losses are estimated to occur between day 8 and day 17 of pregnancy (Thatcher *et al.* 1994). To improve embryo survival during this critical period before implantation (Rüsse and Sinowatz 1994c) a better knowledge of the uterus-conceptus interaction is required.

### **Aim of the study**

Control of the oestrous cycle in dairy cows plays a central role in herd management of dairy farms. A high gravidity rate and short calving intervals assure the profitability of these farms. The exact knowledge of the physiological processes during oestrous cycle and gravidity is required to understand and treat pathological events correctly. The investigation of factors, which are necessary during luteolysis, can furthermore lead to more knowledge about fundamental processes during wound healing and tumor regression.

The aim of the first part of this study was to develop a method for the investigation of different factors in the uterus milk during preimplantation in cattle. Therefore uterus fluid was gained from pregnant heifers using an *in vivo* uterus flushing technic at specific time points. The samples were analysed with enzyme immunoassay (EIA) and radioimmunoassay (RIA).

The aim of the second part was to investigate if extracellular matrix (ECM) degradation and apoptosis occurs in the CL during oestrous cycle and induced luteolysis. Therefore the mRNA expression of different ECM proteases were evaluated in follicles 20 hours after GnRH (Gonadotropin releasing hormone) injection (shortly before ovulation) for comparable reasons and in the CL during oestrous cycle and induced luteolysis. Furthermore the mRNA expression of apoptotic and anti-apoptotic factors were evaluated in the CL during oestrous cycle and induced luteolysis.

## 2 Literature

### 2.1 Regulation of the oestrous cycle in cattle

#### 2.1.1 Folliculogenesis

In female mammalia the complete number of oocytes is already present at the time of birth in the ovaries. 'Follicle' describes the structural and functional unit of oocyte and follicle-epithel, less than 1% of them will ever reach ovulation. All other follicles go through atresia and degeneration at all stages of development. Until its ovulation, the oocyte is arrested in the prophase of its first meiotic division. Depending on the size of the oocyte and the development of the follicle-epithel, different stages of the follicle are distinguished: In the primordial follicle, the oocyte with a diameter of approximately 30µm is embedded in a single layer of flat epithelial cells (Epithelium folliculare). Before puberty, the cells of some follicles generate small primary follicles. Here, the oocyte is surrounded by a single layer of cubic epithelial cells and the zona pellucida. This glycoprotein barrier allows only a single, artspecific sperm to fertilise the oocyte. The secondary follicle shows an enlarged volume with a diameter of approximately 50-100µm. Within this stage, the follicle epithel grows and forms several layers, furthermore, stroma cells differentiate into the theca follicularis. A tertiary follicle is characterised through the development of the antrum folliculare, a liquid filled cavity. In this stage, the oocyte reaches its maximum diameter of approximately 150µm. The follicle epithel differentiates into the granulosa cell layer and the cumulus oophorus, both have nourishment- and control functions. Final stage of the follicular development is reached with the Graafian follicle: in this mature, praeovulatory follicle with a diameter up to 2cm, the oocyte loses its conection to the follicle layer and moves freely in the liquor folliculi. The oocyte finishes the first meiotic division, in which the genetic material is equally distributed among two nuclei. However the cytoplasm is not divided equally, after a second meiosis only one oocyte is able to get fertilised (Rüsse and Sinowatz 1994a).

#### 2.1.2 Regulation of the oestrous cycle

Each bovine oestrous cycle (with a duration of about 21 days, fig.1) shows mostly three follicular waves (Evans and Fortune 1997). Each wave contains the recruitment of a follicle cohort and the selection of one dominant follicle which continues growing whereas all others go through atresia (Stock and Fortune 1993). Dominant follicles control the

development of other follicles through hormones (like oestradiol, inhibin), which act locally as well as systemic (Savio *et al.* 1993). Follicle growth is promoted by two types of gonadotropins, which are secreted from the anterior pituitary as a reaction to pulsatile GnRH release from the hypothalamus (Roche 1996). These two types are the follicle stimulating hormone (FSH) and the luteinizing hormone (LH), both of them sequestered within the whole oestrous cycle. Naturally only the dominant follicle of the last wave comes to ovulation (Ginther *et al.* 1989). Ovulation of the Graafian follicle is the release of the oocyte. In this inflammation like process, the follicle liquid rinses the oocyte as well as the zona pellucida and the cumulus oophorus into the oviduct. Compulsory for this impact is the LH peak, which arises through an increase of frequency and amplitude of the LH pulses (Piquette *et al.* 1991) triggered by the pulsatile release of oestradiol-17 $\beta$ .




Figure 1: Hormone profiles, development and regression of the corpus luteum during the oestrous cycle of cattle (Intervet modified).

### 2.1.3 Corpus luteum (CL) formation, function and regression (luteolysis)

The above mentioned LH peak is also responsible for the formation of a temporary endocrine gland, the CL, which is built from the remaining granulosa- and theca interna cells after ovulation. This formation starts with the folding of the granulosa cell layer, its infiltration by theca cells and its vascularisation. During this process, also a variety of

other cell types, such as pericytes, fibroblasts and macrophages enter the granulosa. The rapid angiogenesis in the early CL development provides a tense capillary network. Parallel occurs the luteinisation of the theca and granulosa cells, which is marked through the inclusion of lipochroms and an increase in volume and synthesis rate. Cells of the follicle granulosa tissue develop into large luteal cells, while former theca cells become small luteal cells. These cubic cells synthesize steroid hormones, mostly progesterone. Progesterone is categorised into the group of gestagens, its main formation takes place in the CL. The preparation of the uterus mucosa for the implantation of the embryo as well as the maintenance of gravidity are the main functions of progesterone (Hesch 1989). Progesterone has a gonadotropin inhibiting effect, more precisely it decreases the pulse frequency. Thus, its inhibiting function aims at the LH peak (Döcke 1994), which means that ovulation only can take place in the absence of a CL and progesterone secretion. Small luteal cells produce less progesterone, but are present in greater numbers than large luteal cells.

If no fertilisation takes place, it is essential for the introduction of a new oestrous cycle, that the CL regresses. Thus, the uterus releases prostaglandin  $F_{2\alpha}$  ( $PGF_{2\alpha}$ ) around day 16.  $PGF_{2\alpha}$  was discovered as a physiological luteolysin nearly three decades ago, cellular events associated with luteolysis however remained poorly characterised.  $PGF_{2\alpha}$  interacts with its G protein-coupled receptor, present predominantly on large luteal cells, but also present on small luteal and endothelial cells of the CL (McCracken *et al.* 1999) and activates  $G_q$ /phospholipase C/protein kinase C pathway (McGuire *et al.* 1994) resulting in decreased steroidogenesis. The intracellular signalling events that lead to structural regression of luteal tissue are poorly characterised. However, proteases (Curry and Osteen 2003; Liu *et al.* 1997) and programmed cell death seem to play central roles in development and regression of the CL in several species (Bacci *et al.* 1996; Yadav *et al.* 2002).

## **2.2 Early pregnancy in cattle**

After fertilisation of an oocyte the development of an embryo begins. The first three divisions of the zygote take place in the oviduct. The conceptus reaches the 8-cell stage after 65 to 72 hours and can be found in the apex of the ipsilateral uterus horn after 4-5 days as a morula. It is transported from the apex to the place of implantation, which is mostly found in the middle of the ipsilateral horn. A migration to the contralateral horn is seldom (Rüsse and Sinowatz 1994b). On day 8 the early blastocyst stage is reached and



the embryo is divided into an “inner cell mass”, also known as embryoblast, and the trophoblast. After nine days the blastocyst emerges the zona pellucida and the differentiation of the ecto- and endoderm follows. The beginning of the elongation stages is reached at day 13. From this time on, the conceptus elongates till it reaches the contralateral uterus horn at day 18-19, which is filled out at day 22. The conceptus has no contact to the endometrium during the preimplantation period before day 18-19. It floats freely in the uterus lumen being nourished only by the so called uterus milk, which is secreted by the endometrium (Guillomot 1995). This uterus milk is found abundantly in the uterus lumen from the early blastocyst stage till day 24 of gravidity (Chang 1952). Bartol *et al.* (1981) were able to detect 18 different proteins in intrauterine fluid at day 19 of gravidity, four of them could not be found in cycling cows during different cycling stages. Some of these proteins have been already characterised like retinol-binding-protein (MacKenzie *et al.* 1997), granulocyte-macrophage-colony-stimulating factor (Emond *et al.* 2000), bovine granulocyte-chemotactic-protein-2 (Teixeira *et al.* 1997), bovine Ubiquitin cross-reacting protein (Austin *et al.* 1996), insulin-like growth factor-binding proteins (Keller *et al.* 1998) and PGF (Bartol *et al.* 1981). It seems possible, that the maternal environment given through the uterine secretion plays an essential role in the survival rate of blastocysts and early concepti till day 16 of gravidity (Keller *et al.* 1998).

## **2.3 Endocrine regulatory factors**

### **2.3.1 Progesterone**

Progesterone is mainly produced through the CL in cattle and functions as a signal for the uterine mucosa to be prepared for the implantation of an embryo. It is also necessary for the maintenance of gravidity (Hesch 1989). Progesterone inhibits the action of gonadotropins through a down-regulation of the pulse frequency. In this kind of way (negative feedback) a blocking of the LH peak occurs. A Graafian follicle can only ovulate, when there is no progesterone secreting CL present (Döcke 1994).

### **2.3.2 Oestradiol-17 $\beta$**

The most important oestrogen, oestradiol-17 $\beta$  is mainly produced in follicles of the ovaries. Its synthesis is stimulated by FSH, which is released from the adenohipophysis. Oestradiol-17 $\beta$  itself acts in a negative feedback mechanism on the secretion of FSH. Granulosa cells of the follicles receive androgens, which are produced in theca interna

cells, and transform them into oestrogens with the help of aromatases. These enzymes produce the biological effective forms of oestrogens together with cytochrom P450, NADPH (nicotinamid-adenosine-dinucleotid-phosphat-hydrogen) and oxygen. The high preovulatory synthesis of oestrogens by the ovulatory follicle triggers the LH peak. Oestrogens cause also a proliferation of the uterine mucosa (Döcke 1994). Oestradiol-17 $\beta$  is not only produced in follicles, but also in 13 days old bovine embryos (Chenault 1980).

### **2.3.3 Prostaglandin F $2\alpha$ (PGF $2\alpha$ )**

The regression of the CL, if no fertilisation occurred, is essential for the beginning of a new oestrous cycle. The luteolytic agent in cattle is PGF $2\alpha$ , which is secreted in a pulsatile manner by the endometrium. Progesterone and oestradiol-17 $\beta$  are responsible for the initiation of the PGF $2\alpha$  release, whereas progesterone acts as inhibitor and oestradiol as promotor (Meyer *et al.* 1988). PGF $2\alpha$  is inhibited during the luteal phase. At the start of luteolysis the secreted oestradiol promotes a rapid distribution of PGF $2\alpha$  (Döcke 1994). Also oxytocin stimulates its secretion. The endometrial PGF $2\alpha$  and the luteal oxytocin are connected by a positive feedback mechanism. The receptor of oxytocin is in turn affected by progesterone and oestradiol (Schams *et al.* 1985). Endothelin-1 seems also important, because it shows a suppression of the oxytocin effect and progesterone production in microdialysis experiments (Miyamoto *et al.* 1997). PGF $2\alpha$  is not only secreted by the endometrium at time of luteolysis, but also by bovine blastocyst from day 13 of gravidity on. The prostaglandin production rises each day of gravidity, whereas the blastocysts *in vitro* secrete much more PGF $2\alpha$  than PGE $2$  (Shemesh *et al.* 1979). Co-incubation with tissue from the endometrium changes the secretion pattern to more PGE $2$  than PGF $2\alpha$  (Lewis and Waterman 1983). PGE $2$  is able to act as a luteotropic agent during early pregnancy and can enhance the progesterone production in luteal tissue (Bazer *et al.* 1991; Godkin *et al.* 1977).

## **2.4 Locally produced factors**

### **2.4.1 Vascular endothelial growth factors (VEGFs)**

VEGFs are glycoproteins which induce angiogenesis. They are a potent mitogens for endothelial cells (Ferrara and Henzel 1989) and enhance the vascular permeability (Senger *et al.* 1986). VEGF-A is a homodimeric heparin binding glycoprotein of 46-48

kDa. Several additional members of the VEGF gene family have been identified, including VEGF-B, VEGF-C, Placenta growth factor and VEGF-D (Garrido *et al.* 1993, Ferrara 2001). The human VEGF gene has a length of approximately 12 kb and is composed of eight exons, separated by seven introns. Alternative exon splicing of a single VEGF gene results in the generation of four different molecular species, having respectively 121, 165, 189 and 206 amino acids after signal sequence cleavage (VEGF<sub>121</sub>, VEGF<sub>165</sub>, VEGF<sub>189</sub>, VEGF<sub>206</sub>). The bovine VEGF is one amino acid shorter than the human factor. VEGF<sub>121</sub> is a soluble secreted form, VEGF<sub>165</sub> is the most common molecular form produced by a variety of normal and transformed cells. In contrast, VEGF<sub>206</sub> is a very rare form (Houck *et al.* 1991). The different isoforms of VEGF have different properties *in vitro* and this may apply also to their *in vivo* functions. VEGF binds on two tyrosinkinase receptors: VEGF-R1 (= flt-1, fms-like-tyrosine kinase-1) and VEGF-R2 (= flk-1, fetal liver kinase-1), whereas the affinity of VEGF-R2 to VEGF is a bit lower than of VEGF-R1. Both receptors are localised on endothelial cells (Jakeman *et al.* 1992). The major regulator of VEGF is the oxygen content of the tissue. Hypoxia induces the expression of VEGF and its receptors. Further stimulating factors are: LH, IGF-1 (insulin-like growth factor-1), EGF (epidermal growth factor), TGF- $\beta$  (transforming growth factor  $\beta$ ), TNF- $\alpha$  (tumor necrosis factor  $\alpha$ ), IL-1 (interleukin-1) and IL-6 (interleukin-6) (Ferrara and Davis-Smyth 1997; Schams *et al.* 2001). High permeability, uterine oedema and angiogenesis occurs during implantation of rabbit embryos. VEGF seems to be critical for a successful implantation in rodents, because it was prevented by inhibition of VEGF (Rabbani and Rogers 2001). Although VEGF and its receptors have been implicated as key players in vascular remodeling and placentation in women (Ahmed *et al.* 1995), sheep (Bogic *et al.* 2001), pigs (Winther *et al.* 1999) and marmosets (Wulff *et al.* 2002).

#### 2.4.2 Housekeeping Genes

Housekeeping genes (HKG) are genes, which are permanently expressed on the same level to keep cell functions sustainable and to assure the survival of the cell. It is assumed that mRNA from HKG is expressed in excess, so that the cells are able to compensate for ineffective posttranscriptional, translational or posttranslational processes (Warrington *et al.* 2000). Quantitative gene expression is typically referenced to an internal control for compensation of fluctuations in the used mRNA amount and quality, which can occur because of discrepancies in the RNA extraction efficiency or through extraction of RNA from different individuals. Interpretation failures should be avoided by elimination of unspecific variations. Ideally the experimental conditions have no influence on the

expression of HKG (Bustin 2000). There is a general consensus, that one HKG as control gene is enough for the normalisation of expression data. GAPDH (Glyceraldehyd-3-phosphat-Dehydrogenase),  $\beta$ -Actin, 18S rRNA and 28S rRNA are most often used as HKG (Suzuki *et al.* 2000). But there are physiological situations existing, where even the expression of HKG show strong variations. Therefore not only one HKG, but the mean value of several carefully selected HKG should be used for normalisation (Vandesompele *et al.* 2002). There are numerous references existing, that also HKG can be regulated (Bustin 2000; Suzuki *et al.* 2000, Thellin *et al.* 1999). The mRNA expression of GAPDH, an enzyme of the glycolysis and gluconeogenesis, is massively regulated by the following effects: different cell cycle stages, gravity, dexamethason, glucose, insulin, growth hormones, oxidative stress, hypoxia, apoptosis etc.  $\beta$ -Actin is a structural protein of the cytoskeleton and its mRNA expression can be influenced by hypoxia, ionising radiation, different growth factors, adrenocorticotropin or gonadotropin (Bustin 2000; Suzuki *et al.* 2000). Ubiquitin is used for the degradation of proteins and is 2-fold increased during DCNP (2,6-dichloro-4-nitrophenol) induced apoptosis in human Chang liver cells (Qi and Sit 2000a). An up-regulation of Ubiquitin is also seen in PGF $2\alpha$  induced luteolysis in primates, when signs of apoptosis are recognisable (Young *et al.* 1998). Histones are abundant, basic proteins, that bind to the DNA to form nucleosomes (Zong 2004). They compromise the protein portion of the nucleosomes, which function to compact the DNA into chromatin and to help regulate its activities (Sedelnikova *et al.* 2003). Several Histone variants have been found to regulate gene expression and even acting as apoptotic factors (Pusarla and Bhargava 2005).

### **2.4.3 Extracellular matrix proteases**

#### **2.4.3.1 General aspects**

The life cycle of the CL involves several strictly regulated proteolytic processes that take place within the same CL during a relatively short period of time, including angiogenesis, tissue remodeling (Smith *et al.* 1994b) and tissue degradation (Kiya *et al.* 1999). The CL therefore provides a useful model to study the regulation and functional roles of matrix remodeling proteases *in vivo*. In other species like human (Duncan *et al.* 1998), rat (Nothnick *et al.* 1996), mouse (Liu *et al.* 2003), porcine (Pitzel *et al.* 2000), ovine (Ricke *et al.* 2002a; Towle *et al.* 2002) and in the bovine species (Zhang *et al.* 2002; Smith *et al.* 1996; Goldberg *et al.* 1996; Juengel *et al.* 1994) the matrix metalloproteases (MMPs), their tissue inhibitors (TIMPs) and the plasminogen activator system seem to play a critical

role in development and regression of the CL. Our request was therefore to investigate these factors at well defined time points in follicles during 20 hours after GnRH application and in the CL during oestrous cycle and induced luteolysis.

#### 2.4.3.2 Matrix metalloproteases (MMPs)

Degradation of specific extracellular matrix (ECM) components occurs by the action of MMPs, which belong to a large family with at least 25 related proteolytic enzymes (Woessner 2002). They are classified on their substrate specificity as collagenases, stromelysins, gelatinases, membran-type MMPs (MT-MMPs) and other MMPs (Kuzuya and Iguchi 2003). All MMPs share certain common features like being zinc- and calcium-dependent endopeptidases (Visse and Nagase 2003), which are synthesised as proenzymes and secreted in an inactive form into the extracellular space (Nagase 1997). Except of MMP-11 and MMP-14 (MT1-MMP), which are activated prior to secretion by furin-like proteases (Kuzuya and Iguchi 2003), MMPs are activated *in vivo* by serine proteases like plasminogen activator (Nagase 1997), mast cell proteases (Suzuki *et al.* 1995), and other MMPs (Sato *et al.* 1994). Also non-proteolytic agents as SH – reactive agents, reactive oxygen and denaturants are activators of MMPs. For activation the prodomain of the MMPs has to be removed (Kuzuya and Iguchi 2003).

A different kind of activation occurs to MMP-2. It takes place on the cell surface by mediation of the membrane-type MMPs like MMP-14, which functions as receptor for MMP-2, and by the interaction with TIMP-2, which belongs to the family of tissue inhibitors of metalloproteases (Strongin *et al.* 1995; Butler *et al.* 1998; Wang *et al.* 2000). By binding to the hemopexin region of proMMP-2 TIMP-2 forms a tight complex and connects to MMP-14 on the cell surface. The now surface - bound - proMMP-2 is then activated by a MMP-14, which is free of TIMP-2. An absence or even a high concentration of TIMP-2 can decrease MMP-2 activation (Strongin *et al.* 1995). Degradation of the ECM by MMPs is required in endothelial cell migration, organization and, hence, angiogenesis (McCawley and Matrisian 2000). All these processes occur during development of the CL, while during luteolysis degradation of the different collagen components is necessary to enable the rapid regression of the CL.

Subdivision	MMP	ECM Substrate
<b>Collagenases</b>	MMP-1 MMP-8 MMP-13 MMP-18	Type I, II, III, VII, X collagen, gelatin Fibrillar Collagen Fibrillar Collagen Fibrillar Collagen
<b>Gelatinases</b>	MMP-2 MMP-9	Type I, IV, V u. fibrillar collagen; gelatin Type IV, V collagen, gelatin
<b>Stromelysins</b>	MMP-3 MMP-10 MMP-11	Laminin, fibronectin, non-fibrillar collagens Laminin, fibronectin, non-fibrillar collagens Laminin, fibronectin, non-fibrillar collagens
<b>Membran-type MMPS</b>	MMP-14 MMP-15 MMP-16 MMP-17 MMP-24 MMP-25	Gelatinase A, fibrillar collagens, Proteoglycans Gelatinase A Gelatinase A
<b>Other MMPs</b>	MMP-7 MMP-12 MMP-19 MMP-20 MMP-26	Laminin, fibronectin, non-fibrillar collagens Collagen type I, IV, elastin, fibronectin, gelatin, laminin Aggrecan, type VI collagen, laminin, fibronectin Fibronectin, gelatin

Table 1: Members of the matrix metalloprotease family

#### 2.4.3.3 Tissue inhibitors of metalloproteases (TIMPs)

Activity of MMPs is strictly regulated in the extracellular environment by the family of tissue inhibitors of metalloproteases (TIMPs). These family of small proteins (21-30 kDa) contains four members, TIMP-1, TIMP-2, TIMP-3 and TIMP-4. For inhibiting active MMPs they form non-covalent complexes by binding to the active site of the catalytic domain of the MMPs. These happens in a 1:1 stochiometric ratio. TIMPs act selectively on different MMPs. For example, TIMP-2 has a high affinity for MMP-2, whereas TIMP-1 preferentially binds to MMP-9. It is reported that TIMPs not only regulate the action of MMPs, but also promote embryo growth (Sato *et al.* 1994), act as antiangiogenic agents (Murphy *et al.* 1993), stimulate cell growth (Hayakawa *et al.* 1994), influence apoptosis (Talhouk *et al.* 1992) and recruit quiescent cells into the cell cycle (Wick *et al.* 1994).

#### 2.4.3.4 Plasminogen activator (PA) system

Also an important role in degradation of the ovarian ECM plays the plasminogen activator (PA) system (Smith *et al.* 1999). It consists of plasminogen, the inactive form of plasmin, tissue and urokinase plasminogen activator (tPA, uPA), the uPA-receptor (uPAR) and two plasminogen activator inhibitors (PAI-1, PAI-2). tPA and uPA transform plasminogen into its active form plasmin in the extracellular space (Luck 1994). uPA is able to bind on its cell surface receptor (uPAR) for building a stable complex. Its purpose is thought to focus the plasmin activity at the cell surface. Plasmin is not only able to degenerate specific ECM components like types III and IV collagen, fibronectin, laminin and proteoglycans (Roldan *et al.* 1990; Barnathan *et al.* 1990), but also activates proenzyme forms of MMP-1, MMP-2 (Monea *et al.* 2002) MMP-3 and MMP-9 (DeClerck and Laug 1996; Lijnen *et al.* 1998; Makowski and Ramsby 1998; Murphy *et al.* 1999). Working hand in hand together the MMPs and the plasminogen activator system are able to degrade all ECM components in the ovary (Dow *et al.* 2002).

#### 2.4.3.5 Monocyte chemoattractant protein-1 (MCP-1)

MCP-1 is a member of the intercrine  $\beta$  family of cytokines. The cytokines in this group are thought to be involved in inflammation and tissue repair (Oppenheim *et al.* 1991). MCP-1 has a potent chemoattractant effect on monocytes and CD4<sup>+</sup> and CD8<sup>+</sup> T lymphocytes. MCP-1 is produced by a variety of cells types including endothelial cells, fibroblasts, monocytes and T lymphocytes. MCP-1 binds to two receptors, CCR-2 and CCR-4, sharing these receptors with other cytokines of its family (Penny 2000). Results of recent studies indicate that MCP-1 is produced in the CL during luteal regression and might aid in its destruction (Penny *et al.* 1998; Townson *et al.* 1996; Townson *et al.* 2002; Bowen *et al.* 1996; Tsai *et al.* 1997). MCP-1 is of particular interest because, once expressed within blood vessels, this chemokine facilitates the attachment and migration of immune cells, especially monocytes, macrophages and T lymphocytes, from the blood stream into sites of inflammation (Mukaida *et al.* 1992). In this regard, macrophages and T lymphocytes have been demonstrated to accumulate in regressing CL of many species (Penny *et al.* 1999; Townson *et al.* 2002; Townson *et al.* 1996; Hehnke *et al.* 1994) and have been implicated in phagocytosis of luteal cells (Paavola 1979), degradation of ECM (Endo *et al.* 1993) and secretion of proinflammatory mediators that influence luteal steroidogenesis (Benyo and Pate 1992; Rueda *et al.* 2000b).

## 2.4.4 Apoptosis

### 2.4.4.1 General aspects

Apoptosis or programmed cell death is a evolutionary highly conserved mechanism, that allows the organism to tightly control cell numbers, tissue size and protect itself from dangerous cells that threaten homeostasis. It is regulated by proteins of the organism that form an intrinsic and extrinsic signaling cascade. The intrinsic apoptotic signaling cascade is generally thought to be activated by apoptotic stimuli that are caused within a cell in response to certain drugs, radiation or growth factor withdrawal and primarily lead to changes in mitochondrial permeability through alterations in the ratio of pro-apoptotic to anti-apoptotic Bcl-2 family members (Adams and Cory 1998). The extrinsic apoptotic signaling cascade on the other hand is activated by extracellular signals like TNF $\alpha$  or Fas-Ligand that interact with cell surface receptors to start cell death (Nagata 1997). All these signals activate a cascade of intracellular proteases known as caspases (fig. 2). Once activated, caspases cleave various cellular substrates including actin, poly(ADP-ribose) polymerase (PARP), DFF45/inhibitor of caspase-activated DNase (ICAD), fodrin, and lamin which contribute to the morphological changes typically for apoptotic cells (Martin and Green 1995). The final cellular event during apoptosis is reached with the fragmentation of DNA. This is mediated by a huge variety of endonucleases such as DFF40/caspase-activated DNase (CAD), Nuc70 etc (Yadav *et al.* 2005).






Figure 2: Apoptotic pathways (Cell Signaling Technologies 2005/2006)

#### 2.4.4.2 Extrinsic pathway

##### 2.4.4.2.1 *Tumor necrosis factor family (TNF $\alpha$ , TNFR1, TNFR2)*

TNF $\alpha$  is a nonglycosylated protein with 17kDa of molecular mass, which belongs to the family of cytokines. TNF $\alpha$  has first been described as a tumoricidal factor, which is produced by activated macrophages. Nowadays it is known, that besides macrophages also granulosa cells (Zolti *et al.* 1990) and luteal cells (Hehnke-Vagnoni *et al.* 1995) are candidates which express TNF $\alpha$  within the ovary. In rats (Brannstrom *et al.* 1994a) and cows (Skarzynski *et al.* 2000) it is shown, that macrophages are attracted to and infiltrate the CL during luteolysis. This accumulation of macrophages in the regressing CL is

believed to be in response to a chemotactic factor. A likely candidate for this is monocyte chemoattractant protein-1 (MCP-1), its expression has been demonstrated to be regulated by local growth factors and cytokines such as TNF $\alpha$  (Kayisli *et al.* 2002). Various researches verify that TNF $\alpha$  stimulates prostaglandin synthesis by luteal cells, and that it furthermore inhibits gonadotropin supported progesterone production in bovine luteal cells (Benyo and Pate 1992). This is supported through further studies proving that locally expressed cytokines such as TNF $\alpha$  induce follicular atresia and CL apoptosis (Friedman *et al.* 2000). TNF $\alpha$  is able to bind to two different TNF-receptors (TNFR1, TNFR2), which are expressed on microvascular endothelial cells in the CL (Okuda *et al.* 1999). TNFR1 mRNA is expressed on bovine luteal and endothelial cells and is responsible for TNF $\alpha$  induced apoptosis during structural luteolysis via the extrinsic pathway mediated by TNFR1 (fig. 2), which mainly effects the endothelial cells (Friedman *et al.* 2000). There is a controverse discussion about the action of TNFR2 in concern to trigger or inhibit apoptosis. Some groups report that TNF $\alpha$  is not only able to induce apoptotic cell death, but can also induce cell proliferation by binding to TNFR2. This receptor can induce gene transcription for cell survival, growth and differentiation, and therefore TNFR2 is involved in an anti-apoptotic effect of TNF $\alpha$  (Inoue *et al.* 2000; Wajant and Scheurich 2001; Stanger *et al.* 1995; Shu *et al.* 1996). On the other hand TNFR2 is able to bind the TNF receptor-associated factor 2 (TRAF2), which is a necessary factor for the activation of the anti-apoptotic NF $\kappa$ B pathway by TNFR1. Depending if TNFR1 is costimulated with TNFR2 or not, apoptosis occurs or not (Fotin-Mleczek *et al.* 2002) (fig. 3).




Figure 3: Model of the apoptotic TNFR1 / TNFR2 crosstalk. A) Exclusive stimulation of TNFR1. B) Prestimulation of TNFR2. C) Costimulation of both TNF receptors. (Fotin-Mleczeck *et al.* 2002)

#### 2.4.4.2.2 Fas and Fas-Ligand (FasL)

The Fas antigen (also known as APO-1 or CD95) is a transmembrane glycoprotein of 48 kDa and encodes a cysteine-rich transmembrane protein of 335 amino acids. It is a member of the TNF family of cell surface receptors (Nagata and Golstein 1995), which also includes other receptors like TNFR1 and TNFR2, death receptor-3, two receptors for the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and many more. Fas is expressed on the cell surface in various tissues like heart and kidney, furthermore on thymocytes and activated T cells (Nagata, 1999). Fas-Ligand (FasL) is a cytokine that belongs to the TNF family (Suda *et al.* 1993). FasL is predominantly expressed in activated T lymphocytes and natural killer cells. It is a type II membrane protein with an extracellular region of about 150 amino acids and an cytoplasmic region of 77 amino acids. Induced expression of the FasL gene occurs through the binding of NFκB to the 5' flanking region of the FasL gene, stresses as UV radiation or gamma-irradiation also show the same effect. Itoh *et al.* (1991) showed that binding of FasL to Fas induces apoptosis in Fas bearing cells. TNF, the prototype of the TNF family has two different receptors TNFR1 and TNFR2, especially the interaction of TNFR1 and TNF mediates apoptosis. Fas and TNFR1 share a homologous domain in their cytoplasmic domain and

mutational analysis indicated that this domain is necessary to transduce the apoptotic signal. Thus, this domain has been designated a death domain (Nagata, 1999). Fas and TNFR1 must be oligomerized to be activated, and since x-ray diffraction analysis showed that TNF induces trimerization of its receptor, the similarity to the structure of FasL suggests that FasL also induces trimerization of Fas. The trimerized cytoplasmic region then has the ability to transduce the apoptotic signal via the recruitment of FADD (FAS-associated protein with death domain) and the following binding of caspase8. The activation of caspase8 and the further extrinsic pathways is already described above.

#### 2.4.4.3 Intrinsic pathway

##### 2.4.4.3.1 *Tumor suppressor p53*

The tumor suppressor p53 is often described as a “guardian of the genome”, because it is a critical component of cellular mechanisms that respond to genotoxic stresses like DNA damage, hypoxia etc. to maintain the genomic integrity in part by arresting the cell cycle progression or by inducing apoptosis. p53 is a short-lived protein with a half life of about 20 minutes that is maintained at very low or undetectable levels under normal circumstances. Under exposure of stressful stimuli, p53 is activated through post-translational modifications that increase its stability and activity (Levine 1997). The human p53 protein contains 393 amino acids and has been divided structurally and functionally into four domains: an acidic amino-terminal domain, which is required for transcriptional activation; a central core sequence-specific DNA-binding domain; a tetramerization domain and a C-terminal regulatory domain (Somasundaram 2000). p53 can alter the transcriptional activity of genes associated with cell death. It was found that p53 increases the expression of Bax, an apoptotic factor of the internal pathway, and by the other hand decreases the Bcl-2 expression, which is a anti-apoptotic factor that inhibits the action of Bax (Miyashita *et al.* 1994; Miyashita and Reed 1995). It is also reported that p53 is able to activate Fas, which belongs to the extrinsic pathway (Kobayashi *et al.* 1998). p53 expression occurs in apoptotic granulosa cells of atretic rat follicles (Tilly *et al.* 1995) and is also induced by reactive oxygen species (ROS) in bovine luteal cells (Nakamura and Sakamoto 2001).

#### 2.4.4.3.2 *Bax and Bcl-X<sub>L</sub>*

The intrinsic pathway is used extensively in response to internal insults such as DNA damage (Rich *et al.* 2000). The diverse response pathways affect the mitochondria through the activation of a set of apoptotic regulators, the Bcl-2 family. This family is divided into three groups, based on structural similarities and functional criteria. Some molecules like Bcl-2 and Bcl-X<sub>L</sub> are attached to the mitochondria-membrane, others can shuttle between the cytosol and organelles (Gross *et al.* 1999). Members of group I (like Bcl-2, Bcl-X<sub>L</sub>) possess anti-apoptotic activity, whereas group II (Bax, Bak) and group III (Bid, Bik) members promote cell death. The Bax protein was originally identified via its ability to interact with Bcl-2 in cells. Bcl-X is a unique gene among the other members of this family as it produces both positive ("short" isoform, death inducer) and negative ("long" isoform, death suppressor) regulators of the cell death pathway (Goodman *et al.* 1998). Bcl-2 members control cell death through their ability to form heterodimers from pro- and anti-apoptotic molecules. Thus, heterodimerization can be thought as resulting in neutralization of these proteins. This leads to the point, that overall levels of pro- and anti-apoptotic factors have to be compared in order to estimate whether cells are sensitive to death or resistant (Hengartner 2000). How the increase in the expression levels of Bcl-2 members is achieved has not been fully investigated yet, but it is obvious, that p53 plays a significant role (Miyashita and Reed 1995). The key function of Bcl-2 family however is to regulate the release of pro-apoptotic factors from the mitochondrial intermembrane compartment into the cytosol (Adams and Cory 1998). The most prominent factor among these is cytochrome c, an electron carrier. This protein is one of the components required for the activation of caspase9 in the cytosol. Unlike other caspases, proteolytic processing of procaspase9 has only a minor effect on its activity. The urgent requirement for the activation of caspase9 is its association with the adaptor protein Apaf-1 (Li *et al.* 1997). Apaf-1 thus is nowadays believed as an essential regulatory subunit of a caspase9 holoenzyme, the so called apoptosome. Heat shock proteins act as multiple steps in the pathway to regulate apoptosis (Xanthoudakis and Nicholson 2000). The extrinsic and intrinsic pathway then converge at the level of caspase3 activation (fig. 2).

#### 2.4.4.3.3 *Second mitochondria derived activator of caspases (Smac )*

In the intrinsic pathway, the key event leading to the activation of caspases is the release of several pro-apoptotic proteins from the intermembrane space of mitochondria into the cytosol (Wang 2001). One such protein is the second mitochondria derived activator (Smac), which is also called Diablo (Verhagen *et al.* 2000). The newly synthesised Smac protein contains of 239 amino acids. Its N-terminal 55 residues encode the mitochondrial targeting sequence and are proteolytically removed in the mature Smac protein (Du *et al.* 2000). This cleavage results in the exposure of four hydrophobic amino acids at the N-terminus of the mature Smac. This tetrapeptide represents the founding member of a family of inhibitors of apoptosis proteins (IAPs) binding motifs in mammals (Shi 2002a). The binding of Smac to IAPs prevent their interactions with caspase9 and the inhibition of the intrinsic pathway (Srinivasula *et al.* 2001).

#### 2.4.4.3.4 *Survivin*

Survivin belongs to the family of inhibitors of apoptosis proteins (IAPs). These proteins prevent aberrant activation of caspases, which can be detrimental to cells. To protect against inadvertent damages and death, cells have evolved a system of checks and balances. At the heart of the system is the evolutionarily conserved IAP family. Membership of this family requires a 80 amino acid zinc-binding module, which is referred to as a baculoviral IAP repeat (BIR) domain. At least eight distinct IAPs have been identified in the mammalian genome, each of which contains 1-3 copies of the BIR domain. Except of survivin, all other IAPs contain other functional domains such as RING (really interesting new gene) (Deveraux and Reed 1999; Salvesen and Duckett 2002). Survivin contains only one BIR domain and does not inhibit caspase activity *in vitro* (Shi 2002b). In contrast to the relatively stable expression levels of other IAPs, expression of survivin oscillates with cell cycle and peaks at the G2/M phase (Li *et al.* 1998). Survivin is able to inhibit Smac and prevent cells from apoptosis (Song *et al.* 2003). Survivin is expressed in human endothelial cells of newly formed blood vessels (Tran *et al.* 1999).

#### 2.4.4.4 Caspase3, -6, -7

Caspases share homology with the *Caenorhabditis elegans* gene, Ced-3, its product is required for mediating apoptosis during development. Caspase3 is the vertebrate-caspase most similar to Ced-3 concerning amino acid sequence homology as well as substrate specificity. The active mammalian form, consisting of p17 and p12 subunits, is processed from an inactive 32-kDa proenzyme after auto- or heterocatalysis, preferentially cleaving substrates containing a DEVD motif (Nicholson and Thornberry 1997). The active form of mammalian caspase6 consists of p18 and p11 subunits (processed from a 34-kDa proenzyme). caspase7 shares its signature cleaving site with caspase3 and thus has a great similarity in substrate specificity. Studies have demonstrated the existence of at least 11 additional homologous mammalian proteases, caspase1 through -14, that together compose the caspase family of cysteine proteases. All identified mammalian caspases are synthesised as inactive proenzymes and activated after cleavage at a specific N-terminal domain aspartate cleavage sites. Within this family of enzymes, caspase7 and caspase9 are considered to be most homologous in sequence to caspase3 and -6, while the amino acid sequences of caspase8 and caspase10 are the next most related (Miller 1997; Nicholson and Thornberry 1997). Although the mechanism of caspase action is highly conserved, differences among primary sequences account for different substrate specificity. As a group, caspase members generally form a cascade of enzymatic activity that results in the initiation and amplification of early apoptotic events (e.g. caspase8, -9, so called initiator-caspases) as well as mediating the later executioner steps of apoptosis (e.g. caspase3, -6, -7, the effector-caspases) (Nicholson and Thornberry 1997). Both apoptotic pathways result in the activation of this cascades, independent whether it is done directly or via activation of the mitochondrial death program. On one hand, the extrinsic pathway starts with ligand-binding to death-receptors such as CD95 (Apo-1/Fas). As an effect, those receptors form membrane-bound signalling complexes, which recruit through adapter proteins several molecules of caspase8. The induced proximity model (Muzio *et al.* 1998) posits that under these conditions the molecules cleave and thus activate each other. As described above, this activated caspase now activates further caspases of the cascade like -3, -6, -7, which leads to cleavage of specific death substrates. The intrinsic pathway on the other hand also activates caspase3 and following caspases, however it starts out in quite a different way.

### **3 Material**

#### **3.1 Development of a method to gain uterus milk *in vivo***

##### **3.1.1 Equipment**

blood withdrawal system	Vacurette 20G, 450.077, Vacurette K3E EDTA K3, 455.036, Greiner Labortechnik, (Kremsmünster, Austria)
buckler	Stopfen Sarstedt 65.806 (Nürnbrecht)
catheter	disposable embryo flushing catheter steril incl. steel mandrin, CH 12, Minitüb (Tiefenbach)
cellulose tissue	Ärztetrepp, Heiland (Hamburg)
centrifuge	Sigma 3-16K (Osterode)
clipping machine	Typ GT 104, Aesculap AG & Co.KG (Tuttlingen)
microscope	Zeiss Axiovert 25, Carl Zeiss AG, (Hallbergmoos)
microtiter plates	Nunc-Immuno-Platte Maxisorb F 96, Nunc GmbH (Wiesbaden)
microtiter plate dispensor	Manifold-8-Changonel, SLT Labinstruments (Crailsheim)
microtiter plate washer	SLT 96.PW, SLT Labinstruments (Crailsheim)
needles sterile	Microlane 3 18G x 1½, BD (Drogheda, Ireland)
pipettes	Abimed, Gilson (Frankreich) Eppendorf (Hamburg) Pipetus akku, Hirschmann Laborgeräte (Eberstadt)
pipettetips	Diamond D10 tips, Gilson (Hamburg) Standardtips Eppendorf (Hamburg) Sarstedt (Hamburg)
reaction tubes	2ml, Eppendorf (Hamburg) 5ml Sarsted-Röhrchen 55.525 (Nürnbrecht) 15ml Cell Star 188.271, Greiner (Frickenhausen)
syringes disposable	Terumo 5ml, Heiland (Hamburg) Basik 20ml, Heiland (Hamburg)
tissue culture dish	Corning, Sigma-Aldirch (München)
vaginal flushing system	Irrigator 2L, Heiland Vet (Hamburg) flexible hose, Heiland Vet (Hamburg)

##### **3.1.2 Medicaments**

Buserelinacetat	Receptal, Intervet Deutschland GmbH
-----------------	-------------------------------------



	(Unterschleißheim)
Cloprostenol	Estrumate, Essex Tierarznei (München)
Gentamicinsulfat	Genta-Sleecol 5, A. Albrecht GmbH + Co. KG (Aulendorf)
0,9% NaCl	Fresenius Kabi Deutschland GmbH (Bad Homburg)
Procainhydrochlorid	Procasel 2%, Selectavet Dr. Otto Fischer GmbH (Weyarn-Holzolling)

### 3.1.3 Biochemicals

99% acetylsalicylic acid	Merck (Darmstadt)
BSA	Fraktion V, pH 5,2; Standard Grade, Serva, 11930 (Heidelberg)
citric acid x 1 H <sub>2</sub> O	Merck, 244 (Darmstadt)
ethanol (100%)	Merck (Darmstadt)
H <sub>2</sub> O <sub>2</sub> -urea	Merck, 818356 (Darmstadt)
H <sub>2</sub> SO <sub>4</sub>	Merck, 100731 (Darmstadt)
Kathon	pH 5.0, Rohm & Haas Ltd., 62368 (U.K.)
NaCl	Merck (Darmstadt)
Na <sub>2</sub> CO <sub>3</sub> x 10 H <sub>2</sub> O	Merck, 6391(Darmstadt)
NaHCO <sub>3</sub>	Merck, 6329 (Darmstadt)
Na <sub>2</sub> HPO <sub>4</sub> x 2 H <sub>2</sub> O	Merck, 6580 (Darmstadt)
sperm deep frozen	FV Weber IN 184593 27.07.01, D-KBR015 EWG (München - Grub)
TMB	Boehringer, 784974 (Mannheim)
0,05% Tween-80	Sigma, P 1754 (Taufkirchen)

### 3.1.4 Reagents

assay-buffer	7.12 g/l Na <sub>2</sub> HPO <sub>4</sub> x 2 H <sub>2</sub> O 8.5 g/l NaCl pH 7.2 1.0 g/l BSA (0.1%)
coating buffer	4.29 g/l Na <sub>2</sub> CO <sub>3</sub> x 10 H <sub>2</sub> O 2.93 g/l NaHCO <sub>3</sub> pH 9.6
substrate solution A	1 g/l H <sub>2</sub> O <sub>2</sub> -urea 18 g/l Na <sub>2</sub> HPO <sub>4</sub> x 2 H <sub>2</sub> O 10.3 g citric acid x 1 H <sub>2</sub> O 0.1 ml Kathon pH 5.0 photosensitiv
substrate solution B	300 mg TMB (Tetramethylbenzidin)

---

	40 ml DMSO (Dimethylsulfoxid)
	960 ml H <sub>2</sub> O
	10.3 g citric acid x 1 H <sub>2</sub> O
	pH 2.4 photosensitiv
peroxidase-labeled oestradiol-17 $\beta$	self-production 17 $\beta$ /2pool1 26.07.95
unlabeled oestradiol-17 $\beta$	Serva 31100 (Heidelberg)
oestradiol-17 $\beta$ antibody (rabbit)	self-production E2/2pool1 23.11.77
peroxidase-labeled PGF2 $\alpha$	self-production 29.10.97
unlabeled PGF2 $\alpha$	Sigma, P0424 (Taufkirchen)
PGF2 $\alpha$ antibody (rabbit)	R. Claus, AS S5, Ka III, E. 20.09.87, (Hohenheim)
peroxidase-labeled progesterone	Sigma, P3659 (Taufkirchen)
unlabeled progesterone	Sigma, P 0130 (Taufkirchen)
progesterone anti-body (rabbit)	K. Okuda, OK-1 03.12.97, (Japan)
prostaglandin stabilisator	111.7g 0.3 m EDTA 10g 1% acetylsalicylic acid pH 7.4 photosensitiv
VEGF-165 antiserum	self-production H21 30.9.93
VEGF-165 protein, bovine, recombinant	D. Gospodarowicz, 28.10.97 (Chiron, Oakland, USA)

## 3.2 Expression of housekeeping genes, proteases, apoptotic and anti-apoptotic factors in the CL during oestrous cycle and induced luteolysis

### 3.2.1 Tissue collection

#### 3.2.1.1 Follicles 20 hours after GnRH application

For comparable reasons follicles ( $n=5$ ) were taken 20h after GnRH application from the experiment published by Berisha et al. (2006). German Fleckvieh cows were superovulated using FSH (Ovagen; Immunochemical Products Ltd, Auckland, New Zealand) injections (in total seven), which were given i.m. at 12h intervals in gradually decreasing doses for 3.5 days, starting between days 8 and 11 of the oestrous cycle after previous oestrus observation. After the sixth FSH injection, a luteolytic dose of 500  $\mu\text{g}$  PGF<sub>2</sub> analogue (cloprostenol, Estrumate; BERNA Veterinärprodukte AG, Bern, Switzerland) was injected i.m., and then 40h after PGF<sub>2 $\alpha$</sub>  injection, 100  $\mu\text{g}$  gonadotrophin-releasing hormone (GnRH) (Receptal; BERNA Veterinärprodukte AG, Bern, Switzerland) were injected to induce the LH surge. For confirmation of LH surge, blood samples were collected from the jugular vein at -24, -12, -1 and 0h before and 3 and 12h after GnRH application. Lack of an endogenous LH surge prior to GnRH was confirmed by LH determination in blood plasma (range 0.8–1.0 ng/ml); 4h after GnRH the mean LH level (induced LH surge) was 11.50 ng/ml (range 8.5–14.1 ng/ml) and at 12h 0.73 ng/ml (range 0.2–1.0 ng/ml). The ovaries were collected by transvaginal ovariectomy ( $n=5$  cows/group) 20h after GnRH application.

#### 3.2.1.2 CL during oestrous cycle

The CLs (4 per group) were collected 10-20 minutes after slaughter, frozen in liquid nitrogen and kept at  $-80^{\circ}$ . According to a modified method by Ireland et al. (Ireland *et al.* 1980) the CLs were divided into four groups:

- Group I + II (day 1-4):
  - Time before ovulation until development of one epithelial cell layer over the rupture site with further differentiations like:
  - Day 1-2: only a blood-clot is present, 2-6mm in diameter (group I)
  - Day 3-4: development of a small umbilicus, growing diameter (group II)

- Group III (day 5-7):
  - Day 5-7: developing stage; blood vessel formation in the periphery is seen; cutting of the CL displays a red apex; 5-12mm in diameter
  
- Group IV (day 8-12):
  - Day 8-12: mature stage; the apex is red, the rest of the CL yellow; the CL is clearly bigger than in group III (over 12mm of diameter) and is softly demarcated

### 3.2.1.3 CL during induced luteolysis

CL tissue was taken from the experiment described by Neuvians et al. (2003). In this experiment 5 CLs per group were taken from cycle synchronised cows after defined time points during induced luteolysis at day 8-12 of the oestrous cycle. The time intervals were as follows:

0, 2, 4, 12, 24, 48 and 64 hours after PGF<sub>2</sub> $\alpha$  injection

Additionally we decided to complement the experiment with an earlier time point at 0.5 hours after luteolysis (Az: 209.1/211-2531.3-29/04). Therefore we synchronised five non lactating Brown Swiss cows with two injections of 500 $\mu$ g Cloprostenol (Estrumate) i.m. within eleven days. 10-12 days after the second injection luteolysis was induced by further administration of 500 $\mu$ g Cloprostenol. After 0.5h the ovaries were taken by transvaginal ovariectomy. The CLs were dissected, cut in slices and either fixated in Bouin's solution or in methanol-glacial acetic acid for immunohistochemistry, or frozen in liquid nitrogen and stored at -80°. Blood samples were taken at each PGF<sub>2</sub> $\alpha$  injection and daily from the second day after the second PGF<sub>2</sub> $\alpha$  injection on for measuring the progesterone level.

### 3.2.2 **Equipment**

blood withdrawal system	Vacurette 20G, 450.077, Vacurette K3E EDTA K3, 455.036, Greiner Labortechnik, (Kremsmünster, Austria)
buckler	Stopfen Sarstedt 65.806 (Nürnbrecht)
centrifuge	Sigma 3-16K (Osterode)
clipping machine	Typ GT 104, Aesculap AG & Co.KG (Tuttlingen)
syringes disposable	Terumo 5ml, Heiland (Hamburg)

### 3.2.3 Surgical instruments

cervix clamp	Hauptner (Dietlikon-Zürich, Schweiz)
effeminator	Hauptner (Dietlikon-Zürich, Schweiz)
knife by Höhne	Hauptner (Dietlikon-Zürich, Schweiz)
ligature carrier by Deschamps 45cm	Eickemeyer (Tuttlingen)
suture material	PBS 2USP, 5EP absorbable, WDT (Garbsen)
swabs sterile	Fuhrmann (Much)

### 3.2.4 Medicaments

Benzylpenicillin-Procaïn	Procillin, Alvetra (Neumünster)
Cefquinomsulfat	Cobactan 2.5%, Intervet (Unterschleißheim)
Cloprostenol	Estrumate, Essex Tierarznei (München)
Metamizol-Natrium	Vetalgin, Intervet (Unterschleißheim)
Poly(1-vinyl-2-pyrrolidon)-Jod-Komplex	Vet-Sept-Lsg., Albrecht (Aulendorf)
Procainhydrochlorid	Procasel 2%, Selectavet Dr. Otto Fischer GmbH (Weyarn-Holzolling)
Xylazinhydrochlorid	Rompun 2%, Bayer Vital (Leverkusen)

### 3.2.5 Laboratory equipment

beads	Matrix Green, Bio 101 Systems, MP Biomedicals (Heidelberg)
Bioanalyzer 2100	Agilent Technologies (Waldbronn)
centrifuge	Biofuge 13, Heraeus Instruments, 75003635/01 (Osterode)
	Biofuge fresco, Heraeus Instruments, 75005510, (Osterode)
	Biofuge pico, Heraeus Instruments, 75003280, (Osterode)
	Zentrifuge 5415 D, Eppendorf (Hamburg)
	Zentrifuge 5415 R, Eppendorf (Hamburg)
	Zentrifuge 5804, Eppendorf (Hamburg)
	Sigma 3K30 (Osterode)
cuvettes	Uvette, Eppendorf (Hamburg)
electrophoresis module	Standard Power Pack P25, Biometra (Göttingen)
embedding form	10mm x 20mm, Plano (Wetzlar)

**Material**

embedding slide	Histosette II tissue, Simport (Beloeil, Canada)
heating plate	hotplate magnetic stirrer, Cenco (Breda, Netherlands))
homogenisator	FastPrep FP 120 Bio 101 Systems, MP Biomedicals (Heidelberg)
homogenisator tubes with cap	Lysing Matrix D, Bio 101 Systems, MP Biomedicals (Heidelberg)
gel-chamber	Agagel Mini/Midi-Wide, Biometra (Göttingen)
microtiter plates	Nunc-Immuno-Platte Maxisorb F 96, Nunc Gmbh (Wiesbaden)
microtiter plate dispenser	Manifold-8-Changonel, SLT Labinstruments (Crailsheim)
microtiter plate washer	SLT 96.PW, SLT Labinstruments (Crailsheim)
microwave-oven	Panasonic NN 6275B (UK)
photometers	Biophotometer Eppendorf (Hamburg) Titrek-Multiscan, Typ 310 C, Flow Laboratories with SLT-Easy-Fit, SLT Labinstruments (Crailsheim)
pipettes	Abimed, Gilson (Frankreich) Eppendorf (Hamburg)
pipettetips	Diamond D10 tips, Gilson (Hamburg) Standardtips Eppendorf (Hamburg) Sarstedt (Hamburg)
reaction tubes	0.2ml micro-tube, Abgene (Epson, UK) 0.5ml Biozym 710912 (Oldendorf) 1.5ml; 2.0ml, Eppendorf (Hamburg) 5ml Sarsted-Röhrchen 55.525 (Nürnberg) 10ml Sarstedt-Röhrchen 26.323 (Nürnberg) 15ml Cell Star 188.271, Greiner (Frickenhausen) 50ml Cell Star 227.261, Greiner (Frickenhausen)
RNA nano chips	Agilent Technologies (Waldbronn)
rotor-gene 3000	Corbett Research (Australia)
scales	Sartorius MC 210 P (Göttingen) Sartorius 2001 MP2 (Göttingen)
shaker	Vortex-Genie 2 Bender & Hobein (München)
thermoblock	Thermomixer 5436, Eppendorf (Hamburg)
thermocycler	Mastercycler gradient, Eppendorf (Hamburg)
video-documentationsystem	Image Master JVDS, Pharmacia 80-6247-01 (Freiburg)
warming cupboard	Shinko MCS, Bachofer (Reutlingen)

### 3.2.6 Biochemicals

agarose	Amresco 710-50G (Ohio, USA)
bromphenolblue	Merck 8122 (Darmstadt)
BSA	Fraktion V, pH 5.2; Standard Grade, Serva, 11930 (Heidelberg)
butanol tert.	Roth (Karlsruhe)
buthyl methyl ether	Roth (Karlsruhe)
chloroform	Merck, 2445 (Darmstadt)
DEPC (diethylpyrocarbonat)	Aldrich 15.922-0 (Steinheim)
DMSO	Serva, 20385 (Heidelberg)
dNTP (each 25 µmol)	deoxynucleoside triphosphate set, R0182, Fermentas (St. Leon-Rot)
EDTA	Merck 8418 (Darmstadt)
ethanol (100%)	Merck (Darmstadt)
ethidiumbromid 1% solution	3.8-Diamino-5-Ethyl-6-Phenylphenanthridinium-Bromid (10mg/ml), Carl Roth GmbH + Co. KG (Karlsruhe)
formaldehyd (35%)	Merck, 1.04001 (Darmstadt)
formaldehyd (37%)	Merck, 1.04094 (Darmstadt)
glacial acetic acid (100%)	Merck, 1.00063 (Darmstadt)
HCL (5M)	Combi Titrisol, Merck (Darmstadt)
H <sub>2</sub> O <sub>2</sub> -urea	Merck, 818356 (Darmstadt)
H <sub>2</sub> SO <sub>4</sub>	Merck, 100731 (Darmstadt)
hexamere	Pharmacia 27-2166-01 (Freiburg)
iso-2-propanol	Merck, 9634 (Darmstadt)
Kathon	pH 5.0, Rohm & Haas Ltd., 62368 (U.K.)
methanol	Merck, 1.06009 (Darmstadt)
MgCl <sub>2</sub>	Merck (Darmstadt)
MOPS	Roth, 6979.2 (Karlsruhe)
NaCl	Merck (Darmstadt)
Na <sub>2</sub> CO <sub>3</sub> x 10 H <sub>2</sub> O	Merck, 6391(Darmstadt)
NaHCO <sub>3</sub>	Merck, 6329 (Darmstadt)
Na <sub>2</sub> HPO <sub>4</sub> x 2 H <sub>2</sub> O	Merck, 6580 (Darmstadt)
NaOH	Merck (Darmstadt)
paraffin	Vogel-Histo-Comp, Vogel (Gießen)
PCR- H <sub>2</sub> O	Sterile, deionized DEPC-H <sub>2</sub> O
PeqGold TriFast	Peq Lab (Erlangen)
petroleum ether	Scharlau (Barcelona, Spain)
picric acid	Merck, 1.00621 (Darmstadt)

---

RNA-H <sub>2</sub> O	Sterile, deionized DEPC-H <sub>2</sub> O
TMB	Boehringer, 784974 (Mannheim)
Tris(hydroxymethyl)-amionethan	Riedel-deHaën, 33742 (Seelze)
0,05% Tween-80	Sigma, P 1754 (Taufkirchen)
citric acid x 1 H <sub>2</sub> O	Merck, 244 (Darmstadt)

### 3.2.7 Reagents

coating buffer	4.29 g/l Na <sub>2</sub> CO <sub>3</sub> x 10 H <sub>2</sub> O 2.93 g/l NaHCO <sub>3</sub> pH 9.6
assay-buffer	7.12 g/l Na <sub>2</sub> HPO <sub>4</sub> x 2 H <sub>2</sub> O 8.5 g/l NaCl pH 7.2 1.0 g/l BSA (0.1%)
substrate solution A	1 g/l H <sub>2</sub> O <sub>2</sub> -urea 18 g/l Na <sub>2</sub> HPO <sub>4</sub> x 2 H <sub>2</sub> O 10.3 g citric acid x 1 H <sub>2</sub> O 0.1 ml Kathon pH 5.0 photosensitiv
substrate solution B	300 mg TMB (Tetramethylbenzidin) 40 ml DMSO (Dimethylsulfoxid) 960 ml H <sub>2</sub> O 10.3 g citric acid x 1 H <sub>2</sub> O pH 2.4 photosensitiv
progesterone antibody (rat)	Sigma, P1922 (Taufkirchen)
peroxidase-labeled progesterone	Sigma, P3659 (Taufkirchen)
unlabeled progesterone	Sigma, P 0130 (Taufkirchen)

### 3.2.8 Kits

DNA-digestion	DNA-free <sup>TM</sup> , Ambion (USA)
Light Cycler FastStart DNA Master SYBR Green I	Roche Diagnostic Gmbh (Mannheim)
RNA 6000 Nano reagents & supplies	Agilent Technologies (Waldbronn)
Wizard SV Gel and PCR Clean-Up System	Promega (Mannheim)

### 3.2.9 Enzymes

reverse transcriptase	Promega (Mannheim)
M-MLV RT Rnase H(-) Point Mutant	



taq-polymerase Roche (Mannheim)

### 3.2.10 Markers

100bp-sizemarker New England Biolabs 100bp DNA  
Ladder N3231S (Frankfurt)

### 3.2.11 Buffers and solutions

agarose-gel 1,5% 0.45g agarose  
30ml 1x TAE-buffer  
3µl Ethiduibromid-solution

Bouin's solution 375ml picric acid (saturated)  
125ml formaldehyd (37%)  
25ml glacial acetic acid

bromphenolblue/glycerin 15ml bromphenolblue solution  
85ml RNA-H<sub>2</sub>O  
100ml glycerin (pure)

DEPC-H<sub>2</sub>O 1ml DEPC in 1l H<sub>2</sub>O bidest, incubate 24h at  
4°, autoclave 20min at 121°C

dNTP-working solution 100µl dATP (100mM)  
100µl dCTP (100mM)  
100µl dGTP (100mM)  
100µl dTTP (100mM)  
600µl DEPC H<sub>2</sub>O

Formaldehyde-Loading Dye Ambion (USA)

Methanol - glacial acetic acid methanol : glacial acetic acid (2:1)

10x MOPS 0.2M MOPS  
50mM Natriumacetat  
10mM EDTA  
autoclave 20min at 121°

RNA-Gel 0.4g Agarose MP  
33.8ml Rnase free H<sub>2</sub>O  
4ml MOPS 10x konz.  
2.2ml formaldehyde 37%  
2µl ethiduibromid-solution

50x TAE-buffer 2M Tris(hydroxymethyl)-amiomethan

	1M acetic acid
	90mM EDTA
Tris-buffer	50mM Tris, pH 8.0 adjust with HCL

### 3.2.12 Primersequences and polymerase chain reaction (PCR) products

Forward (for) and reverse (rev) primers were designed either by colleges of the institut or by myself or taken out of literature and produced by MWG-Biotech AG (Ebersberg).

primer 5'-----3'	reference/ Acc. No	length of PCR-product [bp]
<b>Housekeeping Genes</b>		
<b>β-Actin</b> for AACTCCATCATGAAGTGTGACG rev GATCCACATCTGCTGGAAGG	NM_001033618	233
<b>GAPDH</b> for GTCTTCACTACCATGGAGAAGG rev TCATGGATGACCTTGGCCAG	U85042 U94889	197
<b>Histone</b> for ACTGCTACAAAAGCCGCTC rev ACTTGCCTCCTGCAAAGCAC	AF469469	233
<b>Ubiquitin</b> for AGATCCAGGATAAGGAAGGCAT rev GCTCCACCTCCAGGGTGAT	Z18245	198
<b>Matrixmetalloproteases</b>		
<b>MMP-1</b> for GAGGAGACGCTCATTTTGATG rev ACTGGCTGAGTGGGATTTTG	AF134714	235

<b>MMP-2</b> for CCCAGACAGTGGATGATGC rev TTGTCCTTCTCCCAGGGTC	NM_174745	248
<b>MMP-9</b> for GACCAGGACAAGCTCTACGG rev CAGAAGCCCCACTTCTTGTC	NM_174744	203
<b>MMP-14</b> for ACTTGAAGGGGGACACC rev AGGGGGCATCTTAGTGGG	AF144758	236
<b>MMP-19</b> for TTTCAAGGGGGACTATGTGTG rev CAATAGAGAGCTGCATCCAGG	X92521	240
<b>TIMP-1</b> for CATCTACACCCCTGCCATG rev CAGGGGATGGATGAGCAG	AF144763	231
<b>TIMP-2</b> for GGGTCTCGCTGGACATTG rev TTGATGTTCTTCTCCGTGACC	AF144764	256
<b>Plasminogen activator system</b>		
<b>tPA</b> for GGGGAAGCACAACCACTG rev AGCTGATCAGGATCCCCC	X85800	263
<b>uPA</b> for TGCAGCCATCTACAGGAGG rev TGGTGAGCAAGGCTCTCC	X85801	240
<b>uPAR</b> for TGTTTCCAGAAACCGCTACC rev AAGTGAAGGTGTGGTTGTTG	S70635	234
<b>PAI-1</b> for CAGCGACTTACTTGGTGAAGG rev TCCAGGATGTCGTAGTAACGG	BC103451	231

<b>PAI-2</b> for TACGGGCTTGGAGATGCTAG rev GGTCATTCTTTCCCGACATG	AF416234	218
<b>Monocytes chemoattractant proteins</b>		
<b>MCP-1</b> for CTCACAGTAGCTGCCTTCAGC rev GCTTGGGGTCTGCACATAAC	L32659	205
<b>Apoptotic- and anti-apoptotic factors</b>		
<b>Bax</b> for TCTGACGGCAACTTCAACTG rev AAGTAGGAGAGGAGGCCGTC	L22473 U92569	194
<b>BCL-X<sub>L</sub></b> for GGCATTCAGCGACCTGAC revCCATCCAAGTTGCGATCC	AF245487	203
<b>Caspase3</b> for AACCTCCGTGGATTCAAATC rev TTCAGGRTAATCCATTTTGTAAAC	NM-214131 NM-012922	114
<b>Caspase6</b> for TGTTCAAAGGAGACAAGTGTCAG rev CAGAGTAGCACATGAGGAAGTC	(Sakumoto <i>et al.</i> 2000)	206
<b>Caspase7</b> for CTCTTCAAGTGCTTCRAARC rev TTCTCTARCAGGGTTTTGCATC	NM-033338 AF072124	241
<b>Fas</b> for AGAAGGGAAGGAGTACAYMGA rev TGCACTTGTATTCTGGGTCC	NM-000043 NM-007987	124
<b>FasL</b> for CATCTTTGGAGAAGCAAATAG rev GGAATACACAAAATACAGCCC	X89102	205

<b>p53</b> for CATGACGGAGGTTGTGAGG rev TGGTGCACCTCAGAGTCGATC	NM_174201	191
<b>Smac</b> for AGGAAGATGAGGTGTGGCAG rev AACTGGATGTGATTCCTGGC	AF203914	184
<b>Survivin</b> for AGCTCTACCTCAAGGACCACC rev CTTCTATGGGGTCGTCATCTG	AY606044	195
<b>TNF<math>\alpha</math></b> for TAACAAGCCGGTAGCCCACG rev GCAAGGGCTCTTGATGGCAGA	AF011926	277
<b>TNFR1</b> for CACCACCACCATCTGCTT rev TCTGAACTGGGGTGCAGA	(Sakumoto <i>et al.</i> 2000)	257
<b>TNFR2</b> for AGCAGCACGGACAAGAGG rev CTGTGTCCCTCGTGGAGC	AF031589	220

Since there were no sequence information about cow in this specific gene regions, the author designed multispecies primers fitting for either human, rat or mouse.

Abbreviations in the primer sequences:

r = a or g

y = c or t

m = a or c

## 4 Methods

### 4.1 Development of a method to gain uterus milk *in vivo*

Investigations during the preimplantation period of pregnancy is a difficult undertaking in the bovine species. To gain specific samples like uterus tissue, concepti or uterus milk, pregnant cows are slaughtered at certain time points after artificial insemination. Nowadays exists a national attempt to reduce the number of animals being dispatched in animal experiments. Therefore I attempted to develop an *in vivo* method, which enables me to take uterus milk samples and embryos at specific time points after artificial insemination without slaughtering the cows. Also this would give the possibility to reduce the number of animals being used for experiments. I also wanted to investigate if it was possible able to detect progesterone, oestradiol-17 $\beta$ , PGF2 $\alpha$  and VEGF in the gained uterus milk.

#### Experimental setup

Nine about two years old Brown Swiss heifers were taken as experimental animals (Az: 209.1/211-2531.3-13/04). They were cycle synchronised using the OvSynch method followed by a double artificial insemination. Blood plasma samples were taken from the first day of the synchronisation till day 33 of gravidity for the measurement of progesterone. Within the first 24 days of gravidity the ipsilateral and contralateral uterus horn were flushed each five times with 13ml sterile 0.9% NaCl using a disposable sterile balloon embryo transfer catheter. The catheter was placed 1cm cranial of the bifurcation uteri in both horns. The flushing fluid of the ipsilateral horn was inspected for an embryo under the microscope. Viable embryos would have been separated from the fluid and frozen in a specific RNA-Later at  $-80^{\circ}$ . After that a prostaglandin stabilisator (200 $\mu$ l /10ml) was given to the regained flushing fluid of both horns, which was aliquoted and frozen at  $-20^{\circ}$ .

➤ *OvSynch synchronisation of nine Brown Swiss heifers*

day 0: each 3.5ml Receptal i.m.

day 7: each 2.5ml Estrumat i.m.

day 9: each 3.5ml Receptal i.m. plus first artificial insemination

day 10: second artificial insemination

➤ *Blood withdrawal from the vena jugularis via EDTA-Vacurette:*

During the first 24 days, blood samples were taken every second day. From day 26 till day 33 blood samples were taken daily to see if the heifers were still ipsilateral. The blood was centrifugated for 15min at 2000g and 4°. The gained blood plasma was aliquoted and frozen at –20°.

➤ *Uterus flushing of the ipsilateral and contralateral horn via disposable balloon embryo catheter:*

▪ Time points:

day 5 of gravidity

day 7

day 12

day 17

day 24

▪ Epiduralanaesthesia:

An about 10cm x 15cm large area was shaved at the sacrococcygeal region and disinfected with ethanol 70%. 5ml Procasel 2% was injected into the epidural space between the last sacral and the first tail vertebra.

▪ Ipsi- and contralateral uterus horn:

Both ovaries were transrectally palpated. The uterus horn belonging to the CL bearing ovary was referred to as ipsilateral horn. The other uterus horn was designated as contralateral horn. Dry cleaning of the vulva area and disinfection with ethanol 70% followed.

▪ Flushing:

A sterile embryo catheter was rinsed thoroughly with 3ml of sterile 0.9% NaCl and strengthened with a steel mandrin. After spreading of the labiae vulvae the catheter was brought in to the vagina under rectal control. Passing the cervix it was first placed in the contralateral horn 1cm cranial the bifurcatio uteri. The

balloon was inflated with 10ml air to seal the uterus horn from caudal. The mandrin was removed from the catheter. 13ml of sterile 0.9% NaCl was injected into the catheter using a sterile 20ml syringe. The uterus horn was massaged gently and an aspiration of the injected fluid followed. For flushing the ipsilateral horn in the same way, the balloon was deflated, the catheter removed from the vagina, reinforced with the mandrin and placed into the ipsilateral horn. The flushing was done as described above. 200 $\mu$ l of stabiliser per 10ml was given to the gained fluid. The samples of the contralateral horn were kept in falcon tubes on ice, the samples of the ipsilateral horn were collected in culture plates on ice. This procedure was kept for all nine heifers. A new catheter was used for each heifer, the mandrin was disinfected with ethanol 70% before each use.

- Microscopical inspection of the ipsilateral horn flushing fluid:

From day 7 on all gained flushing fluids from the ipsilateral horns were inspected under the microscope for embryos. A migration of the embryo during the preimplantation period into the contralateral horn is very seldom (Rüsse and Sinowatz 1991b), so that the flushing fluids from these horns were not inspected. Located embryos were characterised according to the developing stage and viability. Afterwards they were removed from the flushing fluid and viable ones were kept in RNA-Later and frozen at  $-80^{\circ}$ . The flushing fluid was pipetted into a falcon tube and kept on ice.

- Aliquotation:

All samples were aliquoted and frozen at  $-20^{\circ}$ .

### 4.1.1 Enzyme immuno assay (EIA) of progesterone, oestradiol-17 $\beta$ and PGF2 $\alpha$

The frozen flushing fluid samples of both horns were defrosted at  $37^{\circ}$  in a water bath. Progesterone, oestradiol-17 $\beta$  and PGF2 $\alpha$  concentration were measured using an EIA with second antibody technique (Prakash *et al.* 1987; Meyer *et al.* 1990; Meyer *et al.* 1989).



**Coating of the microtiter plates:**

Firstly the microtiter plates were coated with sheep anti-rabbit IgG (100µl/well), which was diluted in coating buffer (1µg IgG /100µl) followed by an overnight incubation at 1°C. After the incubation the coating buffer was tipped over and 250µl of a BSA containing assay buffer was given on the wells. BSA is supposed to block unspecific bindings sites on the surface of the wells. The plates were put on a shaker and incubated for 15-30 minutes at room temperature. After tilting the buffer the plates were washed twice in Tween-80 0.05% and beaten well.

**Test procedure:**

For each measurement a standard curve was established using unmarked progesterone, oestradiol-17β or PGF<sub>2α</sub>. The concentration ranged for progesterone from 0.05 to 25ng/ml, for oestradiol-17β from 0.1 to 50pg/50µl and for PGF<sub>2α</sub> from 60 to 70000pg/ml. A dilution of 1:20000 was produced with horseradish peroxidase (HRP) conjugated progesterone, 1:12000 for oestradiol-17β and 1:50000 for PGF<sub>2α</sub> (progesteron-6β-hydroxyhemisuccinat-HRP, oestradiol-6-carboxy-methyl-oxim-HRP and PGF<sub>2α</sub>-Tris-HRP). Rabbit anti-progesterone, anti-oestradiol-17β and anti-PGF<sub>2α</sub> (antibody against progesterone-7α-carboxyethylthioether-BSA, 6-Keto-17β-oestradiol-6-carboxymethyloxim-BSA and PGF<sub>2α</sub>) were diluted like following: 1:150000, 1:400000 and 1:40000.

20µl of undiluted sample or standard were pipetted in each well. Afterwards 100µl with horseradish peroxidase marked progesterone, oestradiol-17β or PGF<sub>2α</sub> and 100µl of the second antibody are given to each well. The unmarked protein of the sample and standard respectively competes against the enzyme marked protein for free binding sites on the first antibody. To estimate unspecific bindings assay buffer without anti-progesterone, anti-oestradiol-17β or anti-PGF<sub>2α</sub> was taken instead of the sample. The microtiter plates are incubated over night in the dark at 4°, slightly shaking. In the morning they were tilted and washed four times with 400µl Tween-80 0.05% for each well. For starting the colouring 11ml of substrate A and B were mixed together and 150µl per each well was given on the plates. After a incubation at 37° for 40min in the dark the colouring was stopped with 50µl of 4N H<sub>2</sub>SO<sub>4</sub> per each well.

**Analysis:**

The extinction of the colouring was measured at 450nm by a photometer and analysed by a specific computer programm (SLT-Easy-Fit, SLT, Crailsheim). The more the samples contain of progesterone, oestradiol-17β or PGF<sub>2α</sub> the lower is the extinction. The ED<sub>50</sub> for

progesterone was 6 ng/ml, for oestradiol-17 $\beta$  3.5 pg/ml and for PGF2 $\alpha$  245pg/ml. The intra-assay variance was 4-5% for progesterone, 6-7% for oestradiol-17 $\beta$  and 7% for PGF2 $\alpha$ . The inter-assay variance rest with 8-9% for progesterone, 9-10% for oestradiol-17 $\beta$  and 13% for PGF2 $\alpha$ .

#### **4.1.2 Radio immuno assay (RIA) of VEGF**

VEGF protein was measured using a RIA according to the method described by Berisha et al. (2000).

### **4.2 Expression of housekeeping genes, proteases, apoptotic and anti-apoptotic factors in the CL during oestrous cycle and induced luteolysis**

#### **4.2.1 Transvaginal ovariectomy**

The perianal regions of the cows were shaved, cleaned and disinfected. The cows were sedated each with 0.8ml Rompun i.v. An epidural anaesthesia was given with 6ml Procasel 2%. The vagina was flushed and disinfected with 1L of Vet-Sept solution. Pulling the cervix caudal with a cervix clamp a crest of the vaginal mucosa was created on the dorsal part of the vagina. An about 3cm large hole was cut into this crest with a Hühne knife. Either the ovary bearing the CL was pulled through this hole and clipped with the effeminator or it was cut off in the abdominal cavity. The stumps of the ovary vessels were compressed for further four minutes with the effeminator to minimise the bleeding risk. The hole in the vagina was closed with 2-3 stitches using an absorbable suture material and the ligature carrier by Deschamps. Several swamps were saturated with Procillin and left in the vagina for two days to prevent an infection of the wound. Furthermore a systemic antibioticum (30ml Cobactan 2.5%) and 40ml Vetalgin were given.

#### **4.2.2 Immunohistochemistry**

##### **4.2.2.1 Fixation and Paraffin embedding**

The CLs were cut in slices and labeled. One part was fixated in Bouin's solution, the other part in methanol-glacial acetic acid according to the following time table:

- 12h in Bouin's solution or methanol-glacial acetic acid, slightly swivelling

- Dehydration, 2h for each step:
  - ethanol 70%, 90%, 96% and 100%
  - ethanol 100%: tertiary butanol (1:1)
  - tertiary butanol at 40°

After dehydration the CL slices were kept for 12h in liquid paraffin at 60° in the warming cuboard. Afterwards the slices were embedded in paraffin. Therefore the slices were placed in specific embedding forms and covered with hot liquid paraffin. The cooling process was slowed down by touching the wax surface with a hot metal loop, so that wax block cooled down constantly. At the end an embedding slide was placed on the still hot surface and the block was given into crashed ice to cool down totally. The completed paraffin blocks are stored at 4°.

### **4.2.3 Molecular techniques**

#### **4.2.3.1 Enzyme immuno assay (EIA)**

To be sure that all five cows were synchronised properly and that all of them had developed a mature CL, an analysis of the progesterone level was made by an enzyme-immunoassay (EIA) (Prakash *et al.* 1987). The EIA was performed as described in chapter 4.1.1. As it was necessary to have a shorter incubation time, a goat anti-rat IgG and a rat anti-progesterone was used. The incubation time for the competition of the enzyme labeled progesterone and the samples changed to 2h in the dark at 20° and for the substrate reaction to 20min at 20° in the dark.

#### **4.2.3.2 RNA extraction**

RNA with its short half-life is quickly degraded by ubiquitous ribonucleases (RNases). This enzymes are found on all surfaces, especially on hands. Thus, in order to prevent degradation, RNA has to be stored at -80°C where RNase activity is reduced to a minimum.

Handling RNA samples induces the use of one-way gloves, autoclaved materials and RNase-free DEPC-water. RNA of CL tissues was extracted with Peq Gold RNAPure. For 100mg tissue 1ml Peq Gold was given into a FastPrep tube filled with 1g inert beads. The small tissue-samples itself were extracted through cutting pieces of the big tissue under -

25°C and inserting them as fast as possible into the provided tubes. Subsequently, samples are homogenised in the FastPrep FP120 with 6.5m/s and 45sec for two times and afterwards incubated at room temperature for five minutes. After addition of 200µl chloroform the mixture was vortexed for 10 seconds and incubated yet another 10 minutes. Through the following centrifugation (15min) with 12000rpm at 4°C the upper phase containing water and RNA is separated from the phenolphase. The upper phase is then collected and the same volume of isopropanol is added in order to precipitate RNA. The tube was inverted several times and incubated at room temperature for 10 minutes. After a 10min centrifugation (4°C, 12000rpm) the solution is discarded and the pellet washed two times with 500µl 75% ethanol. Following, the pellet is dried for 10min at 37°C to completely evaporate remaining alcohol. The dry pellet is then resuspended in 50µl RNA-H<sub>2</sub>O and incubated at 55°C for 5min in order to ensure complete and homogenic solvation. The extracted RNA-solutions are finally stored at -80°C until further usage.

#### 4.2.3.3 DNA digestion

Because of the lack of DNA digestion during the RNA extraction, DNA attendance is quite possible. The disposed DNA-free kit is designed to remove contaminating DNA from RNA preparations and to subsequently remove the DNase and divalent cations from samples. The protocol of this method allows a removal of trace to moderate amounts of contaminating DNA (up to 50µg DNA/ml RNA) from purified RNA to a level that is mathematically insignificant by RT-PCR. At first, 0.1 volume 10x DNase buffer and 1µl rDNase are added to the RNA, the sample is mixed gently and incubated at 37°C for half an hour. Afterwards, 0.1 volume DNase inactivation reagent is added and again mixed well. During adjacent incubation at room temperature for about 2 minutes, it is important to mix the contents well in order to redisperse the DNase inactivation reagent. Finally, the sample is centrifuged at 10000g for 1,5min. The supernatant, which contains the RNA, is then added into a fresh tube, the pelleted inactivation reagent is discarded for it would disturb further enzymatic reactions.

#### 4.2.3.4 Control of the RNA quantity and quality

##### 4.2.3.4.1 Quantity

Quantification of the total RNA concentration is done photometric at a wavelength of 260nm, which is the absorption maximum of nuclein acids. In order to fit the measurement range, all samples have to be diluted to absorption levels of  $0.05 < A_{260} < 0.8$ .

Simultaneously, the absorption of aromatic amino acids in proteins at a wavelength of 280nm is measured in order to achieve the quality of the samples. Ratio of  $A_{260}/A_{280}$  should be at least 1.6 (measurement against water). A third measurement at 230nm furthermore identifies possible sample contaminations with salts or phenol residues. All samples are measured three times and muddled in order to retain precise values and minimise calculation errors. Additionally, the photometer is leveled to the blank value (water) before each measurement in order to ensure unique circumstances and thus allows a comparison of all samples.

#### 4.2.3.4.2 Quality

##### RNA-gel

Denaturing RNA-agarose-gel electrophoresis is used in order to determine RNA quality. The 1% agarose gel contains ethidium bromide, 10x MOPS buffer and formaldehyde and is left to polymerise in a gel chamber that had previously been incubated for 20min with 0.1M NaOH to inactivate RNases. One volume RNA sample (containing 1µg RNA) is mixed with two volumes of 1x Formaldehyde Loading dye, denatured for 5min at 95°C and then placed on ice immediately. Afterwards, the gel is applied into the running chamber (filled with 1x MOPS as running buffer) and loaded with the samples. Electrophoresis is conducted for 1.5 hours at 30 volts. After the run, the quality of the RNA is evaluated under UV-light: The 28S rRNA and 18S rRNA have to be visible as defined, clearly marked bands (fig. 4). Smear of the same intensity throughout the covered distance in the gel represents degraded RNA pieces of all lengths, remaining nucleic acids in the gel bags are contaminating DNA.




Figure 4: RNA agarose gel 1% with 1 $\mu$ g RNA per pocket (CL induced luteolysis samples)

### Bioanalyzer

The bioanalyzer provides a framework for the standardisation of ribonucleic acid (RNA) quality control. Therefore RNA samples are electrophoretically separated on a microfabricated chip and subsequently detected with laser induced fluorescence detection. Each chip contains an interconnected set of microchannels that is used for separation of nucleic acid fragments based on their size as they are driven through it electrophoretically. An electropherogram and a gel like image are generated by the bioanalyzer software and results such as sample concentration and the so-called ribosomal ratio are displayed. The RNA 6000 ladder standard is used as a reference for data analysis. It contains six RNA fragments with following sizes: 0.2 kb, 0.5 kb, 1.0 kb, 2.0 kb, 4.0 kb and 6.0 kb. The software compares the unknown samples to the ladder fragments to determine the concentration and to identify the ribosomal RNA peaks of the unknown sample (Bioanalyzer Service). Major features of a successful ladder run are: six RNA peaks and one marker peak. The Bioanalyzer electropherogram of total RNA shows two distinct ribosomal peaks corresponding to either 18S and 28S for eucaryotic RNA and a relatively flat baseline between the 5S and 18S ribosomal peaks. Major features for a successful total RNA run are: two ribosomal peaks and one marker peak, the baseline between 27 seconds and the 18S rRNA is relatively flat as well as free of small rounded peaks corresponding to smaller molecules.

The electropherogram provides a detailed visual assessment of the quality of a RNA sample. The RNA Integrity Number (RIN) software algorithm allows for the classification of eucaryotic total RNA, based on a numbering system from 1 to 10, with 1 being the most degraded profile and 10 being the most intact (Mueller O *et al.* 2004). Figure 5 shows an example for two different RNA qualities. A further quality-indicator is the ratio of 28S rRNA

amount to 18S rRNA (this is provided through the area under the correlating peaks), which should be 2 at its best.

The measurement preparation starts out with the application of 9µl dye-gel into the lading-well, which is then pressed into the chip channels using the loading-station. As a pool, two more wells are filled with dye-gel furthermore. Following, 1µl RNA-sample and 5µl marker are pipetted into one sample-well respectively and 1µl ladder with 5µl marker into the ladder-well. The loaded chip afterwards is vortexed for one minute and then applied into the bioanalyzer.




Figure 5: Two electropherograms; FU = fluorescence, S = second, first peak = marker, peak at 25s = 5S rRNA, peak at 40s = 18S rRNA, peak at 47s = 28S rRNA, RIN value of sample 11 = 10,0, RIN value of sample 2 = 7,5

#### 4.2.3.5 Reverse transcription

To be able to use extracted mRNA for PCR based expression studies a reverse transcription (RT) reaction is performed with the total RNA of each sample. In this reaction the enzyme reverse transcriptase generates double stranded complementary DNA (cDNA) from single stranded RNA. In an optimal reaction one molecule cDNA is produced for each molecule mRNA, rRNA and tRNA. To enable the RT reaction the enzyme has to be in a correctly buffered solution and supplied with random primers and dNTPs. As preparation for the RT, 1µg total RNA are diluted in 41µl Rnase-free water then heated for 5min with 65°C and immediatly put on ice. This provides the linearisation of the RNA (i.e. no secondary structures) needed for the further transcription process. Following, 19µl mastermix (tab. 2) were added to each reaction.

	1x volume [ $\mu$ l] for RT	1x volume [ $\mu$ l] for neg. RT
5x first strand buffer	12	12
10mM dNTPs	3	3
50 $\mu$ M hexamere	3	3
M-MLV RT Rnase H(-) Point Mutant	1	-

Table 2: RT-mastermixes

To acquire a control for following PCR-steps, which should grant the absence of genomic DNA in the samples, one so called negative RT sample completes the procedure: A pool of all samples is generated and 1 $\mu$ g total RNA of this pool then diluted (the same way than all other samples). This neg. RT is added with a mastermix of 19 $\mu$ l (tab.2) in which the enzyme is displaced by an equal amount of RNase-free H<sub>2</sub>O.

The RT programm starts out with the incubation of all samples 10min at 21°C in order to have an optimised primer annealing, and continues with 48min at 48°C for the RT reaction. At the end of the process, the enzyme is inactivated and RNA templates are disrupted through a heating step of 2min at 90°C. The resulting cDNA is stored at -20°C.

#### 4.2.3.6 Polymerase chain reaction (PCR) methods

##### 4.2.3.6.1 *Block PCR*

Conventional block PCR is a method used to specifically amplify target genes or gene fragments. Short sequences flanking the sequence of interest on both sides are known to be able to design gene specific primers. These should be complementary to sequences located at the 5' and 3' end of the target and about 20 base pairs in length. Both primers take advantage of similar melting points (determined by the GC-content), which should be around 60°C, because of the PCR-reaction being temperature controlled.

Amplification of a target is conducted by a thermo stable DNA polymerase and includes the following three steps. Successive completion of these three steps is called a cycle.

Denaturation: At the beginning of each cycle the DNA is denatured at a high temperature to separate the double stranded (ds) DNA. The first cycle of the PCR starts with a long denaturation step to ensure that both strands of the template DNA are completely



separated.

Annealing: After denaturation the reaction is cooled down in order to enable primers to anneal to the complementary sequences of the template DNA. The annealing temperature is primer specific and has to be optimized for each PCR product.

Elongation: At the optimal temperature for the polymerase (usually at around 72°C), the enzyme can bind to the single stranded DNA and synthesise a new strand that is complementary to the template strand. Thus, a dsDNA is generated from each original strand and functions throughout the next cycle as an additional template.

This semi-conservative replication method leads to an exponential amplification of the target sequence. An optimal reaction results after n cycles in  $2^n$  dsDNA strands. Mastermix components of conventional PCR and general parameters are shown in table 3 and table 4.

substance	1x volume [ $\mu$ l]
PCR-H <sub>2</sub> O	18.9
10x buffer	2.5
dNTP's	0.5
forward primer	0.5
reverse primer	0.5
taq-polymerase	0.1
template DNA	1.5

Table 3: Master mix for conventional PCR

step	temperature [°C]	time [s]	cycles
denaturation	94	120	1
denaturation	94	45	depending on primer
annealing	depending on primer	45	
elongation	72	45	
elongation	72	120	1
hold	5	not limited	

Table 4: PCR-parameters

#### 4.2.3.6.2 Gradient PCR:

Gradient PCR includes the same steps as conventional block PCR, but is conducted in special cyclers that allow different temperature profiles to be programmed for each cavity in the cycler. This method can be used to optimize PCR conditions with respect to the primer annealing temperature. A PCR is done with several replicates of the same sample. All samples are treated equally, only the annealing temperature is changed. In an agarose gel (see below) the PCR efficiency can then be analysed investigating intensity and integrity of the product bands.

#### 4.2.3.6.3 Quantitativ real time PCR (qPCR)

New PCR-platforms, such as Rotor-Gene or Light-Cycler, and modern dyeing and detection systems allow visualisation of PCR reaction in real time and quantification of the DNA amount originally in a sample tube. The fluorescence dye used with the Rotor-Gene is SYBR-GREEN I, it intercalates with the minor groove of dsDNA and emits light at 530nm when excited at 497nm. Due to DNA amplification by polymerase, the amount of dsDNA doubles with each cycle, resulting in more and more intense signals (measured at the end of the elongation step). This event can be monitored for each sample with analysing software even while the PCR is still in progress. This advantage gives the possibility to continue PCR reaction over the exponential phase (in contrast to conventional PCR). Figure 6 displays a characteristic amplification curve calculated by the Rotor-Gene software V5.0, which can be divided into four phases. Phase 1 is described by an exponential amplification and the fluorescence signal below background correction, phase 2 is the exponential amplification phase, phase 3 the linear amplification phase

where the PCR loses efficiency and phase 4 the plateau phase which is limited by inhibition or lack of chemicals (Pfaffl M.W. 2005).




Figure 6: Fluorescence data of a real time RT-PCR

The Rotor-Gene offers as another feature, the determination of the melting point. After amplification the samples are heated from 60°C to 99°C to separate the two DNA strand of the PCR-product, which results in a loss of fluorescence. During this heating process the fluorescence signal is measured continuously to generate a melt curve. This results in a curve that shows a sudden drop in signal intensity at the melting temperature for each amplicon, which can also be displayed as a peak (fig. 7). This melting point is depending on the guanin- and cytosin bases in the PCR-product (GC content) and on the product length. After an initial product size verification in an agarose gel, this graph can be used to check if the right product was amplified or if unspecific product information occurred.




Figure 7: Melt curve analysis calculated by the Rotor-Gene Analysis Software V5.0

Table 5 shows the parameters used for qPCR experiments. Annealing temperatures are primer specific. The optimal annealing temperatures have been determined preliminary using the gradient PCR and were further optimised for the qPCR (fig. 7).

	temperature [°C]	time [s]	cycles
denaturation	95	600	1
denaturation	95	10	40-45, product specific
annealing	primer specific	10	
elongation	72	15	
melt	60-99	0.5°/sec	1
hold	40	not limited	1

Table 5: qPCR parameters

Duration of the single steps is decreased comparing to conventional PCR. This is effected through the minimized reaction volume of 10 $\mu$ l and the effective heating and cooling system which allows quick acquiring of target temperatures. Since the method being extremely sensitive, 9 $\mu$ l master mix are added to only 1 $\mu$ l template cDNA. Contents of qPCR master-mix are listed in table 6.

	1x volume [ $\mu$ l]
cDNA	1
PCR-H <sub>2</sub> O	6.4
MgCl <sub>2</sub> 3mM	1.2
forward primer	0.2
reverse primer	0.2
LCM (including SYBR-GREEN)	1

Table 6: qPCR master mix

Primer	annealing temperature [°C]	melting temperature [°C]
$\beta$ -Actin	63	91.3-91.5
Histone	60	88.7-89.4
GAPDH	60	89.9-90.3
Ubiquitin	60	90.2-91.6
MMP-1	60	87.8-88.5
MMP-2	60	90.4-90.8
MMP-9	60	93.6-94.0
MMP-14	60	91.3-91.4
MMP-19	60	88.8-89.0
TIMP-1	60	89.9-90.2
TIMP-2	60	90.1-90.3
tPA	60	93.5-93.7
uPA	60	89.5-89.9
uPAR	60	90.4-90.8
PAI-1	60	90.3-90.5
PAI-2	60	86.0-86.1
MCP-1	60	88.4-88.9
Fas	60	83.4-84.0
FasL	60	86.5-87.0
TNF $\alpha$	66	92.2-92.6
TNFR1	68	95.59-95.8
TNFR2	60	94.5-94.7
p53	62	89.8-90.1

Bax	62	91.8-92.0
BCL-X <sub>L</sub>	60	89.4-90.0
Smac/Diablo	60	88.5-88.7
Survivin	60	92.5-92.8
Caspase3	60	80.4-80.9
Caspase6	60	91.3-91.8
Caspase7	60	85.4-86.1

Table 7: Product-specific annealing and melting temperatures of the examined factors for qPCR

The tubes for Rotor-Gene qPCR are closed after Mastermix and DNA sample have been added and put into the rotor-chamber, the program given above is started. After the run has ended, crossing point (CP) values were acquired by using the “comparative quantitation” method of the Rotor-Gene Analysis Software V5.0. The CP is a value for the target cDNA/mRNA content of the sample. Since the increase in fluorescence is due to increase in DNA, a sample initially containing more DNA subsequently reaches fluorescence above background earlier (and thus has a lower CP value) than a sample containing less DNA. Theoretically the amplification rate for the PCR product in each cycle is 2. But, with the reaction conditions being dependend on the investigated tissue and primers, the amplification is seldom optimal. Therefore the efficiency of each run is acquired using a standard curve. It is calculated via the inclination of the standard curve according to the following formula (Rasmussen R 2001):

$$E = 10^{[-1/\text{Steigung}]}$$

For the standard curve the cDNA was diluted to the following concentration: 33, 6, 1, 0.2 and 0.05ng/μl. A standard curve was established for each primerpair. An example is given in figure 8 and 9.




Figure 8: An example of a sigmoid amplification curve using a dilution series of TIMP-1; dilution concentrations from left to right: 33, 6, 1, 0.2 and 0.05 ng/ $\mu$ l cDNA; the CP value of each amplification curve is calculated where the threshold crosses the curves.




Figure 9: Determination of the slope of a dilution series for calculation of the PCR-efficiency of TIMP-1.

#### 4.2.3.7 Primer design and optimization

New primers were designed using the HUSAR software (DKFZ, Heidelberg). For the optimal primer pair design the following parameters were considered: length of the PCR-product about 180-250 bp, primer length 18-24 bp, GC content 40-55%, similar melting temperature of the forward and reverse primer, no annealing between both primers, no

primer self-annealing. For the design of multi species primer a homolog region of the coding sequence (CDS) of different species was taken. The primers were first optimised by block PCR using a gradient cycler. Afterwards the primers were tested by real time PCR and adjusted further if necessary.

#### 4.2.3.8 Analysis of the PCR-product

For established primer pairs the PCR-product was identified by the characteristic melting point and by the specific product length in an agarose gel. The melting curve should show only one melting point and the agarose gel only one band. For new primers the PCR-product was furthermore extracted by a DNA extraction kit using a filter column and several washing steps ( Manual of the Wizard SV Gel and PCR Clean-Up System, Promega (Mannheim)) and sent for sequencing (Medigenomix GmbH (Martinsried)). The received cDNA sequence was compared with the bovine sequence in the EMBL database using BLAST software ([www.ncbi.nlm.nih.gov/BLAST/](http://www.ncbi.nlm.nih.gov/BLAST/)). If the primers were not made of a bovine sequence the gained sequence was compared with the sequence the primers were made of. The resulting new bovine sequence was published in the EMBL database.

#### 4.2.4 **Data processing**

To make sure that different CP values are only caused by different amounts of total RNA and that not other factors are able to distinguish samples from each other, four HKGs were used as a reference. HKGs are genes supposed to be not regulated in tissue, this might be genes of nuclein acid synthesis like GAPDH as an example of glycolysis or structure proteins like Histone. In this experiment Ubiquitin, Histone, GAPDH and  $\beta$ -Actin were chosen as reference HKGs. An index was calculated using the CPs of all four housekeeping genes using the Bestkeeper software (Pfaffl *et al.* 2004). With these index a normalisation of the retained qPCR CP-values was done by the  $\Delta\Delta$ CP methode (Livak and Schmittgen 2001) using the following formula:

$$\Delta\Delta\text{CP} = (\text{CP}_t - \text{CP}_i)_{\text{Control}} - (\text{CP}_t - \text{CP}_i)_{\text{Time x}}$$

(t: target gene; i: bestkeeper index )



---

The CI luteolysis group 0.5h after PGF<sub>2</sub> $\alpha$  injection was only investigated when the group 2h showed a significant difference to the control. The statistical analysis of the data was done with the software "SIGMA STAT 3.0" after normalisation. For calculation of significances, the "one-way ANOVA" was disposed. If data reveal normal distribution, significances have been acquired through multiple comparison with the "Holm-Sidak"-test method. Differences are estimated significant, if the significance level P is  $\leq 0.05$ . All datas are shown as mean values  $\pm$  standard error of means (SEM). The expression x-fold is equal to  $2^{\Delta\Delta CP}$ .

## 5 Results

### 5.1 Development of a method to gain uterus milk *in vivo*

#### 5.1.1 Flushing of the uterus horns

The amount of regained flushing fluid ranged between 3ml and 13ml. As can be seen in the following table 8, the flushing was sometimes not possible in two heifers, because the cervix was too narrow. On day 7 of gravidity we were able to gain one embryo, which was already dead since three days. Several flushing fluids were contaminated with sanies at different time points. All heifers having an endometritis, except one, which showed signs of oestrus and slight inflammation. Heifers were treated with 40ml Genta-Sleecol 5 i.v. From day 17 to day 24 all nine heifers were in oestrus.

Heifer	day 5	day 7	day 12	day 17	day24
1	NAD	NAD	NAD	S, G	NAD
2	NAD	embryo †	NAD	S, O	NAD
3	NAD	NAD	NAD	S, G	NAD
4	NAD	NAD	NAD	S, G	NAD
5	NAD	NAD	NAD	O	NAD
6	NAD	missing	S	missing, G	NAD
7	NAD	missing	S	S, G	NAD
8	NAD	NAD	NAD	S	S, G
9	NAD	NAD	S	S, G	NAD

Table 8: Schedule of flushings and special features; NAD= no abnormality detected; missing= flushing was not possible; S= sanies; G= Genta-Sleecol 5; O= oestrous

#### 5.1.2 Progesterone analysis

##### 5.1.2.1 Blood plasma:

The progesterone levels in the blood plasma were not measured, because all nine heifers were in oestrus between day 17 and day 24 after artificial insemination. None of the heifers were gravid after day 21.

### 5.1.2.2 Uterus milk

It was possible to detect progesterone in the uterus milk of the contralateral (A) and ipsilateral (B) horn. The progesterone value ranged from <0.1 to 0.4 ng/ml in both horns.

### 5.1.3 **Oestradiol-17 $\beta$ analysis in the uterus milk**

We were able to detect oestradiol-17 $\beta$  values between 2pg/ml and 333pg/ml. The values between the different animals and between the ipsi- and contralateral horn showed great differences, so that no correlation could be seen. A further test revealed that 0.9% NaCl with EDTA-stabilisator contains 138 pg/ml oestradiol-17 $\beta$ , whereas 0.9% NaCl without stabilisator only contains <2 pg/ml.

### 5.1.4 **VEGF analysis in the uterus milk**

The detected VEGF values ranged between 0.06ng/ml and 2.58ng/ml, whereas the values of both horns were partly similar during the different time points.

### 5.1.5 **PGF2 $\alpha$ analysis in the uterus milk**

It was possible to detect PGF2 $\alpha$  values between 0.23ng/ml and >70.00ng/ml. A level increase can be seen at the beginning and during endometritis, which is reduced after medical treatment and oestrus (tab. 9).

Cow	PGF2 $\alpha$ (ng/ml)				
	day 5	day 7	day 12	day 17	day 24
1A	6.81	2.52	30.00	73.00 *	16.20 **
1B	3.75	2.70	28.00	54.00 *	12.90 **
2A	6.70	1.30	67.70	3.40 * °	1.18
2B	19.60	3.50 ~	21.30	4.40 * °	0.23
3A	2.60	19.00	29.50	25.60 *	6.64 **
3B	5.00	22.00	28.90	21.70 *	6.86 **
4A	5.10	5.94	26.70	20.50	0.78 **
4B	6.80	6.88	38.60	59.70	0.82 **
5A	14.40	21.00	42.70	14.20 °	0.69
5B	10.80	34.50	30.60	32.70 °	0.93
6A	7.60	missing	15.40 *	missing	9.60 **
6B	16.20	missing	>70.00 *	missing	9.50 **
7A	18.00	missing	44.60 *	2.97 *	3.27 **
7B	23.30	missing	36.60 *	15.60 *	9.70 **
8A	11.50	10.80	26.40	20.60 *	51.00 *
8B	13.30	24.50	19.60	12.60 *	25.00 *
9A	11.80	18.50	32.00 *	10.50 *	4.60 **
9B	7.60	26.70	38.00 *	>70.00 *	4.80 **

Table 9: PGF2 $\alpha$  concentration in the uterus milk of the contralateral (A) and ipsilateral (B) uterus horn. \*= sanies; \*\*= after gentamicin treatment; °= in oestrus; ~ = embryo rinsed

### 5.1.6 Recapitulating comment to 5.1.

We were able to gain uterus milk in a sufficient concentration and amount to detect progesterone, VEGF and PGF2 $\alpha$  within the sensitivity of EIA and RIA. Oestradiol-17 $\beta$  levels were also detected via EIA, but these seem to be erratic due to the used EDTA-stabilisator. The ballooned embryo catheter turned out to be a good instrument for gaining uterus milk in a not too invasive kind of way.

## 5.2 Expression of housekeeping genes, proteases, apoptotic and anti-apoptotic factors in the CL during oestrous cycle and induced luteolysis

### 5.2.1 Enzyme immuno assay (EIA) of progesterone

The progesterone level was analysed in blood plasma of five Brown swiss cows to see if their oestrous cycle was correctly synchronised. The progesterone level of all five cows was below 0.2ng/ml three days after the second PGF<sub>2</sub> $\alpha$  injection. 13 days after these injection the level of all five cows ranged between 2.79ng/ml to 4.08ng/ml indicating a functional CL.

### 5.2.2 RNA quality control by the Bioanalyzer

The RNA quality of the CL samples during oestrous cycle on day 1-12 and the CL samples during induced luteolysis 0h, 0.5h, 2h, 4h, 12h, 24h, 48h and 64h were verified. The CL oestrous cycle and CL luteolysis samples showed a good to very good RNA integrity and quality with RIN values between 10.0 to 7.5 and 9.4 to 6. respectively (tab. 10).

Group CL cycle	RIN value	SEM	Group CL luteolysis	RIN value	SEM
1-2	8.88	0.52	0h	8.46	0.47
3-4	9.53	0.23	0.5h	7.74	0.40
5-7	9.77	0.12	2h	8.38	0.13
8-12	9.65	0.17	4h	8.72	0.15
			12h	8.42	0.24
			24h	7.98	0.06
			48h	8.58	0.12
			64h	8.38	0.21

Table 10: RIN values of the CL oestrous cycle samples day 1-12 and CL induced luteolysis samples 0h, 0.5h, 2h, 4h, 12h, 24h, 48h and 64h

### 5.2.3 Sequencing of PCR-products

No bovine sequences were available for MMP-19 and Smac, so that the primers were designed using human or mouse sequences, respectively. The bovine MMP-19 sequence showed 93% homology to the human sequence. The bovine Smac sequence was 87%

homologous to the mouse sequence and was published in the EMBL database under the no. AJ867847.

## 5.2.4 Quantitative real time PCR (qPCR)

### 5.2.4.1 Housekeeping genes

#### 5.2.4.1.1 Follicle phase and CL during oestrous cycle

The housekeeping genes Histone,  $\beta$ -Actin, GAPDH and Ubiquitin were investigated in the follicle 20h after GnRH for comparable reasons and during oestrous cycle in the CL. The relative quantitation is shown in reference to the follicle group 20h after GnRH application and as logarithm to the basis 2. The mRNA expression data of Histone showed no significant differences between the groups.  $\beta$ -Actin was significantly up-regulated at days 1-7. GAPDH reveals nearly the same expression pattern like  $\beta$ -Actin, except that day 1-2 is not only significantly increased to the follicle group and day 8-12 but also to day 5-7. Ubiquitin was not regulated during follicle phase and CL oestrous cycle (fig. 10).




Figure 10: mRNA expression data of four housekeeping genes Histone,  $\beta$ -Actin, GAPDH and Ubiquitin in follicle (20h after GnRH) and in the CL during different days of the oestrous cycle in the CL; data are shown as  $\Delta CP \pm SEM$  to the follicle group. Different superscript letters indicate significant differences ( $P < 0.05$ ).

## 5.2.4.1.2 CL during induced luteolysis

The housekeeping genes Histone,  $\beta$ -Actin, GAPDH and Ubiquitin were also investigated during luteolysis in the CL. The relative quantitation is shown in reference to the control group (day 8-12 = 0h) and as logarithm to the basis 2. The mRNA expression data of Histone showed slight, but significant differences from 12h after  $\text{PGF}_2\alpha$  till 64h. The  $\beta$ -Actin expression increased significantly to control after 0.5h and reached the control level again after 12h. At 24h a significant up-regulation to all groups was seen, which decreased again to the level seen at 2h. GAPDH was not significantly regulated during induced luteolysis. Ubiquitin showed a significant down-regulation at 48h and 64h as compared to all other groups (fig. 11).




Figure 11: mRNA expression data of four housekeeping genes Histone,  $\beta$ -Actin, GAPDH and Ubiquitin in the CL during specific hours after  $\text{PGF}_2\alpha$  injection; data are shown  $\Delta\text{CP} \pm \text{SEM}$  to 0h (control). Different superscript letters indicate significant differences ( $P < 0.05$ ).

### 5.2.4.2 Extracellular matrix proteases

#### 5.2.4.2.1 MMPs and TIMPs during follicle phase and CL during oestrous cycle

The mRNA expression of MMP-1 (fig. 12), MMP-2 and MMP-14 showed no significant regulation during follicle phase and CL oestrous cycle. The mRNA expression of TIMP-2 was constantly increased from 20h after GnRH till day 8-12 of the oestrous cycle in the CL. The follicle phase showed the lowest expression and was significant to the groups day 3-4, day 5-7 and day 8-12 of the oestrous cycle, while all other time points of the oestrous cycle were also significantly lower to day 8-12 (fig. 13). MMP-9 was significantly up-regulated from day 1-12 compared to 20h after. Day 8-12 was also significant higher than all other groups. MMP-19 also revealed significant increase from day 1-12 compared to 20h after GnRH with the highest expression from day 3-12. TIMP-1 showed a significant up-regulation from day 1-12 compared to the follicle group. (fig. 14).




Figure 12: mRNA expression of MMP-1 in follicle group and CL during oestrous cycle; the changes in mRNA expression for the different groups were calculated by normalisation with the Bestkeeper index and relative to the follicle group, where  $\Delta CP = CP_{\text{target}} - CP_{\text{index}}$  and  $\Delta\Delta CP = \Delta CP_{(\text{group I=follicle})} - \Delta CP_{(\text{group II-V})}$ . The statistic analysis were determined from  $\Delta CP$  values (n=4-5). Results are presented as expression changes  $\Delta\Delta CP \pm \text{SEM}$ . Different superscript letters indicate significant differences ( $P < 0.05$ ). CP value of the follicle group was 28.09.






Figure 13: mRNA expression of MMP-2, MMP-14 and TIMP-2 in follicle group and CI during oestrous cycle; the changes in mRNA expression for the different groups were calculated by normalisation with the Bestkeeper index and relative to the follicle group, where  $\Delta\text{CP} = \text{CP}_{\text{target}} - \text{CP}_{\text{index}}$  and  $\Delta\Delta\text{CP} = \Delta\text{CP}_{(\text{group I=follicle})} - \Delta\text{CP}_{(\text{group II-V})}$ . The statistic analysis were determined from  $\Delta\text{CP}$  values ( $n=4-5$ ). Results are presented as expression changes  $\Delta\Delta\text{CP} \pm \text{SEM}$ . Different superscript letters indicate significant differences ( $P < 0.05$ ). CP values of the follicle group were 19.80, 23.45, 17.91.




Figure 14: mRNA expression of MMP-9, MMP-19 and TIMP-1 in follicle group and CI during oestrous cycle; the changes in mRNA expression for the different groups were calculated by normalisation with the Bestkeeper index and relative to the follicle group, where  $\Delta CP = CP_{\text{target}} - CP_{\text{index}}$  and  $\Delta\Delta CP = \Delta CP_{(\text{group I=follicle})} - \Delta CP_{(\text{group II-V})}$ . The statistic analysis were determined from  $\Delta CP$  values ( $n=4-5$ ). Results are presented as expression changes  $\Delta\Delta CP \pm \text{SEM}$ . Different superscript letters indicate significant differences ( $P < 0.05$ ). CP values of the follicle group were 30.20, 26.00, 16.88.

#### 5.2.4.2.2 PA system during follicle phase and CL during oestrous cycle

tPA showed no significant regulation during follicle phase and CL oestrous cycle (fig. 15). The mRNA expression of uPA was constantly increased from the follicle phase to day 8-12 of the oestrous cycle. The follicle phase showed the lowest expression with significant differences to all days of the oestrous cycle. Day 1-2 was also significantly lower expressed than day 8-12. uPAR expression showed nearly the same expression pattern like uPA, but day 8-12 was significant lower expressed than day 5-7 (fig. 16). The mRNA expression of PAI-1 was significantly increased during the first seven days of the oestrous cycle compared to the follicle phase and day 8-12 of the oestrous cycle. PAI-2 revealed the same expression pattern as PAI-1, but the increase from day 1-2 to day 5-7 was much higher than for PAI-1 (fig. 17).




Figure 15: mRNA expression of tPA in follicle group and CL during oestrous cycle; the changes in mRNA expression for the different groups were calculated by normalisation with the Bestkeeper index and relative to the follicle group, where  $\Delta CP = CP_{\text{target}} - CP_{\text{index}}$  and  $\Delta\Delta CP = \Delta CP_{(\text{group I=follicle})} - \Delta CP_{(\text{group II-V})}$ . The statistic analysis were determined from  $\Delta CP$  values (n=4-5). Results are presented as expression changes  $\Delta\Delta CP \pm \text{SEM}$ . Different superscript letters indicate significant differences ( $P < 0.05$ ). CP value of the follicle group was 22.68.




Figure 16: mRNA expression of uPA and uPAR in follicle group and CI during oestrous cycle; the changes in mRNA expression for the different groups were calculated by normalisation with the Bestkeeper index and relative to the follicle group, where  $\Delta CP = CP_{\text{target}} - CP_{\text{index}}$  and  $\Delta\Delta CP = \Delta CP_{(\text{group I=follicle})} - \Delta CP_{(\text{group II-V})}$ . The statistic analysis were determined from  $\Delta CP$  values (n=4-5). Results are presented as expression changes  $\Delta\Delta CP \pm SEM$ . Different superscript letters indicate significant differences ( $P < 0.05$ ). CP values of the follicle group were 28.18 and 27.37.




Figure 17: mRNA expression of PAI-1 and PAI-2 in follicle group and CI during oestrous cycle; the changes in mRNA expression for the different groups were calculated by normalisation with the Bestkeeper index and relative to the follicle group, where  $\Delta CP = CP_{\text{target}} - CP_{\text{index}}$  and  $\Delta\Delta CP = \Delta CP_{(\text{group I=follicle})} - \Delta CP_{(\text{group II-V})}$ . The statistic analysis were determined from  $\Delta CP$  values ( $n=4-5$ ). Results are presented as expression changes  $\Delta\Delta CP \pm \text{SEM}$ . Different superscript letters indicate significant differences ( $P < 0.05$ ). CP values of the follicle group were 23.90 and 29.17.

#### 5.2.4.2.3 MMPs and TIMPs during induced luteolysis

The mRNA expression during luteolysis of MMP-1 showed a highly significant 256- to 1024-fold up-regulation beginning 2h after induction of luteolysis till 64h with the highest increase at 48h. (fig 18). MMP-2 showed a significant increase 48h to 64h after  $\text{PGF2}\alpha$ . A significantly higher expression level to control group was seen for MMP-14 from 12h on to 64h, with the highest expression rate between 24h to 64h. TIMP-2 showed the opposite expression pattern than MMP-14 with a significant down-regulation of maximal 8-fold at 48h to 64h (fig. 19). MMP-9 was steadily significantly up-regulated from 12h till 64h with the highest expression at 48h. The expression of TIMP-1 was significantly increased from 4h to 24h with a peak at 12h. MMP-19 showed an increased expression from 24h to 64h with a maximal up-regulation of 32-fold at 48h (fig. 20).




Figure 18: mRNA expression of MMP-1 in the CI during induced luteolysis; the changes in mRNA expression for the different groups were calculated by normalisation with the Bestkeeper index and relative to control (0h), where  $\Delta\text{CP} = \text{CP}_{\text{target}} - \text{CP}_{\text{index}}$  and  $\Delta\Delta\text{CP} = \Delta\text{CP}_{(\text{group I}=\text{control (0h)})} - \Delta\text{CP}_{(\text{group II-VIII})}$ . The statistic analysis were determined from  $\Delta\text{CP}$  values ( $n=5$ ). Results are presented as expression changes  $\Delta\Delta\text{CP} \pm \text{SEM}$ . Different superscript letters indicate significant differences ( $P < 0.05$ ).




Figure 19: mRNA expression of MMP-2, MMP-14 and TIMP-2 in the CI during induced luteolysis; the changes in mRNA expression for the different groups were calculated by normalisation with the Bestkeeper index and relative to control (0h), where  $\Delta\text{CP} = \text{CP}_{\text{target}} - \text{CP}_{\text{index}}$  and  $\Delta\Delta\text{CP} = \Delta\text{CP}_{(\text{group I} = \text{control (0h)})} - \Delta\text{CP}_{(\text{group II-VII})}$ . The statistic analysis were determined from  $\Delta\text{CP}$  values (n=5). Results are presented as expression changes  $\Delta\Delta\text{CP} \pm \text{SEM}$ . Different superscript letters indicate significant differences ( $P < 0.05$ ).




Figure 20: mRNA expression of MMP-9, MMP-19 and TIMP-1 in the CI during induced luteolysis; the changes in mRNA expression for the different groups were calculated by normalisation with the Bestkeeper index and relative to control (0h), where  $\Delta CP = CP_{\text{target}} - CP_{\text{index}}$  and  $\Delta\Delta CP = \Delta CP_{\text{(group I=control (0h))}} - \Delta CP_{\text{(group II-VII)}}$ . The statistic analysis were determined from  $\Delta CP$  values (n=5). Results are presented as expression changes  $\Delta\Delta CP \pm \text{SEM}$ . Different superscript letters indicate significant differences ( $P < 0.05$ ).



#### 5.2.4.2.4 PA system during induced luteolysis

During induced luteolysis tPA mRNA expression showed a significant increase of all time points to control group with the highest up-regulation at 2h and 24h. uPA expression was significantly increased from 2h to 12h followed by a further increase from 24h to 64h. uPAR showed a significant up-regulation from 2h till 64h, which stayed on the same expression level (fig. 22). PAI-1 revealed a significant rising increase from 2h to 24h, which decreased to a lower expression level from 48h to 64h, which was still significantly up-regulated to control. The expression of PAI-2 was quite similar to PAI-1 with a significant increase on the same level from 2h to 12h, but increase decreased already at 24h to a lower expression level till 64h. This level was still significantly up-regulated to control (fig. 23).




Figure 21: mRNA expression of tPA in the CI during induced luteolysis; the changes in mRNA expression for the different groups were calculated by normalisation with the Bestkeeper index and relative to control (0h), where  $\Delta CP = CP_{\text{target}} - CP_{\text{index}}$  and  $\Delta\Delta CP = \Delta CP_{(\text{group I=control (0h)})} - \Delta CP_{(\text{group II-VIII})}$ . The statistic analysis were determined from  $\Delta CP$  values (n=5). Results are presented as expression changes  $\Delta\Delta CP \pm SEM$ . Different superscript letters indicate significant differences (P < 0.05).




Figure 22: mRNA expression of uPA and uPAR in the CI during induced luteolysis; the changes in mRNA expression for the different groups were calculated by normalisation with the Bestkeeper index and relative to control (0h), where  $\Delta CP = CP_{\text{target}} - CP_{\text{index}}$  and  $\Delta\Delta CP = \Delta CP_{(\text{group I}=\text{control (0h)})} - \Delta CP_{(\text{group II-VIII})}$ . The statistic analysis were determined from  $\Delta CP$  values (n=5). Results are presented as expression changes  $\Delta\Delta CP \pm \text{SEM}$ . Different superscript letters indicate significant differences ( $P < 0.05$ ).




Figure 23: mRNA expression of PAI-1 and PAI-2 in the CI during induced luteolysis; the changes in mRNA expression for the different groups were calculated by normalisation with the Bestkeeper index and relative to control (0h), where  $\Delta CP = CP_{\text{target}} - CP_{\text{index}}$  and  $\Delta\Delta CP = \Delta CP_{(\text{group I}=\text{control (0h)})} - \Delta CP_{(\text{group II-VIII})}$ . The statistic analysis were determined from  $\Delta CP$  values (n=5). Results are presented as expression changes  $\Delta\Delta CP \pm \text{SEM}$ . Different superscript letters indicate significant differences ( $P < 0.05$ ).

### 5.2.4.3 Monocyte chemoattractant protein-1 (MCP-1)

#### 5.2.4.3.1 CL during oestrous cycle

MCP-1 mRNA expression was not regulated during oestrous cycle (fig 24).




Figure 24: mRNA expression of MCP-1 in CI during oestrous cycle; the changes in mRNA expression for the different groups were calculated by normalisation with the Bestkeeper index and relative to the day 8-12 (group IV), where  $\Delta CP = CP_{\text{target}} - CP_{\text{index}}$  and  $\Delta\Delta CP = \Delta CP_{(\text{group IV}=\text{day 8-12})} - \Delta CP_{(\text{group I-III})}$ . The statistic analysis were determined from  $\Delta CP$  values ( $n=4$ ). Results are presented as expression changes  $\Delta\Delta CP \pm \text{SEM}$ . Different superscript letters indicate significant differences ( $P < 0.05$ ).

## 5.2.4.3.2 CL during induced luteolysis

All time points after  $\text{PGF2}\alpha$  treatment showed a significant increase of mRNA for MCP-1 compared to control group. The first increase is seen 0.5h, which is significantly lower than the next increase from 2h to 12h. From 24h to 48h the expression rises again significantly higher than from 2h to 12h with a decline at 64h to the level seen at 4h.




Figure 25: mRNA expression of MCP-1 in the CI during induced luteolysis; the changes in mRNA expression for the different groups were calculated by normalisation with the Bestkeeper index and relative to control (0h), where  $\Delta\text{CP} = \text{CP}_{\text{target}} - \text{CP}_{\text{index}}$  and  $\Delta\Delta\text{CP} = \Delta\text{CP}_{(\text{group I}=\text{control (0h)})} - \Delta\text{CP}_{(\text{group II-VIII})}$ . The statistic analysis were determined from  $\Delta\text{CP}$  values ( $n=5$ ). Results are presented as expression changes  $\Delta\Delta\text{CP} \pm \text{SEM}$ . Different superscript letters indicate significant differences ( $P < 0.05$ ).

## 5.2.4.4 Apoptosis

## 5.2.4.4.1 Extrinsic pathway during oestrous cycle in the CL

The mRNA expression of Fas showed no significant regulation in the CL during oestrous cycle (fig. 26). Fas-Ligand, TNF $\alpha$  and TNFR1 revealed the same expression pattern with a significant down-regulation from day 1 to 7 compared to day 8-12. TNFR2 on the other hand was significantly decreased from day 1 to 4 during oestrous cycle (fig. 26, fig. 27).




Figure 26: mRNA expression of Fas and Fas-Ligand in CL during oestrous cycle; the changes in mRNA expression for the different groups were calculated by normalisation with the Bestkeeper index and relative to the day 8-12 (group IV), where  $\Delta CP = CP_{\text{target}} - CP_{\text{index}}$  and  $\Delta\Delta CP = \Delta CP_{\text{(group IV=day 8-12)}} - \Delta CP_{\text{(group I-III)}}$ . The statistic analysis were determined from  $\Delta CP$  values ( $n=4$ ). Results are presented as expression changes  $\Delta\Delta CP \pm SEM$ . Different superscript letters indicate significant differences ( $P < 0.05$ ).




Figure 27: mRNA expression of TNF- $\alpha$ , TNFR1 and TNFR2 in CI during oestrous cycle; the changes in mRNA expression for the different groups were calculated by normalisation with the Bestkeeper index and relative to the day 8-12 (group IV), where  $\Delta CP = CP_{\text{target}} - CP_{\text{index}}$  and  $\Delta\Delta CP = \Delta CP_{(\text{group IV}=\text{day 8-12})} - \Delta CP_{(\text{group I-III})}$ . The statistic analysis were determined from  $\Delta CP$  values ( $n=4$ ). Results are presented as expression changes  $\Delta\Delta CP \pm \text{SEM}$ . Different superscript letters indicate significant differences ( $P < 0.05$ ).

#### 5.2.4.4.2 Intrinsic pathway during oestrous cycle in the CL

The mRNA expression of p53, Bax and Smac revealed no significant regulation during oestrous cycle. Bcl-X<sub>L</sub> was significantly downregulated from day 1 to day 7 compared to the midluteal phase. The expression of Survivin was significantly increased during the first seven days of oestrous cycle (fig. 28, fig. 29).




Figure 28: mRNA expression of p53 and Bax in CL during oestrous cycle; the changes in mRNA expression for the different groups p53 were calculated by normalisation with the Bestkeeper index and relative to the day 8-12 (group IV), where  $\Delta CP = CP_{\text{target}} - CP_{\text{index}}$  and  $\Delta\Delta CP = \Delta CP_{(\text{group IV}=\text{day 8-12})} - \Delta CP_{(\text{group I-III})}$ . The statistic analysis were determined from  $\Delta CP$  values ( $n=4$ ). Results are presented as expression changes  $\Delta\Delta CP \pm SEM$ . Different superscript letters indicate significant differences ( $P < 0.05$ ).






Figure 29: mRNA expression of Bcl-X<sub>L</sub>, Smac and Survivin in CI during oestrous cycle; the changes in mRNA expression for the different groups were calculated by normalisation with the Bestkeeper index and relative to the day 8-12 (group IV), where  $\Delta CP = CP_{\text{target}} - CP_{\text{index}}$  and  $\Delta\Delta CP = \Delta CP_{(\text{group IV}=\text{day 8-12})} - \Delta CP_{(\text{group I-III})}$ . The statistic analysis were determined from  $\Delta CP$  values (n=4). Results are presented as expression changes  $\Delta\Delta CP \pm \text{SEM}$ . Different superscript letters indicate significant differences (P < 0.05).

#### 5.2.4.4.3 Caspase3, -6, -7 during oestrous cycle in the CL

Caspase3 and caspase7 showed no regulation during oestrous cycle (fig 30). The mRNA expression of caspase6 was significantly down-regulated from day 1 to day 7 compared to the mid luteal group. The expression during the first two days was also significant lower than at day 5-7 (fig 31.).




Figure 30: mRNA expression of caspase3 and caspase6 in CL during oestrous cycle; the changes in mRNA expression for the different groups were calculated by normalisation with the Bestkeeper index and relative to the day 8-12 (group IV), where  $\Delta CP = CP_{\text{target}} - CP_{\text{index}}$  and  $\Delta\Delta CP = \Delta CP_{(\text{group IV} = \text{day 8-12})} - \Delta CP_{(\text{group I-III})}$ . The statistic analysis were determined from  $\Delta CP$  values ( $n=4$ ). Results are presented as expression changes  $\Delta\Delta CP \pm \text{SEM}$ . Different superscript letters indicate significant differences ( $P < 0.05$ ).




Figure 31: mRNA expression of caspase7 in CI during oestrous cycle; the changes in mRNA expression for the different groups were calculated by normalisation with the Bestkeeper index and relative to the day 8-12 (group IV), where  $\Delta CP = CP_{\text{target}} - CP_{\text{index}}$  and  $\Delta\Delta CP = \Delta CP_{(\text{group IV}=\text{day 8-12})} - \Delta CP_{(\text{group I-III})}$ . The statistic analysis were determined from  $\Delta CP$  values ( $n=4$ ). Results are presented as expression changes  $\Delta\Delta CP \pm \text{SEM}$ . Different superscript letters indicate significant differences ( $P < 0.05$ ).

#### 5.2.4.4.4 Extrinsic pathway during induced luteolysis in the CL

The expression of Fas in the CL during induced luteolysis was constantly increased from 2h onwards till 64h. All time points were significantly up-regulated to control group. Fas-Ligand was significantly up-regulated after 0.5h with a further significant increase to 12h and 24h. These increase was reduced at 48h nearly to the level of 0.5h again with a slight increase at 64h (fig. 32). For  $\text{TNF}\alpha$  a significant increase of 16-fold was seen after 0.5h, which increased to a significant expression level of 32-fold at 2h. All other time points were significantly less expressed compared to 2h, but still significantly increased compared to control group.  $\text{TNFR1}$  was not regulated during induced luteolysis. The expression of  $\text{TNFR2}$  was significantly increased from 2h to 64h on a constant level (fig. 33).




Figure 32: mRNA expression of Fas and Fas-Ligand in the CL during induced luteolysis; the changes in mRNA expression for the different groups were calculated by normalisation with the Bestkeeper index and relative to control (0h), where  $\Delta\text{CP} = \text{CP}_{\text{target}} - \text{CP}_{\text{index}}$  and  $\Delta\Delta\text{CP} = \Delta\text{CP}_{(\text{group I-VIII})} - \Delta\text{CP}_{(\text{control (0h)})}$ . The statistic analysis were determined from  $\Delta\text{CP}$  values ( $n=5$ ). Results are presented as expression changes  $\Delta\Delta\text{CP} \pm \text{SEM}$ . Different superscript letters indicate significant differences ( $P < 0.05$ ).




Figure 33: mRNA expression of TNF $\alpha$ , TNFR1 and TNFR2 in the CI during induced luteolysis; the changes in mRNA expression for the different groups were calculated by normalisation with the Bestkeeper index and relative to control (0h), where  $\Delta CP = CP_{\text{target}} - CP_{\text{index}}$  and  $\Delta\Delta CP = \Delta CP_{(\text{group I-VIII})} - \Delta CP_{(\text{control (0h)})}$ . The statistic analysis were determined from  $\Delta CP$  values (n=5). Results are presented as expression changes  $\Delta\Delta CP \pm SEM$ . Different superscript letters indicate significant differences ( $P < 0.05$ ).

#### 5.2.4.4.5 Intrinsic pathway during induced luteolysis in the CL

During induced luteolysis only Smac showed no significant regulation in the CL at all. The mRNA expression of p53 increased significantly from 24h to 64h compared to control group. Bax showed the same expression pattern than p53 with a significant up-regulation from 24h to 64h (fig. 34). In contrast to Bax, Bcl-X<sub>L</sub> revealed a significantly increased expression only from 48h to 64h. Survivin was significantly downregulated from 2h to 12h after PGF2 $\alpha$ , with an increase to control level from 24h to 64h (fig. 35).




Figure 34: mRNA expression of p53 and Bax in the CL during induced luteolysis; the changes in mRNA expression for the different groups were calculated by normalisation with the Bestkeeper index and relative to control (0h), where  $\Delta CP = CP_{\text{target}} - CP_{\text{index}}$  and  $\Delta\Delta CP = \Delta CP_{(\text{group I}=\text{control (0h)})} - \Delta CP_{(\text{group I-VII})}$ . The statistic analysis were determined from  $\Delta CP$  values ( $n=5$ ). Results are presented as expression changes  $\Delta\Delta CP \pm SEM$ . Different superscript letters indicate significant differences ( $P < 0.05$ ).




Figure 35: mRNA expression of Bcl-X<sub>L</sub>, Smac and Survivin in the CI during induced luteolysis; the changes in mRNA expression for the different groups were calculated by normalisation with the Bestkeeper index and relative to control (0h), where  $\Delta\text{CP} = \text{CP}_{\text{target}} - \text{CP}_{\text{index}}$  and  $\Delta\Delta\text{CP} = \Delta\text{CP}_{(\text{group I-VII})} - \Delta\text{CP}_{(\text{control (0h)})}$ . The statistic analysis were determined from  $\Delta\text{CP}$  values ( $n=5$ ). Results are presented as expression changes  $\Delta\Delta\text{CP} \pm \text{SEM}$ . Different superscript letters indicate significant differences ( $P < 0.05$ ).

## 5.2.4.4.6 Caspase3, -6, -7 during induced luteolysis in the CL

Caspase3 mRNA expression during induced luteolysis showed a significant increase from 12h to 64h with the highest expression at 64h. Caspase6 showed a rising up-regulation from 2h to 64h, which was significant to control group at all time points (fig. 36). The expression of caspase7 was significantly increased from 24h on with the highest up-regulation of 45-fold at 64h (fig. 37).




Figure 36: mRNA expression of caspase3 and caspase6 in the CL during induced luteolysis; the changes in mRNA expression for the different groups were calculated by normalisation with the Bestkeeper index and relative to control (0h), where  $\Delta CP = CP_{\text{target}} - CP_{\text{index}}$  and  $\Delta\Delta CP = \Delta CP_{(\text{group I-VIII})} - \Delta CP_{(\text{control (0h)})}$ . The statistic analysis were determined from  $\Delta CP$  values (n=5). Results are presented as expression changes  $\Delta\Delta CP \pm \text{SEM}$ . Different superscript letters indicate significant differences ( $P < 0.05$ ).






Figure 37: mRNA expression of caspase7 in the CI during induced luteolysis; the changes in mRNA expression for the different groups were calculated by normalisation with the Bestkeeper index and relative to control (0h), where  $\Delta CP = CP_{\text{target}} - CP_{\text{index}}$  and  $\Delta\Delta CP = \Delta CP_{(\text{group I}=\text{control (0h)})} - \Delta CP_{(\text{group I-VIII})}$ . The statistic analysis were determined from  $\Delta CP$  values (n=5). Results are presented as expression changes  $\Delta\Delta CP \pm SEM$ . Different superscript letters indicate significant differences ( $P < 0.05$ ).

## 6 Discussion

### 6.1 Development of a method to gain uterus milk *in vivo*

#### 6.1.1 Method

The aim of the first part of these study was to develop a method to gain uterus milk *in vivo* at specific time points during the preimplantation periode in cattle. Therefore a technique used for flushing embryos during embryo transfer with a specific balloon catheter for heifers was modified. The first concern was to evaluate the correct volume of the used flushing fluid. As less as possible should be used for not disturbing the development of the embryo till day 24 of pregnancy, but the regained volume had to be enough for the investigations via different biomolecular methods. Normaly flushing of embryos is made with 5 x 50ml flushing fluid for each uterus horn (H. Thenhumberg personal notice). As no flushing of the embryo should occur till day 24, the volume of the catheter was evaluated, which was 3ml, and it was decided to try the flushing with a total volume of 13ml per horn. It was possible to gain between 3ml to 13ml back, which was enough for the measurment of different factors, placing the catheter 1cm cranial to the bifurcatio uteri and massaging gently. But despite using sterile instruments and fluid, and working as clean as possible an infection of the uterus occurred in three heifers after the second and in five heifers after the third flushing. In one heifer no infection was found. The flushing fluids of all these heifers were contaminated with sanies. After treatment with Genta-Sleecol 5 the flushing fluid was clear again. One embryo was gained by chance at day 7 of gravidity, which showed no viability and the developing stage of day 4 of gravidity. All heifers showed signs of oestrus between day 17 and 24 of gravidity. Therefore the value of progesterone in the blood plasma for confirming the gravidity was not evaluated. For the evaluation of prostaglandins an EDTA-stabilisator was given to the gained flushing fluid, which was found by further tests to desturbe the oestradiol-17 $\beta$  evaluation via EIA. The first attempt of developing an *in vivo* method for gaining uterus fluid showed positive and negative aspects, so that further changes are necessary. The biggest problem was the infection of the uterus using these flushing method five times in a row at different time points during preimplantation, which led to a resorbtion of the embryo. To prevent these infection, just one flushing should be done per gravidity time point with gaining of the embryo afterwards for confirmation of pregnancy, so that the heifer can be inseminated again after two oestrous cycles. Again both horns should be flushed, whereas one sterile disposable catheter should be used for each horn and the flushing should be devided into two parts: first flushing with 13ml of sterile 0.9% NaCL for biomolecular methodes, then flushing of the embryo using 5 x 50ml sterile PBS buffer. With this procedure the embryo and the

uterus milk can be gained at the same time, which might be necessary for the investigation of the source of proteins found in the uterus milk. The embryo can be classified by the developing stage and stored in RNA-Later at  $-80^{\circ}$  for further biomolecular investigations. The received flushing fluid should be separated in two aliquotes, whereas one is used for the oestradiol- $17\beta$  measurement and must not contain EDTA-stabilisator. These two aliquotes should be centrifugated and the fluid should be stored separately at  $-20^{\circ}$  from the received cell pellet. Part of the cell pellet can be used for the identification of the cells found in the uterus lumen and the rest stored in RNA-Later at  $-80^{\circ}$  for further biomolecular investigations. For the evaluation of prostaglandins in the uterus milk it should be considered to treat the heifers with a prostaglandin synthetase inhibitor shortly before flushing. It was reported in pony mares that cervical stimulation elevates the intrauterin PGF level. This increase was inhibited by treatment with flunixin-meglumine before flushing (Berglund *et al.* 1982).

### **6.1.2 Results**

We were able to measure progesterone, oestradiol- $17\beta$ ,  $PGF2\alpha$  and VEGF in the uterus milk. It was seen that the concentration of the measured factors were in the detectable range of the used EIA and RIA. It should be kept in mind that the uterus milk was diluted in 13ml of flushing fluid, so that all values are higher in the undiluted uterus milk. As the uterus infection occurred after the second and third flushing respectively, no statistic evaluation was made. It was seen that progesterone ranged between  $<0.1$  and  $0.4\text{ng/ml}$ , whereas no correlation to the inflammation was found. The pattern of oestradiol- $17\beta$  was erratic, because the oestradiol- $17\beta$  levels of the flushing fluid from heifers with no infection till day 12 of gravidity could not be related to each other. This could be due to the fact, that a EDTA-stabilisator was given to the samples, which seems to influences the EIA measurement of oestradiol- $17\beta$  (erratic higher level), which we evaluated in further tests. VEGF was evaluated by RIA and revealed levels between  $0.08$  and  $2.58\text{ng/ml}$ , whereas the higher levels were seen during inflammation. The level of  $PGF2\alpha$  showed a clear correlation to the infection. The differences seen between the different heifers or even between the two uterus horns of one animal during the first flushing might be also due to the different massage intensity or sensitivity of the uterus horns while flushing, which can induce prostaglandin secretion (Berglund *et al.* 1982). In general we can assume that the hormone levels in undiluted uterine milk are about 10-fold higher according to the diluting effect.

## 6.2 Expression of housekeeping genes, proteases, apoptotic and anti-apoptotic factors in the CL during oestrous cycle and induced luteolysis

### 6.2.1 Housekeeping Genes (HKGs)

RT-PCR specific errors in the quantification of mRNA transcript are easily generated by any variation in the amount of starting material between samples. These can happen through pipetting failures or by uncorrect photometric measurement of the total RNA amount per  $\mu\text{l}$ . The quantification errors are especially relevant when the samples have been obtained from different individuals like in this experiment, and can result in misinterpretation of the expression profiles of the target genes. Consequently, the question of what constitutes an appropriate standard arises (Thellin *et al.* 1999). The accepted method for minimising these errors and correcting for sample to sample variation is to amplify a cellular RNA that serves as an internal reference against which other RNA values can be normalised (Karge *et al.* 1998). The ideal standard should be expressed at a constant level among different tissues of an organism or in the same tissue of different individuals, at all stages of development, and should be unaffected by the experimental treatment. It was not possible to find such a housekeeping gene, which is stable expressed during oestrous cycle and induced luteolysis. Therefore we decided to calculate an index out of the four different housekeeping genes Histone,  $\beta$ -Actin, GAPDH and Ubiquitin using the Bestkeeper software (Pfaffl *et al.* 2004) and to normalise all target gene data with these index following the  $\Delta\Delta\text{CP}$  method (Livak and Schmittgen 2001). There is evidence that the gene expression of all these four housekeeping genes changes during different physiological stages of the cells and that they have specific cell functions (Bustin 2000; Gillespie and Vousden 2003; Thellin *et al.* 1999; Warrington *et al.* 2000). Histones are abundant, basic, structural proteins that bind to the DNA and enable a tight packing of the DNA into nucleosomes. 147bp of DNA is folded over a Histone octamer (two molecules each of the four core Histones H2A, H2B, H3 and H4) to form a nucleosome. In between two nucleosomes another Histone (H1) binds to 20bp of DNA to enable the spiralisation of the DNA into solenoides (Koolmann and Röhm 1998). Different variants were found for the four core Histones H2A, H2B, H3, H4 and for the linker Histone H1 (Gillespie and Vousden 2003; Pusarla and Bhargava 2005). These linker variant (H1.2) was found to be a pro-apoptotic factor in cells undergoing X-ray irradiation (Konishi *et al.* 2003). These group showed that H1.2 has the ability to release cytochrom c from the mitochondria, which leads to apoptosis via the intrinsic pathway. How these release actually functions is not known definitively, but it seems to be a p53 dependent mechanism (Zong 2004). The pro-apoptotic action of H1.2 could be the reason for the

increase of mRNA expression of Histone from 12h to 64h shortly before the structural luteolysis begins. p53 shows nearly the same expression pattern like Histone, which could be due to its possible regulatory action on Histone.  $\beta$ -Actin, a structural protein of the cytoskeleton, is up-regulated during the first 7 days of the oestrous cycle and after 0.5h as well as from 24h to 64h after luteolysis. The luteal tissue of the developing CL consists of highly mitotic cells, mainly endothelial cells, which could explain the increase of expression at the early luteal stages. How  $\beta$ -Actin expression is regulated in apoptotic cells is presently not known. The work of Naora *et al.* (1995) indicates that  $\beta$ -Actin is differently expressed in different cells and that these expression is also dependent on the apoptotic stimulus. It is possible that  $\text{PGF2}\alpha$  is responsible for the increased expression after 0.5h. At the time of structural luteolysis, 24h after  $\text{PGF2}\alpha$ , apoptotic cells are found in the CL of marmoset monkeys (Young *et al.* 1998) showing the formation of apoptotic bodies. These formation effects the cytoskeleton of the cells and is associated with the depolymerisation of Actin, which also plays a particular role in the formation and maintenance of these apoptotic bodies (Suarez-Huerta *et al.* 2000). These results might indicate the reason for the up-regulation of the  $\beta$ -Actin expression during structural luteolysis. GAPDH is an enzyme necessary for the glycolysis and gluconeogenesis. It shows an increased expression during the first seven days of the oestrous cycle, which could be due to the higher mitotic cell rate and the higher metabolic rate of these cells compared to the midluteal stage. It is reported that GAPDH expression is different during the cell cycle (Mansur *et al.* 1993) and that growth hormones can activate its transcription (Freyschuss *et al.* 1994). Two groups (Qi and Sit 2000b) also reported that GAPDH is up-regulated during apoptosis and that it is regulated by p53 (Chen *et al.* 1999). Our data show that GAPDH is not regulated during luteolysis, although an increase of expression can be seen from 24h onwards just like the expression of p53. It might be due to the greater variances in the groups that no significancies were found. Ubiquitin is necessary for the degradation of proteins and acts as regulator of all aspects of cell biology, including cell division, growth, communication, movement and apoptosis (Johnson 2002; Pickart 2001). It is reported that Ubiquitin is up-regulated during  $\text{PGF2}\alpha$  induced luteolysis in marmoset monkeys (Young *et al.* 1998) and in sheep (Murdoch *et al.* 1996). This is in contrast to our data, which revealed a slight but significant decreased expression of Ubiquitin from 48h to 64h during induced luteolysis. The reason for these down-regulation is not know and has to be further investigated. For the evaluation of factors in tissues undergoing apoptosis it seems to be necessary to normalise these datas with more than one HKG, because of their specific roles during apoptosis.

## 6.2.2 Extracellular matrix proteases in the CL during oestrous cycle and induced luteolysis

### 6.2.2.1 CL during oestrous cycle

#### 6.2.2.1.1 *Matrix metalloproteases (MMPs)*

After ovulation, the follicular tissue is reorganised as granulosa cells hypertrophy, theca and granulosa-cells differentiate into luteal cells, and vasculature forms in the granulosa luteal compartment (Young *et al.* 2002). The CL is a most highly vascularised organ and receives the greatest rate of blood flow per unit of tissue of any organ in the body (Wiltbank *et al.* 1988). Degradation of the ECM by MMPs is required in endothelial cell migration, organisation and, hence, angiogenesis (McCawley and Matrisian 2000). For the formation of new vessels, the basement membrane of capillaries must be degraded (fig. 38) to allow migration of endothelial cells from the theca interna compartment into the surrounding avascular granulosa luteal tissue. Even if the expression of MMP-1 during 20h after GnRH and during the first seven days of oestrous cycle is not significantly regulated, which might be caused by a higher variance within the groups, there is evidence that MMP-1 is able to facilitate the *in vitro* migration of microvascular endothelial cells, and is therefore associated with advancing angiogenesis (Partridge *et al.* 2000). Although a number of studies on the regulation of *in vitro* endothelial MMP expression by angiogenic growth factors have shown an induction of MMPs. bFGF and VEGF have been reported to induce MMP-1 expression, whereas VEGF also increases MMP-2 expression (Lamoreaux *et al.* 1998; Sato *et al.* 2000; Unemori *et al.* 1992). As shown for the bovine CL (Berisha *et al.* 2000) VEGF is up-regulated in the first seven days of the oestrous cycle, while bFGF (FGF-2) increases at day 1-2 in the bovine CL (Schams *et al.* 1994), so that a regulatory effect of these growth factors on MMPs could be assumed. Not only MMP-1, but also MMP-2, its receptor MMP-14 and inhibitor TIMP-2 may play a critical role in angiogenesis. Even though no statistically significant regulation for MMP-2 and MMP-14 could be evaluated during oestrous cycle, TIMP-2 mRNA expression was significantly increased during the first seven days. Our hypothesis is, that at the beginning of CL formation not all bindings site of MMP-14 are blocked by TIMP-2, because of its reduced expression compared to the mid luteal phase. This could suggest, that MMP-2 might not be inhibited at the beginning of vessel sprouting in the CL, but during mid luteal phase, when angiogenesis is completed. Our findings are in agreement with recent data (Goldberg *et al.* 1996; Smith *et al.* 1996; Zhang *et al.* 2002; Zhang *et al.* 2005). MMP-2, MMP-14 and TIMP-2 are localized in bovine luteal endothelial cells during early and mid cycle (Zhang *et al.* 2002, Zhang *et al.* 2003), which enables these cells to digest collagen

type IV, a major component of the basement membrane (Moses 1997), which has to be penetrated to ensure their migration. A lack of MMP-14 leads to insufficient angiogenesis in mice (Zhou *et al.* 2000) and a neutralising MMP-2 antibody could inhibit capillary tube formation by bovine endothelial cells, an indispensable step in angiogenesis (Zhang *et al.* 2005). In ewes, administration of a MMP-2 antibody results in incomplete CL formation, whereby the build up of normal vasculature is blocked (Gottsch 2001). All these findings suggest, MMP-2 play an essential role in neovascularisation events in the developing CL. MMP-2, MMP-14 and TIMP-2 were also found to be expressed in large luteal cells and the activation of MMP-2 during CL development enables these cells to degrade the pericellular ECM, which is necessary to accommodate the enlargement of these cells during this time (Zhang *et al.* 2003). The same action as activated MMP-2 on basal membranes is thought of MMP-19, which was detected in endothelial and vascular smooth muscle cells (Djonov *et al.* 2001; Kolb *et al.* 1999). In the rat CL the lowest expression of MMP-19 mRNA was seen during day 2 to 8 of the oestrous cycle (Jo and Curry, Jr. 2004). TIMP-1 is able to counteract with MMP-19 (Kolb *et al.* 1999), which could be possible in the developing bovine CL to hold the action of MMP-19 in bay. MMP-9 shows a steadily increased expression 20h after GnRH till the mid luteal phase. This expression pattern could be caused by invading macrophages, which are known to produce MMP-9 (Welgus *et al.* 1990).

#### 6.2.2.1.2 Tissue inhibitors of matrix metalloproteases (TIMPs)

The massive capability of proteases to degrade the ECM must be held in bay by inhibitors like TIMPs. These inhibitory action of TIMP-1 and TIMP-2 can be assumed in the developing CL, where TIMP-1 is, among others, expressed in vascular smooth muscle cells. These cells play a critical role in vascular maturation and survival. TIMP-1 might be a protective factor for newly formed capillaries by curbing MMP-19 activity (Nehls *et al.* 1992; Zhang *et al.* 2003). TIMP-1 deficient mice display reduced serum progesterone levels during CL development, which can be linked to its ability to regulate MMP action (Nothnick 2003). Additionally to their inhibitory activities TIMP-1 and TIMP-2 stimulate the growth of endothelial cells and fibroblasts as well as other cell types unrelated to their MMP inhibitory activity (Hayakawa *et al.* 1992; Hayakawa *et al.* 1994). In the bovine, ovine and porcine CL TIMP-1 is expressed in large luteal cells during the oestrous cycle (Pitzel *et al.* 2000; Smith *et al.* 1994a; Zhang *et al.* 2003). The presence of TIMP-1 in steroidogenic cells may be associated with its ability to enhance steroid production during maturation of the CL, which could explain the higher mRNA expression in the first seven

---

days of CL development additionally to its ability to inhibit MMP-19.


#### 6.2.2.1.3 Plasminogen activator system (PAs)

Another important proteolytic system, which influences the rapid angiogenesis in the CL are the plasminogen activators tPA and uPA with its receptor uPAR and their inhibitors PAI-1 and PAI-2. Our data revealed a constant expression of tPA, which was not regulated during oestrous cycle, while uPA, uPAR, PAI-1 and PAI-2 levels were increased from 20h after GnRH onwards till the mid luteal phase, respectively till day 5-7 for PAI-1. Previous studies in the rat (Bacharach *et al.* 1992), mouse (Liu *et al.* 2003) and monkey (Liu *et al.* 1997) showed a distinct expression of uPA and PAI-1 in the developing CL. uPA was found to be expressed by endothelial cells along the route of capillary extensions, while PAI-1 was expressed in fibroblasts in the environments of uPA expressing capillary like structures. These results suggest, that PAI-1 may protect neovascularised tissues from excessive proteolysis (Bacharach *et al.* 1992; Bacharach *et al.* 1998). Interaction between uPA and its receptor appear to be mandatory for the angiogenic effect of uPA as was shown with monoclonal antibodies anti-uPA and anti-uPAR that blocked the proangiogenic effects of uPA at the endothelial cell level (Fibbi *et al.* 1998). In addition to their proteolytic impact uPA, uPAR and PAI-1 seem to play an essential role in cell migration. Both uPAR and PAI-1 are able to bind to vitronectin (Okumura *et al.* 2002), an adhesive glycoprotein in the ECM, which attaches cells to the ECM. uPA increases the affinity of uPAR to vitronectin and at the same time enables PAI-1 to compete with uPAR for the binding site on vitronectin. This process leads to endocytosis of the uPA/uPAR/PAI-1 complex and detachment of the cells from their environment, which is necessary for migration. It is thought that PAI-1 is only able to detach cells, if cell surface uPAR is increased over the engaged integrins. This hypothesis is supported by the observation that overexpression of uPAR in CHO cells (i.e. increased ratio of uPAR to integrins) led to a pronounced increase in the efficiency of PAI-1 to detach the cells from fibronectin (Czekay *et al.* 2003). A recent study (Isogai *et al.* 2001) revealed that endothelial cells escape the vitronectin rich environment of their perivascular space and penetrate the unvascularised and fibronectin rich stroma. In terms of these data it seems possible that endothelial cells in the CL expressing uPA/uPAR interact with PAI-1 secreted from fibroblast, become detached from the ECM and are now able to migrate into the unvascularised stroma to form new capillaries, which is the fundamental step to enable the supply of luteal cells. One could assume an angiogenic effect during oestrous cycle due to the high expression of uPA, its receptor uPAR and PAI-1 during the time of




angiogenesis, which is normally completed at days 5-7 of the oestrous cycle (Berisha *et al.* 2000). Like some MMPs the PAs are induced in endothelial cells upon stimulation with angiogenic factors like VEGF and bFGF (Mandriota and Pepper 1997). PAI-2 shows an equal expression pattern like PAI-1. PAI-2 is known to be expressed by monocytes (von Heijne *et al.* 1991) and eosinophils (Swartz *et al.* 2004). Eosinophils seem to play an essential role in neovascularisation of the newly formed CL (Murdoch and Steadman 1991). Immediately before ovulation a recruitment of eosinophils into the junction between the theca and granulosa cell layer of the dominant follicle takes place. Our data suggest, that this happens between 20h after GnRH and ovulation. After follicle ruptur high numbers of eosinophils gather in the former follicle antrum and are accumulating within and around dilated vessels in the developing bovine CL (Reibiger and Spanel-Borowski 2000). In sheep, eosinophils are assumed to influence angiogenesis, because cortisol induced eosinopenia causes small-sized corpora lutea with an underdeveloped vascular bed and thus insufficient endocrine function (Murdoch and Steadman 1991). Having these circumstances in mind it seems possible that the increased mRNA expression of PAI-2 is due to the invasion of eosinophils into the developing CL. The role of PAI-2 in eosinophils is not clear thus a protective function against degradation of their cell membran through uPA being released from endothelial cells seems possible.

**A. Degradation of basement membranes during angiogenesis**



**B. Migration of endothelial cells while sprouting of new capillaries**



- up-regulation
- ⊥ inhibition
- expression
- complex formation

Figure 38: Schematic presentation of cells, which express matrix metalloproteases, their inhibitors and the plasminogen activator system during angiogenesis in the bovine CL.

6.2.2.2 CL during induced luteolysis

6.2.2.2.1 *Matrix metalloproteases (MMPs) and tissue inhibitors of matrix metalloproteases (TIMPs):*

A complete different mRNA expression pattern then during the oestrous cycle was seen for all investigated factors during PGF<sub>2</sub> $\alpha$  induced luteolysis. To our astonishment MMP-1 mRNA expression was 256-fold up-regulated within two hours after PGF<sub>2</sub> $\alpha$  application and remained constant at this high level till 64h with a peak of 1024-fold increase at 48h compared to control group. MMP-1 and the plasminogen activator system were the only

ones of the investigated factors showing an increased expression already at the beginning of luteolysis 0.5h and 2h after PGF<sub>2</sub> $\alpha$  injection, respectively. These synergistic expression might be linked to the infiltration of T lymphocytes and macrophages into the regression CL as was demonstrated in cattle (Penny *et al.* 1999), rat (Townson *et al.* 1996), pig (Standaert *et al.* 1991) and human (Brannstrom *et al.* 1994b). Recently, the expression of the monocyte chemoattractant protein-1 (MCP-1) by cells of the CL has been postulated as mechanism for the recruitment of monocytes/macrophages within the CL during luteolysis (Townson *et al.* 2002), which have been implicated in phagocytosis of luteal cells (Paavola 1979), degradation of ECM (Endo *et al.* 1993) and secretion of proinflammatory mediators (Benyo and Pate 1992; Rueda *et al.* 2000). Our own study of MCP-1 as well as results from other groups (Bowen *et al.* 1996; Penny *et al.* 1998; Tsai *et al.* 1997) shows a significant increase of mRNA expression from 0.5h until 64h after induction of luteolysis with a 16- to 32-fold up-regulation at 2h and 24h. MCP-1 is expressed in bovine endothelial cells in the CL as well as in fibroblasts, monocytes and T lymphocytes (Penny 2000). We hypothesise that the early increase of MCP-1 after 0.5h might be due to expression by endothelial cells, which recruit monocytes from the circulation into the cellular compartment of the CL. Monocytes themselves express MCP-1, which could lead to a higher expression level seen from 2h onwards after induction of luteolysis. They are also thought to contribute to the loss of connective tissue component of the ECM through production of MMP-1, MMP-9, MMP-2 (Welgus *et al.* 1990) and the plasminogen activator system (Sitrin *et al.* 1994) while migrating from blood vessels into the surrounding tissue. There is evidence that collagen I, which is a major component of the ECM in the CL (Luck and Zhao 1993) induces the expression of MMP-1 in macrophages already after 2h in culture (Shapiro S.D. *et al.* 1993) and that laminin up-regulates uPA as well as MMP-9 expression after 1h and 4h, respectively (Khan and Falcone 1997). Collagen I is degraded primarily by MMP-1 whereas MMP-9 is involved in degrading collagen I that has been denatured by the initial cleavage by MMP-1 (Zhou *et al.* 2003). In context of these data the chronology of MMP-1 and MMP-9 expression during luteolysis could be explained.

Considering all these data monocytes/macrophages seem likely to play an important role in degrading the ECM in the regressing CL through their ability to secrete different proteases. There is evidence that TNF $\alpha$ , INF $\gamma$ , IL- $\beta$  and GM-CSF enhance the protein secretion of MMP-1, MMP-9, uPA and uPAR in monocytes when they are differently combined among each other (Kirchheimer *et al.* 1988; Sitrin *et al.* 1994; Zhang *et al.* 1998; Zhou *et al.* 2003). The same regulatory mechanism through inflammatory cytokines like TNF $\alpha$ , INF $\gamma$  and IL- $\beta$  can be hypothesised in the regressing CL. All of these cytokines

show an increased expression during luteolysis in cattle and are known to be produced by macrophages, lymphocytes, fibroblasts and endothelial cells all of them being abundant in the CL (Neuvians *et al.* 2004). Another MMP regulated by  $\text{TNF}\alpha$  is MMP-2. Different groups showed in cell culture experiments that  $\text{TNF}\alpha$  up-regulates the MMP-2 expression in luteal cells in porcine (Pitzel *et al.* 2000) and bovine (Zhang *et al.* 2005) species in a time and concentration depending manner. In bovine luteal cells mRNA expression of MMP-2 is significantly increased after 12h to 48h, which is in contrast to our *in vivo* data showing a significant up-regulation only at 48h and 64h after induced luteolysis. This could be due to lower  $\text{TNF}\alpha$  concentration acting in the *in vivo* system than used in cell culture. The connecting link between  $\text{TNF}\alpha$  and MMP-2 is p53, a tumor suppressor gene, which expression is increased by  $\text{TNF}\alpha$  (Bian and Sun 1997b; Gotlieb *et al.* 1994; Yeung and Lau 1998). p53 acts as a transcription factor on the promoter of MMP-2 and thereby increasing the MMP-2 mRNA expression (Bian and Sun 1997). We could show during induced luteolysis that the p53 mRNA expression pattern is identical to the MMP-2 expression. This congruence in mRNA expression might give evidence of a connection between ECM degradation and apoptosis of cells, which is also necessary for the regression of the CL. Detachment of cells from the ECM results in apoptosis (Alexander *et al.* 1996), whereas endothelial cells expressing MMP-2 in the regressing CL (Duncan *et al.* 1998; Ricke *et al.* 2002b; Young *et al.* 2002; Zhang *et al.* 2005) seems to be the first cells to undergo separation from the ECM and apoptosis (Modlich *et al.* 1996). At the beginning of structural regression of the CL an alteration on the vascular elements, which includes detachment of endothelial cells from the basal membrane and occlusion of small blood vessels, occurs (Davis *et al.* 2003). MMP-2 is known to degrade basement membranes and is therefore necessary for detaching endothelial cells (Moses 1997). The activation of MMP-2 is regulated through the expression of its receptor MMP-14 and TIMP-2, which either enhances or suppresses the MMP-2 activation depending on the concentration of TIMP-2 (Curry, Jr. and Osteen 2003). At the time of structural regression after 12h of induced luteolysis an up-regulation of MMP-14 and simultaneous decrease of TIMP-2 till 64h can be seen. It might be that TIMP-2 being high expressed at the midluteal phase suppresses MMP-2 activation and as recently as its expression decreases an activation of MMP-2 can occur while structural regression. Our data concerning TIMP-2 are in contrast to older findings (Juengel *et al.* 1994), who showed an up-regulation of TIMP-2 mRNA expression at 8h and a decrease at 48h after induced luteolysis. This could be due to different detection methods. The same action as activated MMP-2 on basal membranes is thought for MMP-19, which was detected in endothelial and vascular smooth muscle cells (Djonov *et al.* 2001; Kolb *et al.* 1999). In the rat ovary the highest expression

of MMP-19 mRNA was localised in the regressing CL (Jo and Curry, Jr. 2004), which is in agreement with our mRNA expression data. TIMP-1 is able to counteract with MMP-19 (Kolb *et al.* 1999), which can be assumed till 12h after induced luteolysis when TIMP-1 is high and MMP-19 still low expressed. MMP-19 expression starts to increase after the beginning of structural luteolysis, which could potentiate the degradation of laminin and therefore the detachment and apoptosis of endothelial cells.

#### 6.2.2.2 Plasminogen (PA) activator system

The plasminogen activator system, especially uPA, uPAR and PAIs, is supposed to play a important role in enabling monocytes, neutrophils and activated T cells to migrate through basal membrans by degrading laminin (Khan and Falcone 1997). Migrating monocytes polarise uPAR at the leading edge focusing the chemotactic gradient and thereby binding uPA on their specific site of the plasma membran (Plesner *et al.* 1997). It has been shown that monocytes synthesise PAI-2, which function extracellularly to limit uPA activity and thus regulate the invasive capabilities of monocytes (Estreicher *et al.* 1990). The vast majority of PAI-2 synthesized by monocytes, however, remains intracellular (von Heijne *et al.* 1991). Activation of monocytes by inflammatory agents such as  $TNF\alpha$  induces a rapid accumulation of high levels of PAI-2 in the cytoplasm that does not appear to be correlated with uPA synthesis (Vassalli *et al.* 1992) and may play a functional role in regulating apoptotic cell death in these cells (Chapman *et al.* 1990; Dickinson *et al.* 1995). Chapman *et al.* (1990) revealed that macrophages also produce PAI-1, which is mainly found in the extracellular space. This indicates that PAI-1 is the major extracellular PA inhibitor which is able to retard tPA and uPA. An increased expression of tPA was recently shown in monkey and rat CL during luteolysis (Liu *et al.* 1996; Liu *et al.* 2003). The source of tPA seem to be luteal cells (Liu *et al.* 2003) and macrophages (Hart *et al.* 1989). The functional role of tPA while luteolysis is not clear, but addition of exogenous tPA to cultured rat or monkey luteal cells significantly decreased their progesterone production (Feng *et al.* 1993; Liu *et al.* 1995). This suggests that tPA might be not only a molecule that participates in the extracellular matrix degradation during luteal tissue regression, but also a molecule that may have other activities to inhibit progesterone synthesis via possible autocrine and paracrine pathways.

### 6.2.3 Apoptosis in the CL during oestrous cycle and induced luteolysis

#### 6.2.3.1 CL during oestrous cycle

##### 6.2.3.1.1 *Fas antigen (Fas) and Fas-Ligand (FasL)*

The Fas antigen is a member of the tumor necrosis factor family of cell surface receptors (Nagata and Golstein 1995) and engagement of Fas with its ligand induces apoptosis. FasL is expressed at high levels on activated T lymphocytes (Suda *et al.* 1993) and mediates apoptosis of target cells (Nagata and Golstein 1995). Expression of Fas and FasL mRNA has been demonstrated in CL of mice, rats and humans (Sakamaki *et al.* 1997; Roughton *et al.* 1999; Kondo *et al.* 1996). Moreover, FasL has been shown to enhance mouse structural luteolysis *in vivo* (Sakamaki *et al.* 1997). The present study demonstrates that Fas mRNA expression is not regulated during the first twelve days of oestrous cycle as is in agreement with the data of Taniguchi *et al.* (2002), who found an up-regulation only during regression of the bovine CL. Fas is expressed on human granulosa cells (Quirk *et al.* 1995) as well as on bovine (Taniguchi *et al.* 2002) and mouse luteal cells (Quirk *et al.* 2000b), which became only sensible to Fas mediated apoptosis when treated with  $\text{INF}\gamma$  alone or with  $\text{INF}\gamma$  in combination with  $\text{TNF}\alpha$ . These cytokines are expressed by activated T cells and macrophages (Pate 1995), which are located in the bovine CL during the whole oestrous cycle. But an activation of these cells with a greater increase in numbers occurs not before day 14 (Penny *et al.* 1999). Also progesterone and growth factors like insulin-like-growth-factor (IGF) suppress the up-regulation of Fas expression, proving an anti-apoptotic function of growth factors and progesterone (Kuranaga *et al.* 2000; Quirk *et al.* 2000). Our data reveal that FasL is significantly up-regulated on day 8-12, which could be interpreted as a slight increased numbers of invading T cells.

##### 6.2.3.1.2 *Tumor necrosis factor alpha (TNF $\alpha$ ), TNF receptor 1 and 2 (TNFR1, TNFR2)*

The expressions of  $\text{TNF}\alpha$  and its receptors, TNFR1 and TNFR2, show a equally higher level during the midluteal phase compared to the early luteal phase in the bovine CL.  $\text{TNF}\alpha$  is known to have luteotropic as well as luteolytic functions in the CL, depending on its concentration. A high dose of  $\text{TNF}\alpha$  leads to a prolongation of the luteal lifespan, whereas a low dose induces luteolysis and shortens the oestrous cycle (Skarzynski *et al.* 2003).  $\text{TNF}\alpha$ , TNFR1 and TNFR2 are evident in the early stage CL in cows (Sakumoto *et al.* 2000; Skarzynski *et al.* 2003), pigs (Wuttke *et al.* 1997; Miyamoto *et al.* 2002) and

human (Vaskivuo *et al.* 2002).  $\text{TNF}\alpha$  is a potent stimulator of luteal prostaglandins (PGs) including  $\text{PGF}_2\alpha$  and  $\text{PGE}_2$  (Benyo and Pate 1992; Sakumoto *et al.* 2000). Luteal PGs are known to stimulate progesterone secretion from bovine CL *in vitro*, suggesting that they have luteotropic abilities (Miyamoto *et al.* 1993). Macrophages (Zhao *et al.* 1998, Hehnke-Vagnoni *et al.* 1995) and endothelial cells are sources of  $\text{TNF}\alpha$ , and these cells infiltrate into newly formed CL concomitant with vascular angiogenesis (Reynolds *et al.* 1994). These findings could be the reason, why the mRNA expression of  $\text{TNF}\alpha$  elevates during the development of the CL. Thus it could be assumed that  $\text{TNF}\alpha$  contributes to the production of PGs in the early CL and may partly promote the formation of the CL. Additional studies in human luteinised granulosa cells support a luteotropic role of  $\text{TNF}\alpha$  (Yan *et al.* 1993). This effect is not limited to steroidogenic cells since  $\text{TNF}\alpha$  is capable of stimulating  $\text{PGE}_2$  secretion in bovine luteal endothelial cells (Okuda *et al.* 1999). Since both  $\text{TNF}\alpha$  (Leibovich *et al.* 1987) and  $\text{PGE}_2$  (Schorr 1985) are known to affect the proliferation of endothelial cells, both of these factors may have a regulatory influence on the proliferation of endothelial cells during the luteal development. The action of  $\text{TNF}\alpha$  is mediated through its two receptors TNFR1 and TNFR2 (Okuda *et al.* 1999). In the bovine CL TNFR1 is expressed by small and large luteal cells as well as by endothelial cell. In these cells the expression was significantly higher as in the steroidogenic cells (Friedman *et al.* 2000). TNFR1 is increasing in the same pattern as  $\text{TNF}\alpha$  during oestrous cycle, which might be due to the proliferative stage of the endothelial cells during angiogenesis in the early CL. Our data are in contrast to earlier findings of Sakumoto *et al.* (2000), who could show an increased expression during days 3-7 followed by a decrease at day 8-12 to the level seen at days 1-2. A higher sensitivity of the real time PCR compared to the block PCR could be the reason for these differences. TNFR2 is also expressed in bovine endothelial cells in the CL (Okuda *et al.* 1999) as well as in T cells and macrophages (Carpentier *et al.* 2004; Mukhopadhyay *et al.* 2001). In macrophages both receptors seem to be required for  $\text{TNF}\alpha$  induced proliferation (Mukhopadhyay *et al.* 2001). If TNFR2 is also needed for endothelial cell proliferation is not known. The increased expression during oestrous cycle could be a sign of infiltration of macrophages into the developing CL.

#### 6.2.3.1.3 p53, Bax and Bcl-X<sub>L</sub>

The mRNA expression of p53 and Bax showed no significant regulation during oestrous cycle in the bovine CL. There are no data available how p53 is regulated in other species during oestrous cycle. But different groups reported a regulated expression of p53 in bovine luteal cells, human and rat granulosa cells during apoptosis (Nakamura and Sakamoto 2001; Herr *et al.* 2004; Amsterdam *et al.* 2003). It seem unlikely that apoptosis occurs during the the first seven days of oestrous cycle being the time were massive formation of new capillaries occurs (Berisha *et al.* 2000) as well as during days 8-12, when the CL reaches its highest secretory abilities. bFGF seems to have a suppressive action on the expression of p53 in human granulosa cells. It enhances MDM2 expression, which blocks p53 activity (Amsterdam *et al.* 2003). VEGF as angiogenic factor is also linked with p53. Wild type p53 is able to decrease VEGF expression in human leiomyosarcoma cells and to inhibit angiogenesis, which is very important for the development of the CL (Zhang *et al.* 2000). These data could explain, why p53 is not regulated during oestrous cycle. p53 is associated with the mitochondrial pathway during apoptosis and increases the expression of Bax, an apoptotic factor of the intrinsic pathway, and by the other hand decreases the Bcl-2 expression, which is an anti-apoptotic factor that inhibits the action of Bax (Miyashita *et al.* 1994; Miyashita and Reed 1995). Bax was found to be expressed in human granulosa and theca cells, bovine luteal cells and rat granulosa cells (Rodger *et al.* 1998; Liszewska *et al.* 2005; Tilly *et al.* 1995). We showed that Bax is not regulated during oestrous cycle as well as its enhancer p53 in the bovine CL, which was also found in the human CL during early and midluteal phase (Sugino *et al.* 2000). There is evidence that progesterone not only regulates Fas expression, but also prevents an up-regulation of Bax in bovine luteal cells during early to mid luteal phase. The same result is seen for PGE<sub>2</sub>, which stimulates the progesterone secretion in bovine CLs and so might prevent apoptosis (Liszewska *et al.* 2005). How progesterone regulates the expression of Bax is not clear, but there seems to be a possible correlation with the progesterone receptor (Marone *et al.* 1998). The opponents of Bax are either Bcl-2 or Bcl-X<sub>L</sub>, which are forming heterodimers with Bax and preventing the activation of capsase3 through the mitochondrial pathway (Hengartner 2000). Bcl-X<sub>L</sub> was found in rat granulosa cells and in the bovine corpus luteum during structural luteolysis (Tilly *et al.* 1995; Rueda *et al.* 1997). As for Bax, progesterone plays a regulatory role in Bcl-2 expression in bovine luteal cells. It increases the Bcl-2 expression and prevents apoptosis of these cells (Liszewska *et al.* 2005). We were not able to detect Bcl-2 cDNA in the bovine CL despite the use of several primer pairs, which were designed using the bovine Bcl-2 sequence



(acc. no. XM\_612457), which was also used by Liszewska *et al.* (2005). The same experience was made by Rueda *et al.* (1997), who decided to use Bcl-X<sub>L</sub> instead. These Bcl-2 family member has the same anti-apoptotic functions like Bcl-2, so that a comparable regulation could be assumed. If progesterone up-regulates Bcl-X<sub>L</sub> in the same manner like Bcl-2, the increase of the Bcl-X<sub>L</sub> expression during the midluteal phase could be explained by a higher progesterone level compared to the early luteal phase. Other regulatory factors of Bcl-2 and Bcl-X<sub>L</sub> are bFGF and VEGF, which were found to increase the expression of these factors in endothelial cells (Pardo *et al.* 2002; Del Bufalo *et al.* 2003). Inhibition of Bcl-X<sub>L</sub> with antisense oligonucleotides lead to an antiangiogenic effect with a decrease in endothelial cell proliferation (Del Bufalo *et al.* 2003).

#### 6.2.3.1.4 Smac and Survivin

Pro-angiogenic factors seem to play a critical role in the regulation of not only p53, Bax and Bcl-X<sub>L</sub>, but also of Smac and Survivin. Angiopoietin-1 (Ang-1) promotes endothelial cell survival during vascular development and maintains the vascular integrity (Suri *et al.* 1996; Thurston *et al.* 2000). Recent findings show that Ang-1 plays an important role in the modulation of angiogenesis in the human and bovine CL during oestrous cycle (Wulff *et al.* 2000; Tanaka *et al.* 2004). It was found that Ang-1 is able to suppress the expression of Smac and to enhance the expression of Survivin in serum deprived endothelial cells, whereas cell survival is mediated. These effects were only seen, when Ang-1 interacted with Tie-2 and not with integrins (Harfouche *et al.* 2002). Minimal detectable levels of Survivin are found in quiescent endothelial cells, whereas an abundantly expression is seen in endothelial cells of three-dimensional vascular tubes *in vitro* and in newly formed capillaries during angiogenesis *in vivo*. Survivin expression can be stimulated by VEGF (O'Connor *et al.* 2000) and bFGF (Tran *et al.* 1999), which is consistent with the cell cycle dependent expression of the survivin gene in G2/M phase (Li *et al.* 1998) and suggests that this pathway maintain a critical anti-apoptotic threshold at cell division. bFGF is not only able to increase Survivin, but also to decrease the release of Smac from the mitochondria of lung cancer cells (Pardo *et al.* 2003). Survivin regulates cell survival during angiogenesis either by binding to Smac, which is then not able to inhibit XIAP (Song *et al.* 2003), or by inhibiting caspase3 in a direct or indirect way (Johnson *et al.* 2002). Having this in mind it seems possible that the up-regulation of Survivin during the first seven days of the oestrous cycle is related to the massive angiogenesis occurring during this time.

#### 6.2.3.1.5 Caspase3, -6 and -7

The caspases 3, -6 and -7 belong to the so called effector caspases, which are able to cleave specific substrates during apoptosis including poly (ADP-ribose) polymerase, DNA-dependent protein kinase and structural proteins like actin and lamins (Rosen and Casciola-Rosen 1997). These caspases play an essential role in the regression of the CL as was seen in caspase3 deficient mice (Carambula *et al.* 2002). Not many data can be found about their expression, especially of caspase6 and -7, during oestrous cycle in different species. It is reported, that caspase3 protein is constantly expressed through out the oestrous cycle in the human CL (Vaskivuo *et al.* 2002). In the macaque CL immunohistochemistry revealed a constant expression of caspase3 during early and mid luteal phase with a higher expression at the onset of regression. The mRNA expression was not regulated during the whole menstrual cycle (Peluffo *et al.* 2005). This confirms our data, which showed a not regulated expression of caspase3 during the first twelve days of the oestrous cycle. D'haeseleer *et al.* (2006) also found an expression of caspase3 in small and large luteal cells during different stages of the bovine oestrous cycle- which were not significantly regulated. In the human CL only few cells are found to undergo apoptosis during early and mid luteal phase (Vaskivuo *et al.* 2002), which could be also possible for the bovine CL, so that no regulation of caspase3 and -7 can be found. Caspase6 is significantly up-regulated from the early to the mid luteal stage, which one could see as gradual progress of accumulation of mRNA for the following regression of the CL. Studies with non-pregnant and pregnant ewes showed, that such a accumulation of mRNA is not needed for caspase3 (Rueda *et al.* 1999b). Progesterone is thought to be one of the suppressors of caspase3 activation, because a specific progesterone antagonist increased the caspase3 mRNA level in bovine luteal cells of the mid luteal phase (Okuda *et al.* 2004). The same action on caspase3 activation has VEGF. It was shown that a VEGF antagonist induces apoptosis and caspase3 activation in endothelial cells of the CL in marmoset monkeys (Fraser *et al.* 2005). The highest levels of VEGF mRNA and protein is seen during the first seven days with a decline in expression in the mid and late luteal stage of the bovine CL (Berisha *et al.* 2000).

#### 6.2.3.2 CL during induced luteolysis

Structural luteolysis is a complex process that eliminates the CL from the ovary. There is evidence that structural luteal regression in the cattle occurs via apoptosis (Juengel *et al.* 1993; Zheng *et al.* 1994). This has also been demonstrated in the regression CL of rabbits (Dharmarajan *et al.* 2004), sheep (Rueda *et al.* 1995), rats (Orlicky *et al.* 1992) and

humans (Shikone *et al.* 1996). Two major intracellular apoptosis signaling cascades have been characterised, the extrinsic pathway via the death receptors and the intrinsic pathway via factors released from the mitochondria.

#### 6.2.3.2.1 Extrinsic pathway

Apoptosis can be initiated via several cytokine receptors including the TNF superfamily receptors (TNFRs). TNF $\alpha$  is acting via TNFR1, which is expressed on steroidogenic (Petroff *et al.* 2001) and endothelial cells (Friedman *et al.* 2000) of the bovine CL, and TNFR2, which was demonstrated to be expressed on the granulosa cells of porcine ovaries (Nakayama *et al.* 2003) and bovine endothelial cells (Okuda *et al.* 1999). Cytokines, especially TNF $\alpha$  and INF $\gamma$ , produced by immune cells, which infiltrate the CL during luteolysis, seem to participate in the regression of the bovine CL (Pate and Landis 2001). The number of leukocytes (cytotoxic T cells and macrophages) increases at the time of luteolysis (Penny *et al.* 1999; Townson *et al.* 2002). Subluteolytic release of PGF2 $\alpha$  from the uterus acts on T cells (Penny *et al.* 1999) and endothelial cells (Townson *et al.* 2002) to promote the monocyte chemoattractant protein-1 (MCP-1) production during the late luteal phase. MCP-1 is a member of the chemokine family of cytokines that is involved in leukocyte physiology and chemotaxis (Penny 2000). Provement that PGF2 $\alpha$  is involved in the regulation of MCP-1 is given by a study in which PGF2 $\alpha$  production was inhibited between day 16 and 18 (around natural time of luteolysis) of the oestrous cycle in cattle. No increase in MCP-1 expression or macrophage infiltration was observed in the animals in which luteolysis was inhibited (Penny 2000). These findings could explain the rapid up-regulation of MCP-1 expression seen after 0.5h of PGF2 $\alpha$  injection. This is in agreement with data from Tsai *et al.* (1997), where MCP-1 expression was increased 1h, 4h and 24h after PGF2 $\alpha$  treatment in the CL of ewes. Luteal endothelial cells may express MCP-1 in response to a product from steroidogenic luteal cells or eosinophils (Murdoch 1987). Reactive oxygen species are produced as an early response to PGF2 $\alpha$  (Sawada and Carlson 1991) and these products have been found to stimulate MCP-1 expression in endothelial cells (Kilgore *et al.* 1997; Xu *et al.* 1996). In response to the MCP-1 action there is an influx of macrophages and cytotoxic T cells into the CL, which may also express MCP-1 and explain the further increase seen at 24h after PGF2 $\alpha$  treatment. Macrophages and T cells secrete TNF $\alpha$  and INF $\gamma$  (Pate and Landis 2001), which is in agreement with our data, where a rapid increase of TNF $\alpha$  can be seen from 0.5h after the beginning of induced luteolysis with the highest expression at 2h, which declines to a still

significantly increased expression level at 64h compared to control group.  $\text{TNF}\alpha$  acts by binding to its two receptors TNFR1 and TNFR2, which are both expressed in bovine endothelial cells in the CL (Friedman *et al.* 2000; Okuda *et al.* 1999). Friedman *et al.* (2000) found that TNFR1 is higher expressed in endothelial cells than in steroidogenic cells and that apoptosis was seen in these cells after 6h incubation with  $\text{TNF}\alpha$ . There is evidence that capillary regression and endothelial cell death is a hallmark of  $\text{PGF2}\alpha$  induced luteal regression, these include studies in the pig (Bacci *et al.* 1996), guinea pig (Azmi and O'Shea 1984), sheep (Rueda *et al.* 1995) and human CL (Gaytan *et al.* 1999). Steroidogenic luteal cells were found to undergo apoptosis at a later stage, when a massive degeneration of capillaries had already occurred (Juengel *et al.* 1993; Bacci *et al.* 1996). We found a constant, but not regulated expression of TNFR1 during induced luteolysis as well as a significantly increased expression of TNFR2 from 2h till 64h. It could be that apoptosis of endothelial cell in the CL is triggered through the interaction of TNF with both receptors as it was described by Fotin-Mleczek *et al.* (2002). The prestimulation of TNFR2, compared to the expression of TNFR1, can lead to its binding of tumor necrosis factor receptor-associated factor-2 (TRAF2), which is a necessary factor for the activation of the anti-apoptotic  $\text{NF}\kappa\text{B}$  pathway by TNFR1, and lead to apoptosis of endothelial cells. Pru *et al.* (2003) reported that  $\text{TNF}\alpha$  mainly acts on microvascular endothelial cells of the bovine CL, which induces apoptosis potentiated by  $\text{INF}\gamma$ . It was shown that progesterone is able to inhibit apoptosis in endothelial and luteal cells (Friedman *et al.* 2000; Rueda *et al.* 2000a), suggesting that progesterone may serve as a regulator of luteal cell survival. The decrease of progesterone during luteolysis is initiated by  $\text{PGF2}\alpha$ , which also increases the production of endothelin-1 (ET-1) (Meidan *et al.* 1999) and angiotensin (Schams *et al.* 2003) in endothelial cells. ET-1 augments  $\text{PGF2}\alpha$  induced inhibition of progesterone synthesis and then may act by stimulation of  $\text{TNF}\alpha$  secretion from macrophages (Meidan *et al.* 1999), thereby promoting the apoptotic cascade in cells of the CL.  $\text{TNF}\alpha$  may also induce a further increase of ET-1 (Woods *et al.* 1999) at the time of luteolysis. If progesterone is able to regulate the TNFRs is not known up to date, but there is evidence that the mRNA expression of Fas, another death receptor belonging to the TNFR family, can be increased by a progesterone antagonist onapristone (OP) in cultured bovine luteal cells (Okuda *et al.* 2004). This was also found in rat luteal cells, where progesterone suppresses prolactin induced steroidogenic cell apoptosis via a reduction of the Fas expression levels (Kuranaga *et al.* 2000). This could be in agreement with our findings that the expression of Fas is steadily up-regulated from 2h onwards till 64h. Fas induces apoptosis in luteal cells (Taniguchi *et al.* 2002; Kuranaga *et al.* 2000) by binding of Fas-Ligand (FasL), which is expressed on cytotoxic ( $\text{CD8}^+$ ) T

cells (Suda *et al.* 1993). Expression of Fas and FasL has been demonstrated in the CL of mice, rats and humans (Sakamaki *et al.* 1997; Roughton *et al.* 1999; Kondo *et al.* 1996). The highest protein expression of Fas was found during regression of the CL in rats (Roughton *et al.* 1999). Moreover, FasL has been shown to enhance mouse structural luteolysis *in vivo* (Sakamaki *et al.* 1997), while Kuranaga *et al.* (2000) found that FasL expression on immune cells are necessary to induce apoptosis in rat luteal cells. But it was also found that FasL alone has no cytotoxic effect on luteal cells. However, treating luteal cells with FasL in combination with OP resulted in killing of 55% of the cells, while with OP alone only 30% were killed (Okuda *et al.* 2004). Other cytokines may also initiate and escalate Fas apoptotic action in the CL. The expression of Fas mRNA was increased by  $\text{INF}\gamma$ , and  $\text{TNF}\alpha$  augmented the stimulatory action of  $\text{INF}\gamma$  on Fas expression. Moreover, apoptotic bodies were observed in luteal cells treated by FasL in the presence of  $\text{INF}\gamma$  and/or  $\text{TNF}\alpha$ , showing that leukocyte-derived  $\text{TNF}\alpha$  and  $\text{INF}\gamma$  play important roles in FasL/Fas mediated luteal cell death in the bovine CL (Taniguchi *et al.* 2002). The increase of Fas seen during induced luteolysis can therefore be enabled by the decrease in progesterone and further elevated through the secretion of  $\text{TNF}\alpha$  and  $\text{INF}\gamma$  by invading macrophages, whereas the increased expression of FasL might be due to the infiltration of the CL by cytotoxic T cells.

#### 6.2.3.2.2 *Intrinsic pathway*

The intrinsic apoptotic signaling cascade is generally thought to be activated by apoptotic stimuli that originate within a cell in response to certain drugs, radiation or growth factors withdrawal and primarily cause changes in mitochondrial permeability through alterations in the ratio of pro- and anti-apoptotic Bcl-2 family members (Adams and Cory 1998). There is evidence that the activation of luteal cell death during luteolysis can be triggered by oxidative stress (Rueda *et al.* 1995a).  $\text{PGF}2\alpha$  increases the free intracellular calcium concentration, activates protein kinase C and affects progesterone production by inhibiting cholesterol transport or  $3\beta$ -hydroxysteroid dehydrogenase ( $3\beta$ -HSD) expression (Niswender *et al.* 1994).  $\text{PGF}2\alpha$  also increases the production of reactive oxygen species (ROS) (Riley and Behrman 1991; Sawada and Carlson 1991; Aten *et al.* 1992; Shimamura *et al.* 1995), while progesterone inhibits ROS production (Sugino *et al.* 1996). Decreased blood flow in the CL during regression also activates a xanthine-xanthine oxidase system and produces ROS in the presence of oxygen (Sugino *et al.* 1993). The mononuclear phagocytes produce ROS in the CL throughout the luteal phase, but this production is inhibited during the mid luteal phase by high concentrations of progesterone

(Sugino *et al.* 1996). When ROS overcomes the anti-apoptotic system, nuclear translocation of p53 is known to be induced by H<sub>2</sub>O<sub>2</sub> (Uberti *et al.* 1999) and p53 induced apoptosis requires the generation of ROS (Li *et al.* 1999). It was shown that bovine luteal cells treated with H<sub>2</sub>O<sub>2</sub> underwent apoptosis with an increased mRNA expression of p53 and Bax (Nakamura and Sakamoto 2001). This indicates that p53 and Bax are increased by ROS, which production is induced by PGF2 $\alpha$  and inhibited by progesterone. It was also found that progesterone decreases Bax expression (Liszewska *et al.* 2005), which might not be possible during the beginning of structural luteolysis, when the progesterone level has declined. Our data show an increased mRNA expression of p53 and Bax from the beginning of the structural luteolysis at 24h to 64h after PGF2 $\alpha$  treatment, while the anti-apoptotic factor Bcl-X<sub>L</sub> only shows a slight increase from 48h to 64h. This up-regulation of p53 might be due to an increase in oxidative stress and the beginning of p53 accumulation in the nucleus of the compromised cells (Kastan *et al.* 1991). The expression of Bax shows a higher and earlier increase than Bcl-X<sub>L</sub>, which might indicate a insufficient inhibition of Bax and therefore an activation of the intrinsic pathway leading to apoptosis of luteal cells. An up-regulation of Bax and a constant expression of Bcl-2 mRNA and protein was found in buffalo CL 4h after PGF2 $\alpha$  treatment (Yadav *et al.* 2002). In this study a different PGF2 $\alpha$  analogon in a higher dose was used, which might explain the more rapid increase in expression. Nevertheless it was also reported that p53 and Bax are higher expressed in the regressing than in the bovine CL during pregnancy and that the level of Bcl-X<sub>L</sub> was unchanged (Rueda *et al.* 1997). The same was seen in the human CL (Sugino *et al.* 2000). The both opponents Smac and Survivin are expressed in the bovine CL during induced luteolysis, but Smac is not regulated, while Survivin shows a down-regulation during the first twelve hours of luteolysis. It seems that Smac as pro-apoptotic factor might be posttranscriptionally regulated, which needs to be further evaluated. Survivin is only up-regulated during cell cycle, otherwise it is constantly expressed. The down-regulation during functional luteolysis is not explainable to date.

#### 6.2.3.2.3 Caspase3, -6 and -7:

Both apoptotic pathways lead to the activation of certain effector caspases. The intrinsic pathway leads to the activation of caspase3, -6 and -7, whereas the initiator caspase9 activates caspase3 and -7. In the extrinsic pathway the activation of caspase3 is made by caspase8, if it also activates caspase7 is not known. Caspase6 is activated in both pathways through caspase3, which is able to cleave caspase8 in positiv feedback loop.

These feedback is also seen for caspase3 by cleaving caspase9 (Slee *et al.* 1999). Among the 11 caspases presently known, the vast majority of data support a fundamental role for caspase3 in proteolytic disruption of cellular homeostasis and the ultimate dismantling of the cells destined for apoptosis (Nicholson *et al.* 1995; Casciola-Rosen *et al.* 1996; Wang *et al.* 1994). Caspase3 was found to be expressed in various cells in the ovary of different species (Carambula *et al.* 2002; Vaskivuo *et al.* 2002; Boone and Tsang 1998; Rueda *et al.* 1999; Yadav *et al.* 2005; Peluffo *et al.* 2005; Johnson and Bridgham 2000). It was found, that caspase3 mRNA expression was increased during PGF2 $\alpha$  induced luteolysis in the ovine CL after 12h and that these increase was followed by a significant elevation of activity of caspase3. Also no changes in the mRNA expression was seen on day 12 or day 14 of the oestrous cycle or pregnancy. Thus, if induction of caspase3 is an important factor in luteolysis, changes in caspase3 mRNA level appear to tightly coincide with the actual initiation of luteolysis as opposed to being the result of a gradual process of accumulation throughout the luteal phase (Rueda *et al.* 1999). These findings are in agreement with our data, where the caspase3 mRNA expression also increases from 12h till 64h after PGF2 $\alpha$  and was not regulated during oestrous cycle. This might indicate, that the activity of caspase3 could be equally in the cow as in the sheep CL during luteolysis. Yadav *et al.* (2005) report that caspase3 activation was highly increased 18h after induction of luteolysis. In the monkey CL capsase3 protein expression was highest during the regression phase (Peluffo *et al.* 2005) and caspase3 deficient mice show a resistant to PGF2 $\alpha$  induced apoptosis (Carambula *et al.* 2003) that further confirms the involvement of these caspase in luteal cell apoptosis. Matikainen *et al.* (2001) showed that apoptosis in granulosa cells from caspase3 knock out mice occur later than in wild typ mice, which might be due to the stimulatory activation of caspase7 in the mitochondrial pathway. Caspase7 is later up-regulated in granulosa cells of wild type mice than caspase3, which could explain the later onset of apoptosis in the knock out mice. This might also explain the late up-regulation of caspase7 seen in the bovine CL starting at 24h with an immense increase of 23-fold at 64h. Not many data are available about caspase6 expression in ovarian cells. Only Johnson and Bridgham (2000) reported capsase6 mRNA and protein expression as well as enzyme activity in granulosa and theca cells of hen follicles. Caspase6 is activated by caspase3, both showing similar mRNA expression patterns during induced luteolysis in the bovine CL.

The infiltration of macrophages and T cells seems to be a necessary step in the induced luteolysis of the bovine CL, because of their ability to degradate components of the ECM by expressing matrix metalloproteinases and the plasmingen activator system, and through their induction of apoptosis in endothelial and luteal cells.

#### 6.2.4 Conclusion

It can be ascertained by reviewing our findings and the data published by other groups that ECM degrading proteases play a critical role in the successful angiogenesis during development of the CL after ovulation. VEGF and bFGF seem to be important regulatory factors in these process. They are able to stimulate the expression of MMP-1, MMP-2 in luteal endothelial cells, which enable these cells to degrade the vascular basement membranes for sprouting new capillaries. MMP-19 is also expressed by these cells and has the same action like MMP-2 on basement membranes. The action of MMP-2 is not only regulated by VEGF and bFGF, but also by TIMP-2, which is lower expressed during angiogenesis in the CL and therefore might not block the action of MMP-2. TIMP-1 and TIMP-2 seem to be not only necessary for the inhibition of MMPs, but they are also able to enhance the proliferation of endothelial cell during angiogenesis. VEGF and bFGF also stimulate the expression of uPA in endothelial cells during angiogenesis. By forming a complex with uPAR and PAI-1 on the outer cell membrane these cells might be now able to detach from the vitronectin rich perivascular region and migrate towards the fibronectin rich stroma of the CL in order to form new capillaries.

Not only angiogenesis plays a critical role during CL formation, but also the inhibition of apoptotic action during vessel sprouting. Progesterone, bFGF and VEGF seem to inhibit an increased expression of apoptotic factors like p53 and Bax, while progesterone also inhibits Fas and caspase3. Additionally to the suppression of apoptotic factors an up-regulation of anti-apoptotic factors like Bcl-X<sub>L</sub> and Survivin occurs. TNF $\alpha$ , produced by invading macrophages during CL formation, acts not only as an apoptotic factor, but is also able to enhance the production of PGE<sub>2</sub> in endothelial and luteal cells, which stimulates together with TNF $\alpha$  the proliferation of endothelial cells during luteal angiogenesis.

During regression of the CL the inhibitory action of progesterone, VEGF and bFGF vanish. PGF<sub>2</sub> $\alpha$  as luteolytic agents leads to the expression of MCP-1 on luteal endothelial cells. Thereupon monocytes and cytotoxic T cells migrate into the regressing CL and also start to express MCP-1 to recruit further mononuclear cells. For these migration into the stroma of the CL monocytes express uPA, uPAR and PAI-2. Macrophages are necessary for the phagocytosis of apoptotic cells and the degradation of ECM components in the CL during luteolysis. They are able to express different MMPs like MMP-1, MMP-9 and MMP-2. These MMPs degrade collagen I, the main structural collagen in the stroma of the CL,



which might enhance the migration abilities of these macrophages. MMP-2 is also up-regulated in microvascular endothelial cells by  $\text{TNF}\alpha$ , which is produced by macrophages. At the same time a decrease of TIMP-2 occurs, so that no inhibition of MMP-2 happens and a detachment of the endothelial cells from the basement membrane follows. This leads to apoptosis of the endothelial cells, which seem to be the first cells to undergo cell death during luteolysis of the CL.

Endothelial cells express TNFR1 and TNFR2 on their surface during luteolysis, which leads to the activation of the extrinsic apoptotic pathway by binding of  $\text{TNF}\alpha$ .  $\text{INF}\gamma$  enhances these apoptotic actions on endothelial cells. It seems possible that apoptosis of luteal cells occurs after the degradation of capillaries, which leads to an undersupply with oxygen and an increase of ROSs. These reactive oxygen species up-regulate p53 and Bax as apoptotic factors of the intrinsic pathway, which leads to an activation of the caspases and apoptosis of luteal cells. These apoptotic actions are further enhanced by the activation of the extrinsic pathway. Luteal cells stimulated by  $\text{TNF}\alpha$  and  $\text{INF}\gamma$  express Fas on their cell surface when the progesterone level declines. Cytotoxic T cells, which also migrate into the CL during luteolysis, express FasL and promote luteal cell death by activating the extrinsic pathway. This happens only when the progesterone level is decreased, which is known to happen at the end of the functional luteolysis (fig. 39).




Figure 39: Survey of the procedures during luteolysis of the CL concerning apoptotic factors, MMPs and PA system members.

## 7 Summary

The study is subdivided into two different parts: the first part deals with the development of a method to gain uterus milk *in vivo* during the preimplantation periode in cattle for the investigation of regulatory factors. The second part investigates different proteases in bovine follicles 20 hours after GnRH (Gonadotropin releasing hormone) injection (shortly bevor ovulation) for comparable as well as in the corpus luteum (CL) during oestrous cycle and induced luteolysis. In addition apoptotic as well as anti-apoptotic factors were evaluated in the CL during oestrous cycle and induced luteolysis.

For the development of a method for gaining uterus milk *in vivo* during the first 24 days of gravidity in cattle, nine heifers were cycle synchronised using the Ovsynch method and artificially inseminated. Before flushing an epiduralanaesthesia was given and both uterus horns were flushed with 13ml 0.9% NaCl using a balloon embryo transfer catheter at day 5, 7, 12, 17 and 24 of gravidity. The catheter was placed 1cm cranial to the bifurcatio uteri in both horns. It was possible to retriive between 3ml and 13ml of the used flushing fluid. The uterus milk from the ipsilateral horn was inspected for an embryo and an EDTA-stabilisator was given to the uterus milk of both horns. An infection of the uterus occured in three heifers after the second and in five heifers after the third flushing. In one heifer no infection was found. Between day 17 and day 24 all heifers showed clear signs of oestrus. It was possible to detect progesterone, oestradiol-17 $\beta$ , PGF2 $\alpha$  and VEGF via enzyme immunoassay (EIA) and radio immunoassay (RIA), respectively. Because of the occurred infection no statistic analysis was made. But it could be seen that the level of progesterone ranged between <0.1 and 0.4ng/ml, whereas no correlation to the inflammation was found. The values of the native uterus milk should be about 10-fold higher, because of the diluting effect of the flushing fluid. The pattern of oestradiol-17 $\beta$  was erratic, because the oestradiol levels of the flushing fluid from heifers with no infection till day 12 of gravidity could not be related to each other. It could be shown in further tests that high oestradiol-17 $\beta$  levels were measured via EIA in 0.9% NaCl with EDTA-stabilisator compared to 0.9% NaCl without the stabilisator. VEGF revealed levels between 0.08 and 2.58ng/ml, whereas the higher levels were seen during inflammation. The level of PGF2 $\alpha$  showed a clear correlation to the infection. But there were also differences seen between the different heifers or even between the two uterus horns of one animal during the first flushing, which might be due to the massage of the uterus horns while flushing, which can induce prostaglandin secretion. The method of gaining uterus milk *in vivo* should be changed as follows: to prevent an endometritis just one flushing should be done per gravidity with gaining of the embryo, so that the heifer can be inseminated again after two oestrous cycle. Again both horns should be flushed, whereas one sterile disposable catheter should be used for each horn and the flushing should be devided into two parts: first flushing with 13ml of sterile 0.9% NaCL for biomolecular methodes, then flushing of the embryo using 5 x 50ml sterile PBS buffer. The embryo should be frozen in RNA-Later at -80° for further investigations. The received flushing fluid should be separated in two aliquotes, whereas one is used for the oestradiol-17 $\beta$  measurement and must not contain the

EDTA-stabilisator. These two aliquotes should be centrifugated and the fluid should be stored seperatly at  $-20^{\circ}$  from the received cell pellet. Part of the cell pellet can be used for the identification of the cells found in the uterus lumen and the rest stored in RNA-Later at  $-80^{\circ}$  for further biomolecular investigations. For the evaluation of prostaglandins in the uterus milk it should be considered to treat the heifers with a prostaglandin synthetase inhibitor shortly before flushing.

For the investigations of different extracellular matrix proteases and apoptotic as well as anti-apoptotic factors in bovine follicles and CL, RNA samples of a previous experiment were taken. In these experiment 26 cows received luteolytic dosis of a  $\text{PGF2}\alpha$ -analogon and the CLs were removed by transvaginal ovariectomy 0, 2, 4, 12, 24, 48 and 64 hours after induction of luteolysis. Additionally to these experiment five more cows were ovariectomised and the CLs were taken 0.5 hours after  $\text{PGF2}\alpha$  treatment. For the investigation during oestrous cycle CL samples were collected at the slaughter house. For comparable reasons also follicles 20 hours after GnRH injection were taken using a superovulation model. The mRNA quality was inspected using the Bioanalyzer and good to very good results were seen for all samples. The mRNA expression levels were detected using quantitativ real time PCR (Rotor-Gene with SYBR Green I). The expression datas were normalised with the Bestkeeper index of four housekeeping genes using the  $\Delta\Delta$  CP method. The matrix metalloproteases (MMP-1, MMP-2, MMP-9, MMP-14, MMP-19), their tissue inhibitors (TIMP-1, TIMP-2), the plasminogen activator (PA) system (tissue -PA (tPA), urokinase-PA (uPA), urokinase-PA-receptor (uPAR), PA-inhibitor-1(PAI-1), PA-inhibitor-2 (PAI-2)), which are able degradate the extracellular matrix were investigated in follicles 20h after GnRH injection and in the CL during oestrous cycle and induced luteolysis. Furthermore the mRNA expression of the monocyte chemoattractant protein-1 (MCP-1), factors of the extrinsic apoptotic pathway (Tumor necrosis factor alpha ( $\text{TNF}\alpha$ ), TNF-Receptor-1 (TNFR1), TNF-Receptor-2 (TNFR2), Fas, Fas-Ligand (FasL)) and intrinsic apoptotic pathway (p53, Bax, Bcl-X<sub>L</sub>, Smac, Survivin) as well as the caspses 3, -6 and 7 were evaluated in the CL during oestrous cycle and induced luteolysis. During the first seven days of the oestrous cycle angiogenesis plays a critical role in the development of the CL. Basal membranes of blood vessels have to be removed to enable endothelial cell migration, which is necessary for the formation of new capillaries. MMP-1, MMP-2 and MMP-14 were not regulated, but TIMP-2, MMP-9, MMP-19 and TIMP-1 showed an increasing expression from 20h after GnRH till day 8-12 of the oestrous cycle in the CL. VEGF and bFGF seem to be able to stimulate the expression of MMP-1 and MMP-2 in luteal endothelial cells, which enable these cells to degrade the vascular basement membranes for sprouting new capillaries. MMP-19 is also expressed by these cells and has the same action like MMP-2 on basement membranes. The action of MMP-2 is not only regulated by VEGF and bFGF, but also by TIMP-2, which is lower expressed during angiogenesis in the CL and therefore might not block the action of MMP-2. TIMP-1 and TIMP-2 seem to be not only necessary for the inhibition of MMPs, but they are also able to enhance the proliferation of endothelial cell during angiogenesis. VEGF and bFGF also stimulate the expression of uPA in endothelial cells during angiogenesis. By forming a complex with uPAR and PAI-1 on the outer cell membrane these cells might be now able to detach from the vitronectin

rich perivascular region and migrate towards the fibronectin rich stroma of the CL in order to form new capillaries. Not only angiogenesis plays a critical role during CL formation, but also the inhibition of apoptotic action during vessel sprouting. Progesterone, bFGF and VEGF seem to inhibit an increased expression of apoptotic factors like p53 and Bax, while progesterone also inhibits Fas and caspase3. Additionally to the suppression of apoptotic factors an up-regulation of anti-apoptotic factors like Bcl-X<sub>L</sub> and Survivin occurs. TNF $\alpha$ , produced by invading macrophages during CL formation, acts not only as an apoptotic factor, but is also able to enhance the production of PGE2 in endothelial and luteal cells, which stimulates together with TNF $\alpha$  the proliferation of endothelial cells during luteal angiogenesis.

During induced luteolysis all investigated MMPs showed an increased expression as well as TIMP-1. Only TIMP-2 was down-regulated till 64h after PGF2 $\alpha$ . PGF2 $\alpha$  as luteolytic agents leads to the expression of MCP-1 on luteal endothelial cells. Thereupon monocytes and cytotoxic T cells migrate into the regressing CL and also start to express MCP-1 to recruit further mononuclear cells. For these migration into the stroma of the CL monocytes express uPA, uPAR and PAI-2. Macrophages are necessary for the phagocytosis of apoptotic cells and the degradation of ECM components in the CL during luteolysis. They are able to express different MMPs like MMP-1, MMP-9 and MMP-2. These MMPs degrade collagen I, the main structural collagen in the stroma of the CL, which might enhance the migration abilities of these macrophages. MMP-2 is also up-regulated in microvascular endothelial cells by TNF $\alpha$ , which is produced by macrophages. At the same time a down-regulation of TIMP-2 occurs, so that no inhibition of MMP-2 happens and a detachment of the endothelial cells from the vessel basement membrane follows. This leads to apoptosis of the endothelial cells, which seem to be the first cells to undergo cell death during luteolysis of the CL. Apoptosis seems to play an important role during luteolysis of the CL. The extrinsic pathway mediated by TNF $\alpha$ , its two receptors, Fas and FasL seem to be more important than the intrinsic pathway, due to the massive up-regulation of these factors seen during induced luteolysis. TNF $\alpha$  and FasL show a high increased expression from the beginning of induced luteolysis onwards, which might be due to the infiltration of T cells and macrophages expressing these factors. Endothelial cells express TNFR1 and TNFR2 on their surface during luteolysis, which leads to the activation of the extrinsic apoptotic pathway by binding of TNF $\alpha$ . INF $\gamma$  enhances these apoptotic action on endothelial cells. It seems possible that apoptosis of luteal cells occurs after the degradation of capillaries, which leads to an undersupply with oxygen and an increase of ROS. These reactive oxygen species up-regulate p53 and Bax as apoptotic factors of the intrinsic pathway, which leads to an activation of the caspases and apoptosis of luteal cells during induced luteolysis. These apoptotic action is further enhanced by the activation of the extrinsic pathway. Luteal cells stimulated by TNF $\alpha$  and INF $\gamma$  express Fas on their cell surface when the progesterone level declines. Cytotoxic T cells, express FasL and promote luteal cell death by activation the extrinsic pathway. This happens only when the progesterone level is decreased, which is known to happen at the end of the functional luteolysis.

## **Summary**

The results of these study show that ECM degrading proteases have two different roles in the life span of the CL: first they enable the sprouting of capillaries during angiogenesis in the developing CL, but during induced luteolysis their role seems to be to degrade ECM components of the CL stroma, which detaches endothelial cells from vessel basement membranes. These leads together with the infiltration of macrophages and cytotoxic T cells to apoptosis of endothelial and luteal cells.

## 8 Zusammenfassung

### Untersuchungen zu extrazellulären Matrix Proteasen sowie apoptotischen und anti-apoptotischen Faktoren im bovinen Corpus Luteum

Die Arbeit wurde in zwei Teile unterteilt, wobei sich der erste Teil mit der Entwicklung einer Methode zur Gewinnung von boviner Uterus Milch *in vivo* während der Prä-Implantationsphase für die Erforschung regulativer Faktoren beschäftigt. Im zweiten Teil wurden zwei verschiedene Proteasesysteme zum Vergleich in Follikeln 20 Stunden nach GnRH (Gonadotropin releasing hormon) Applikation (kurz vor Ovulation) als auch während des Östrus Zyklus und der induzierten Luteolyse im bovinen Corpus Luteum (CL) untersucht. Desweiteren wurde die Expression von apoptotischen als auch anti-apoptotischen Faktoren während des Östrus Zyklus und der induzierten Luteolyse im bovinen CL evaluiert.

Für die Entwicklung einer Methode zur Gewinnung von Uterus Milch *in vivo* während der ersten 24 Graviditätstage im Rind wurden 9 Kalbinnen mit Hilfe des Ovsynch Verfahrens synchronisiert und künstlich besamt. Eine Epiduralanästhesie wurde vor Beginn der Uterusspülung gegeben und alle zwei Uterus Hörner wurden mit 13ml 0,9% NaCl gespült, wobei ein Embryokatheter mit Ballon verwendet wurde. Die Spülungen erfolgten bei allen Kalbinnen am 5., 7., 12., 17. und 24. Graviditätstag. Der Katheter wurde in beiden Hörnern 1cm cranial der Bifurcatio uteri placiert. Es konnten zwischen 3ml und 13ml Spülflüssigkeit zurückgewonnen werden. Die Uterus Milch des ipsilateralen Hornes wurde nach einem Embryo durchsucht und ein EDTA-Stabilisator wurde zu der Uterus Milch beider Hörner gegeben. Eine Infektion des Uterus trat bei drei Kalbinnen nach der zweiten Spülung und bei fünf Kalbinnen nach der dritten Spülung auf. Eine Kalbin zeigte keine Anzeichen einer Infektion. Zwischen dem 17. und 24. Trächtigkeitstag zeigten alle neuen Kalbinnen deutlich Anzeichen einer Brunst. Es war möglich Progesteron, Östradiol-17 $\beta$ , PGF2 $\alpha$  und VEGF mittels Enzym Immunassay (EIA) und Radio Immunassay (RIA) in der Uterus Milch nachzuweisen. Wegen der Infektion des Uterus konnte keine statistische Auswertung vorgenommen werden. Es konnte jedoch festgestellt werden, daß sich das Progesteron Level zwischen <0,1 und 0,4ng/ml bewegte und keine Korrelation zur Entzündung zeigte. Durch den Verdünnungseffekt der Spülflüssigkeit sollten die Werte der nativen Uterus Milch um das ca. 10-fache höher liegen. Die Werte der Östradiol-17 $\beta$  Expression schwankten sehr stark, was daran zu erkennen war, daß die Werte der Kalbinnen ohne Infektion bis zum 12. Trächtigkeitstag nicht miteinander in Beziehung gesetzt werden konnten. Es konnte in einer Testreihe gezeigt werden, das in mit EDTA-Stabilisator versetztes 0,9% NaCl hohe Östradiol-17 $\beta$  Werte mittels EIA im Vergleich zu 0,9% NaCl ohne Stabilisator messbar sind. Das Level von VEGF lag zwischen 0,08 und 2,58ng/ml, wobei eine höhere Expression während der Infektion gemessen wurde. Der Verlauf der PGF2 $\alpha$  Expression zeigte eine deutliche Korrelation zur Infektion. Allerdings zeigten sich auch Unterschiede zwischen einzelnen Kalbinnen und auch zwischen beiden Uterus Hörnern einer

Kalbin während der ersten Spülung. Dies könnte durch die unterschiedliche Massagestärke oder Sensitivität der Uterus Hörner während der Spülung verursacht sein, die eine Freisetzung von  $\text{PGF2}\alpha$  verursachen kann. Folgende Änderungen sollten bei der Methode zur Gewinnung von Uterus Milch *in vivo* vorgenommen werden: um eine Endometritis zu verhindern, sollte nur eine Spülung per Gravidität durchgeführt werden, wobei auch der Embryo gewonnen werden sollte. Es sollten wieder alle zwei Hörner gespült werden, wobei für jedes Horn ein Katheter verwendet werden und sich die Spülung in zwei Abschnitte teilen sollte: zuerst sollte eine Spülung zu Gewinnung von Uterusmilch mit 13ml 0,9% NaCl durchgeführt werden, danach sollte der Embryo mit 5x50ml sterilem PBS Puffer ausgespült werden. Der gewonnene Embryo kann dann in RNA-Later bei  $-80^\circ$  eingeforen werden. Die gewonnene Uterus Milch sollte in zwei Aliquots unterteilt werden, wobei das Aliquot für die Östradiol- $17\beta$  Untersuchung keinen EDTA-Stabilisator enthalten darf. Außerdem sollte eine Zentrifugation erfolgen, um die zellulären Bestandteile der Uterus Milch abzutrennen. Die verbleibende Flüssigkeit kann bei  $-20^\circ$  aufbewahrt werden. Ein Teil der gewonnen Zellen kann zur Zellidentifikation herangezogen werden, der Rest sollte bei  $-80^\circ$  für weitere molekular-biologische Untersuchungen aufbewahrt werden. Für die Untersuchung des Prostaglandin Gehaltes in der Uterus Milch, sollte eine mögliche Behandlung der Kalbinnen mit einem Prostaglandin Synthese Hemmer kurz vor der Spülung erwogen werden.

Für die Untersuchung von verschiedenen extrazellulären Matrix Proteasen and apoptotischen als auch anti-apoptotischen Faktoren im bovinen Follikel und CL wurden RNA Proben eines vorhergehenden Experimentes verwendet. In diesem Experiment wurden 26 Kühe mit einer luteolytischen Dosis eines  $\text{PGF2}\alpha$ -Analoges behandelt und die CLs wurden mittels transvaginaler Ovariectomie zu folgenden Zeitpunkten entnommen: 0, 2, 4, 12, 24, 48 und 64 Stunden (h) nach Induktion der Luteolyse. Zusätzlich zu diesem Experiment wurden noch weitere fünf Kühe 0,5h nach  $\text{PGF2}\alpha$  Applikation ovariektomiert. Für die Untersuchungen während des Östrus Zyklus wurden CLs vom Schlachthof gesammelt. Aus Vergleichsgründen wurden Follikel 20 Stunden nach GnRH Injektion im Rahmen einer Superovulation entnommen. Die mRNA Qualität wurde mittels Bioanalyser untersucht und zeigte eine gute bis sehr gute Qualität aller Proben. Die mRNA Expressions Level wurden mittels quantitativer real time PCR (Rotor-Gene mit SYBR Green I) untersucht. Die erhaltenen Expressionsdaten wurden mit dem Bestkeeper Index aus vier verschiedenen Housekeeping Genen normalisiert, indem die  $\Delta\Delta$  CP Methode verwendet wurde. Es wurden folgende Faktoren im Follikel 20h nach GnRH Injektion und im bovinen CL während des Östrus Zyklus und der induzierter Luteolyse untersucht: Matrixmetalloproteinasen (MMP-1, MMP-2, MMP-9, MMP-14, MMP-19), deren Gewebe Inhibitoren (TIMP-1, TIMP-2), das Plasminogen Aktivator (PA) System (Tissue-PA (tPA), Urokinase-PA (uPA), Urokinase-PA-Rezeptor (uPAR), PA-Inhibitor-1 (PAI-1), PA-Inhibitor-2 (PAI-2)), welche in der Lage sind extrazelluläre Matrix (ECM) abzubauen. Desweiteren wurden folgende Faktoren im CL während des Östrus Zyklus und der induzierten Luteolyse evaluiert: Monocyte chemoattractant protein-1 (MCP-1), Faktoren des extrinsischen apoptotischen Weges (Tumor necrosis factor alpha ( $\text{TNF}\alpha$ ), TNF-Rezeptor-1 (TNFR1), TNF-Rezeptor-2 (TNFR2), Fas, Fas-Ligand (FasL)) und des intrinsischen Weges (p53,



Bax, Bcl-X<sub>L</sub>, Smac, Survivin) als auch die Caspasen 3, -6 and 7. Während der ersten sieben Tage des Östrus Zyklus spielt die Angiogenese eine entscheidende Rolle in der Entwicklung des CL. Basal Membranen der Blutgefäße müssen durchbrochen werden, um Endothelzellen die Migration zu ermöglichen, welche für die Bildung neuer Kapillaren wichtig ist. MMP-1, MMP-2 und MMP-14 waren nicht reguliert, aber TIMP-2, MMP-9, MMP-19 und TIMP-1 zeigten eine zunehmende Expression von 20h nach GnRH Applikation bis Tag 8-12 des Östrus Zyklus im CL. VEGF und bFGF können eine Stimulierung der Expression von MMP-1 und MMP-2 in lutealen Endothelzellen bewirken. Diese Proteasen ermöglichen es diesen Zellen während der Sprossung von neuen Kapillaren die vaskuläre Basalmembranen zu degradieren. MMP-19 wird auch von diesen Zellen exprimiert und hat die gleiche Wirkung auf Basalmembranen wie MMP-2. Die Wirkung von MMP-2 wird nicht nur von VEGF und bFGF reguliert, sondern auch von TIMP-2, welches während der Angiogenese im CL niedriger exprimiert wird. Dadurch könnte die MMP-2 Wirkung nicht inhibiert werden. TIMP-1 und TIMP-2 scheinen nicht nur für die Inhibierung der MMPs wichtig zu sein, sondern sie sind auch in der Lage die Proliferation von Endothelzellen während der Angiogenese zu stimulieren. Eine weitere Protease die von VEGF und bFGF während der Gefäßbildung stimuliert wird ist uPA. Dieser Faktor bildet zusammen mit uPAR und PAI-1 einen Komplex an der äußeren Zellmembran und ermöglicht es nun der Zelle sich von der vitronektin-reichen perivaskulären Region abzulösen und in das fibronektin-reiche Stroma des CL zu wandern, um neue Kapillaren zu bilden. Nicht nur die Angiogenese spielt eine kritische Rolle in der Formierung des CL, sondern auch die Inhibierung von apoptotischen Vorgängen während der Blutgefäßsprossung. Progesteron, bFGF und VEGF scheinen eine erhöhte Expression von apoptotischen Faktoren, wie p53 und Bax, zu inhibieren. Progesteron unterdrückt außerdem noch die Expression von Fas und Caspase3. Zusätzlich zur Suppression von apoptotischen Faktoren findet eine Aufregulierung von anti-apoptotischen Faktoren, wie Bcl-X<sub>L</sub> und Survivin, statt. TNF $\alpha$  wird während der Entwicklung des CL von einwandernden Makrophagen produziert und kann nicht nur als apoptotischer Faktor wirken, sondern erhöht auch die Produktion von PGE2 in Endothel- und Lutealzellen. PGE2 stimuliert zusammen mit TNF $\alpha$  die Proliferation von Endothelzellen während der lutealen Angiogenese.

Während der induzierten Luteolyse zeigten alle untersuchten MMPs und TIMP-1 eine erhöhte Expression. Nur TIMP-2 wurde bis 64h nach PGF2 $\alpha$  Injektion abreguliert. PGF2 $\alpha$  wirkt als luteolytisches Agens und führt zur Expression von MCP-1 auf lutealen Endothelzellen. Daraufhin migrieren Monozyten und zytotoxische T-Zellen in den regressierenden CL und beginnen auch MCP-1 auf ihrer Oberfläche zu exprimieren, welches zu weiteren Anlockung von mononukleären Zellen führt. Monozyten exprimieren uPA, uPAR und PAI-2, um in das Stroma des CL einwandern zu können. Makrophagen werden während der Luteolyse für die Phagozytose von apoptotischen Zellen und für die Degradierung von ECM Komponenten benötigt. Sie sind in der Lage verschiedene MMPs, wie MMP-1, MMP-9 und MMP-2, zu exprimieren. Diese MMPs degradieren Kollagen I, welches den größten Teil der Strukturkollagene im CL Stroma bildet, um möglicherweise die Migrationsfähigkeit der Makrophagen zu erhöhen. MMP-2 wird auch durch von

Makrophagen produziertes  $\text{TNF}\alpha$  in mikrovaskulären Endothelzellen aufreguliert. Zur selben Zeit findet eine Abregulierung von TIMP-2 statt, so dass es zu keiner Inhibierung von MMP-2 kommt und eine Ablösung der Endothelzellen von der Gefäßbasalmembran erfolgt. Dies führt zur Apoptose von diesen Zellen, welche während der Luteolyse scheinbar als erste der Apoptose anheimfallen. Der Zelltod scheint eine wichtige Rolle während der Luteolyse des CL zu übernehmen. Der extrinsische Weg, der durch  $\text{TNF}\alpha$ , dessen beiden Rezeptoren, Fas und FasL vermittelt wird, scheint während der induzierten Luteolyse aufgrund der massiven Aufregulierung dieser Faktoren eine größere Rolle als der intrinsische Weg zu spielen.  $\text{TNF}\alpha$  und FasL zeigen eine stark erhöhte Expression von Beginn der induzierten Luteolyse, welche man auf die Infiltration von T-Zellen und Makrophagen, die diese Faktoren exprimieren, zurückführen kann. Endothelzellen exprimieren TNFR1 und TNFR2 auf ihrer Oberfläche während der Luteolyse. Dies führt durch die Bindung von  $\text{TNF}\alpha$  zur Aktivierung des extrinsischen apoptotischen Weges.  $\text{INF}\gamma$  verstärkt diese apoptotische Wirkung auf Endothelzellen. Es scheint möglich zu sein, dass die Apoptose von Lutealzellen erst nach der Degradierung von Kapillaren, welche zu einer Unterversorgung mit Sauerstoff und der Bildung von ROS führt, stattfindet. Diese reaktiven Sauerstoff Radikale führen zu einer Aufregulierung von p53 und Bax als apoptotische Faktoren des intrinsischen Weges. Daraufhin folgt die Aktivierung der Caspasen und die Apoptose der Lutealzellen. Dieser apoptotische Prozess wird außerdem noch durch die Aktivierung des extrinsischen Weges verstärkt, wobei mit  $\text{TNF}\alpha$  und  $\text{INF}\gamma$  stimulierte Lutealzellen Fas auf ihrer Oberfläche exprimieren sobald der Progesteronspiegel abfällt. Zytotoxische T-Zellen exprimieren FasL und fördern den Tod der Lutealzellen durch die Aktivierung des extrinsischen Weges. Dies findet allerdings nur nach Abfall des Progesteronlevels am Ende der funktionellen Luteolyse statt.

Die Ergebnisse dieser Studie zeigen, dass ECM degradierende Proteasen verschiedene Rollen während der Lebensspanne des CL übernehmen: zum einen ermöglichen sie die Sprossung von Kapillaren während der Angiogenese im sich formierenden CL, zum anderen scheinen sie eine wichtige Rolle während der induzierten Luteolyse durch Degradierung von ECM Komponenten zu spielen. Diese Degradierung führt zur Ablösung der Endothelzellen von den vaskulären Basalmembranen, welches zusammen mit der Einwanderung von Makrophagen und zytotoxischen T-Zellen zur Apoptose von Endothel- und Lutealzellen führt.

## 9 Reference List

- Adams JM, Cory S (1998) The Bcl-2 protein family: arbiters of cell survival. *Science* 281, 1322-1326.
- Ahmed A, Li XF, Dunk C, Whittle MJ, Rushton DI, Rollason T (1995) Colocalisation of vascular endothelial growth factor and its Flt-1 receptor in human placenta. *Growth Factors* 12, 235-243.
- Alexander CM, Howard EW, Bissell MJ, Werb Z (1996) Rescue of mammary epithelial cell apoptosis and  $\alpha$ -actinin degradation by a tissue inhibitor of metalloproteinases-1 transgene. *J.Cell Biol.* 135, 1669-1677.
- Amsterdam A, Sasson R, Keren-Tal I, Aharoni D, Dantes A, Rimon E, Land A, Cohen T, Dor Y, Hirsh L (2003) Alternative pathways of ovarian apoptosis: death for life. *Biochem.Pharmacol.* 66, 1355-1362.
- Aten RF, Duarte KM, Behrman HR (1992) Regulation of ovarian antioxidant vitamins, reduced glutathione, and lipid peroxidation by luteinizing hormone and prostaglandin F<sub>2</sub> alpha. *Biol.Reprod.* 46, 401-407.
- Augustin HG, Kuhn WS, (1999) Zyklische Angiogeneseprozesse im Ovar. *Der Gynäkologe* 32, 582-589.
- Austin KJ, Ward SK, Teixeira MG, Dean VC, Moore DW, Hansen TR (1996) Ubiquitin cross-reactive protein is released by the bovine uterus in response to interferon during early pregnancy. *Biol.Reprod.* 54, 600-606.
- Azmi TI, O'Shea JD (1984) Mechanism of deletion of endothelial cells during regression of the corpus luteum. *Lab Invest* 51, 206-217.
- Bacci ML, Barazzoni AM, Forni M, Costerbosa GL (1996) In situ detection of apoptosis in regressing corpus luteum of pregnant sow: evidence of an early presence of DNA fragmentation. *Domest.Anim Endocrinol.* 13, 361-372.
- Bacharach E, Itin A, Keshet E (1992) In vivo patterns of expression of urokinase and its inhibitor PAI-1 suggest a concerted role in regulating physiological angiogenesis. *Proc.Natl.Acad.Sci.U.S.A* 89, 10686-10690.
- Bacharach E, Itin A, Keshet E (1998) Apposition-dependent induction of plasminogen activator inhibitor type 1 expression: a mechanism for balancing pericellular proteolysis during angiogenesis. *Blood* 92, 939-945.
- Barnathan ES, Kuo A, Kariko K, Rosenfeld L, Murray SC, Behrendt N, Ronne E, Weiner D, Henkin J, Cines DB (1990) Characterization of human endothelial cell urokinase-type plasminogen activator receptor protein and messenger RNA. *Blood* 76, 1795-1806.
- Bartol FF, Thatcher WW, Bazer FW, Kimball FA, Chenault JR, Wilcox CJ, Roberts RM (1981) Effects of the estrous cycle and early pregnancy on bovine uterine, luteal, and follicular responses. *Biol.Reprod.* 25, 759-776.
- Bazer FW, Thatcher WW, Hansen PJ, Mirando MA, Ott TL, Plante C (1991) Physiological mechanisms of pregnancy recognition in ruminants. *J Reprod.Fertil.Suppl* 43, 39-47.

## Reference List

- Benyo DF, Pate JL (1992) Tumor necrosis factor-alpha alters bovine luteal cell synthetic capacity and viability. *Endocrinology* 130, 854-860.
- Berglund LA, Sharp DC, Vernon MW, Thatcher WW (1982) Effect of pregnancy and collection technique on prostaglandin F in the uterine lumen of Pony mares. *J Reprod.Fertil.Suppl* 32, 335-341.
- Berisha B, Schams D, Kosmann M, Amselgruber W, Einspanier R (2000) Expression and tissue concentration of vascular endothelial growth factor, its receptors, and localization in the bovine corpus luteum during estrous cycle and pregnancy. *Biol.Reprod.* 63, 1106-1114.
- Berisha B.; Welter H.; Shimizu T.; Miyamoto A.; Meyer H.H.; Schams D (2006) Expression of Fibroblast Growth Factor 1 (FGF1) and FGF7 in Mature Follicles during the Perioovulatory Period after GnRH in the Cow. *J Reprod.Dev.* 2006 (in press)
- Bian J, Sun Y (1997) Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter. *Mol.Cell Biol.* 17, 6330-6338.
- Bogic LV, Brace RA, Cheung CY (2001) Developmental expression of vascular endothelial growth factor (VEGF) receptors and VEGF binding in ovine placenta and fetal membranes. *Placenta* 22, 265-275.
- Boone DL, Tsang BK (1998) Caspase-3 in the rat ovary: localization and possible role in follicular atresia and luteal regression. *Biol.Reprod.* 58, 1533-1539.
- Bowen JM, Keyes PL, Warren JS, Townson DH (1996) ProlActin-induced regression of the rat corpus luteum: expression of monocyte chemoattractant protein-1 and invasion of macrophages. *Biol.Reprod.* 54, 1120-1127.
- Brannstrom M, Norman RJ, Seamark RF, Robertson SA (1994a) Rat ovary produces cytokines during ovulation. *Biol.Reprod.* 50, 88-94.
- Brannstrom M, Pascoe V, Norman RJ, McClure N (1994b) Localization of leukocyte subsets in the follicle wall and in the corpus luteum throughout the human menstrual cycle. *Fertil.Steril.* 61, 488-495.
- Bustin SA (2000) Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. *J Mol.Endocrinol.* 25, 169-193.
- Butler GS, Butler MJ, Atkinson SJ, Will H, Tamura T, van Westrum SS, Crabbe T, Clements J, d'Ortho MP, Murphy G (1998) The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A. A kinetic study. *J Biol Chem.* 273, 871-880.
- Carambula SF, Matikainen T, Lynch MP, Flavell RA, Goncalves PB, Tilly JL, Rueda BR (2002) Caspase-3 is a pivotal mediator of apoptosis during regression of the ovarian corpus luteum. *Endocrinology* 143, 1495-1501.
- Carambula SF, Pru JK, Lynch MP, Matikainen T, Goncalves PB, Flavell RA, Tilly JL, Rueda BR (2003) Prostaglandin F2alpha- and FAS-activating antibody-induced regression of the corpus luteum involves caspase-8 and is defective in caspase-3 deficient mice. *Reprod.Biol.Endocrinol.* 1, 15.
- Carpentier I, Coornaert B, Beyaert R (2004) Function and regulation of tumor necrosis factor type 2. *Curr.Med.Chem.* 11, 2205-2212.

## Reference List

Casciola-Rosen L, Nicholson DW, Chong T, Rowan KR, Thornberry NA, Miller DK, Rosen A (1996) Apopain/CPP32 cleaves proteins that are essential for cellular repair: a fundamental principle of apoptotic death. *J Exp.Med.* 183, 1957-1964.

Chang MC (1952) Development of bovine blastocyst with a note on implantation. *Anat.Rec.* 113, 143-161.

Chapman HA, Yang XL, Sailor LZ, Sugarbaker DJ (1990) Developmental expression of plasminogen activator inhibitor type 1 by human alveolar macrophages. Possible role in lung injury. *J.Immunol.* 145, 3398-3405.

Chen RW, Saunders PA, Wei H, Li Z, Seth P, Chuang DM (1999) Involvement of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and p53 in neuronal apoptosis: evidence that GAPDH is upregulated by p53. *J Neurosci.* 19, 9654-9662.

Chenault JR (1980) Steroid metabolism by the early bovine conceptus-I. 5 beta-Reduction of neutral C19-steroids. *J Steroid Biochem.* 13, 499-506.

Curry TE, Jr., Osteen KG (2003) The matrix metalloproteinase system: changes, regulation, and impact throughout the ovarian and uterine reproductive cycle. *Endocr.Rev.* 24, 428-465.

Czekay RP, Aertgeerts K, Curriden SA, Loskutoff DJ (2003) Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. *J.Cell Biol.* 160, 781-791.

D'haeseleer M, Cocquyt G, Cruchten SV, Simoens P, Broeck WV (2006) Cell-specific localisation of apoptosis in the bovine ovary at different stages of the oestrous cycle. *Theriogenology* 65, 757-772.

Davis JS, Rueda BR, Spanel-Borowski K (2003) Microvascular endothelial cells of the corpus luteum. *Reprod.Biol.Endocrinol.* 1, 89.

DeClerck YA, Laug WE (1996) Cooperation between matrix metalloproteinases and the plasminogen activator-plasmin system in tumor progression. *Enzyme Protein* 49, 72-84.

Del Bufalo D, Trisciuglio D, Scarsella M, Zangemeister-Wittke U, Zupi G (2003) Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity. *Oncogene* 22, 8441-8447.

Deveraux QL, Reed JC (1999) IAP family proteins--suppressors of apoptosis. *Genes Dev.* 13, 239-252.

Dharmarajan AM, Goodman SB, Atiya N, Parkinson SP, Lareu RR, Tilly KI, Tilly JL (2004) Role of apoptosis in functional luteolysis in the pregnant rabbit corpus luteum: evidence of a role for placental-derived factors in promoting luteal cell survival. *Apoptosis* 9, 807-814.

Dickinson JL, Bates EJ, Ferrante A, Antalis TM (1995) Plasminogen activator inhibitor type 2 inhibits tumor necrosis factor alpha-induced apoptosis. Evidence for an alternate biological function. *J.Biol.Chem.* 270, 27894-27904.

Djonov V, Hogger K, Sedlacek R, Laissue J, Draeger A (2001) MMP-19: cellular localization of a novel metalloproteinase within normal breast tissue and mammary gland tumours. *J.Pathol.* 195, 147-155.

Döcke F. (1994) 'Veterinärmedizinische Endokrinologie.' (Gustav Fischer: Jena, Stuttgart)

## Reference List

- Dow MP, Bakke LJ, Cassar CA, Peters MW, Pursley JR, Smith GW (2002) Gonadotropin surge-induced up-regulation of the plasminogen activators (tissue plasminogen activator and urokinase plasminogen activator) and the urokinase plasminogen activator receptor within bovine periovulatory follicular and luteal tissue. *Biol Reprod* 66, 1413-1421.
- Du C, Fang M, Li Y, Li L, Wang X (2000) Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. *Cell* 102, 33-42.
- Duncan WC, McNeilly AS, Illingworth PJ (1998) The effect of luteal "rescue" on the expression and localization of matrix metalloproteinases and their tissue inhibitors in the human corpus luteum. *J.Clin.Endocrinol.Metab* 83, 2470-2478.
- Emond V, Asselin E, Fortier MA, Murphy BD, Lambert RD (2000) Interferon-tau stimulates granulocyte-macrophage colony-stimulating factor gene expression in bovine lymphocytes and endometrial stromal cells. *Biol.Reprod.* 62, 1728-1737.
- Endo T, Aten RF, Wang F, Behrman HR (1993) Coordinate induction and activation of metalloproteinase and ascorbate depletion in structural luteolysis. *Endocrinology* 133, 690-698.
- Estreicher A, Muhlhauser J, Carpentier JL, Orci L, Vassalli JD (1990) The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. *J.Cell Biol.* 111, 783-792.
- Evans AC, Fortune JE (1997) Selection of the dominant follicle in cattle occurs in the absence of differences in the expression of messenger ribonucleic acid for gonadotropin receptors. *Endocrinology* 138, 2963-2971.
- Feng Q, Liu K, Hu ZY, Zou RJ, Yang SC, Liu YX (1993) The possible involvement of tissue type plasminogen activator in luteolysis of rhesus monkey. *Hum.Reprod.* 8, 1640-1644.
- Ferrara N (2001) Role of vascular endothelial growth factor in regulation of physiological angiogenesis. *Am. J. Physiol. Cell Physiol.* 280, C1358-C1366
- Ferrara N, Davis-Smyth T (1997) The biology of vascular endothelial growth factor. *Endocr.Rev.* 18, 4-25.
- Ferrara N, Henzel WJ (1989) Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. *Biochem.Biophys.Res.Commun.* 161, 851-858.
- Ferrara N, Houck K, Jakeman L, Leung DW (1992) Molecular and biological properties of the vascular endothelial growth factor family of proteins. *Endocr.Rev.* 13, 18-32.
- Fibbi G, Caldini R, Chevanne M, Pucci M, Schiavone N, Morbidelli L, Parenti A, Granger HJ, Del Rosso M, Ziche M (1998) Urokinase-dependent angiogenesis in vitro and diacylglycerol production are blocked by antisense oligonucleotides against the urokinase receptor. *Lab Invest* 78, 1109-1119.
- Fotin-Mleczek M, Henkler F, Samel D, Reichwein M, Hausser A, Parmryd I, Scheurich P, Schmid JA, Wajant H (2002) Apoptotic crosstalk of TNF receptors: TNF-R2-induces depletion of TRAF2 and IAP proteins and accelerates TNF-R1-dependent activation of caspase-8. *J Cell Sci* 115, 2757-2770.
- Fraser HM, Wilson H, Morris KD, Swanston I, Wiegand SJ (2005) Vascular endothelial growth factor Trap suppresses ovarian function at all stages of the luteal phase in the macaque. *J Clin.Endocrinol.Metab* 90, 5811-5818.

## Reference List

- Freyschuss B, Sahlin L, Masironi B, Eriksson H (1994) The hormonal regulation of the oestrogen receptor in rat liver: an interplay involving growth hormone, thyroid hormones and glucocorticoids. *J Endocrinol.* 142, 285-298.
- Friedman A, Weiss S, Levy N, Meidan R (2000) Role of tumor necrosis factor alpha and its type I receptor in luteal regression: induction of programmed cell death in bovine corpus luteum-derived endothelial cells. *Biol.Reprod.* 63, 1905-1912.
- Garradio V, Schmidt T, Kimmina S, Kozian D, Augustin HG (1998) Analysis of blood vessel maturation processes during cycle ovarian angiogenesis. *Lab invest.* 78, 1385-1394
- Gaytan F, Morales C, Garcia-Pardo L, Reymundo C, Bellido C, Sanchez-Criado JE (1999) A quantitative study of changes in the human corpus luteum microvasculature during the menstrual cycle. *Biol.Reprod.* 60, 914-919.
- Gillespie DA, Vousden KH (2003) The secret life of Histones. *Cell* 114, 655-656.
- Ginther OJ, Knopf L, Kastelic JP (1989) Ovarian follicular dynamics in heifers during early pregnancy. *Biol.Reprod.* 41, 247-254.
- Godkin JD, Black DL, Duby RT (1977) Stimulation of cyclic AMP and progesterone synthesis by LH, PGE2 and isoproterenol in the bovine CL in vitro. *Biol.Reprod.* 17, 514-518.
- Goldberg MJ, Moses MA, Tsang PC (1996) Identification of matrix metalloproteinases and metalloproteinase inhibitors in bovine corpora lutea and their variation during the estrous cycle. *J.Anim Sci.* 74, 849-857.
- Goodman SB, Kugu K, Chen SH, Preutthipan S, Tilly KI, Tilly JL, Dharmarajan AM (1998) Estradiol-mediated suppression of apoptosis in the rabbit corpus luteum is associated with a shift in expression of bcl-2 family members favoring cellular survival. *Biol.Reprod.* 59, 820-827.
- Gotlieb WH, Watson JM, Rezai A, Johnson M, Martinez-Maza O, Berek JS (1994) Cytokine-induced modulation of tumor suppressor gene expression in ovarian cancer cells: up-regulation of p53 gene expression and induction of apoptosis by tumor necrosis factor-alpha. *Am.J.Obstet.Gynecol.* 170, 1121-1128.
- Gottsch MLVKEAMWJ (2001) Role of matrix metalloproteinase-2 in the folliculo-luteal transition. *Denver, CO.p Abstract P2-368.*
- Gross A, Yin XM, Wang K, Wei MC, Jockel J, Milliman C, Erdjument-Bromage H, Tempst P, Korsmeyer SJ (1999) Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death. *J Biol.Chem.* 274, 1156-1163.
- Guillomot M (1995) Cellular interactions during implantation in domestic ruminants. *J Reprod.Fertil.Suppl* 49, 39-51.
- Harfouche R, Hassessian HM, Guo Y, Faivre V, Srikant CB, Yancopoulos GD, Hussain SN (2002) Mechanisms which mediate the antiapoptotic effects of angiopoietin-1 on endothelial cells. *Microvasc.Res.* 64, 135-147.
- Hart PH, Vitti GF, Burgess DR, Singleton DK, Hamilton JA (1989) Human monocytes can produce tissue-type plasminogen activator. *J.Exp.Med.* 169, 1509-1514.
- Hayakawa T, Yamashita K, Ohuchi E, Shinagawa A (1994) Cell growth-promoting activity of tissue

- inhibitor of metalloproteinases-2 (TIMP-2). *J Cell Sci.* 107 ( Pt 9), 2373-2379.
- Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, Iwata K (1992) Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. *FEBS Lett.* 298, 29-32.
- Hehnke KE, Christenson LK, Ford SP, Taylor M (1994) Macrophage infiltration into the porcine corpus luteum during prostaglandin F2 alpha-induced luteolysis. *Biol.Reprod.* 50, 10-15.
- Hehnke-Vagnoni KE, Clark CL, Taylor MJ, Ford SP (1995) Presence and localization of tumor necrosis factor alpha in the corpus luteum of nonpregnant and pregnant pigs. *Biol.Reprod.* 53, 1339-1344.
- Hengartner MO (2000) The biochemistry of apoptosis. *Nature* 407, 770-776.
- Herr D, Keck C, Tempfer C, Pietrowski D (2004) Chorionic gonadotropin regulates the transcript level of VHL, p53, and HIF-2alpha in human granulosa lutein cells. *Mol.Reprod.Dev.* 69, 397-401.
- Hesch R.D. (1989) 'Endokrinologie Teil A.' (Urban & Schwarzenberg: München, Wien, Baltimore)
- Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW (1991) The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. *Mol. Endocrinol.* 5, 1806-1814
- Inoue J, Ishida T, Tsukamoto N, Kobayashi N, Naito A, Azuma S, Yamamoto T (2000) Tumor necrosis factor receptor-associated factor (TRAF) family: adapter proteins that mediate cytokine signaling. *Exp.Cell Res.* 254, 14-24.
- Ireland JJ, Murphee RL, Coulson PB (1980) Accuracy of predicting stages of bovine estrous cycle by gross appearance of the corpus luteum. *Journal of Dairy Science* 63, 155-160.
- Isogai C, Laug WE, Shimada H, Declerck PJ, Stins MF, Durden DL, Erdreich-Epstein A, DeClerck YA (2001) Plasminogen activator inhibitor-1 promotes angiogenesis by stimulating endothelial cell migration toward fibronectin. *Cancer Res.* 61, 5587-5594.
- Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, Hase A, Seto Y, Nagata S (1991) The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. *Cell* 66, 233-243.
- Jakeman LB, Winer J, Bennett GL, Altar CA, Ferrara N (1992) Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. *J Clin.Invest* 89, 244-253.
- Jo M, Curry TE, Jr. (2004) Regulation of matrix metalloproteinase-19 messenger RNA expression in the rat ovary. *Biol.Reprod.* 71, 1796-1806.
- Johnson AL, Bridgham JT (2000) Caspase-3 and -6 expression and enzyme activity in hen granulosa cells. *Biol.Reprod.* 62, 589-598.
- Johnson AL, Langer JS, Bridgham JT (2002) Survivin as a cell cycle-related and antiapoptotic protein in granulosa cells. *Endocrinology* 143, 3405-3413.
- Johnson ES (2002) Ubiquitin branches out. *Nat.Cell Biol.* 4, E295-E298.
- Juengel JL, Garverick HA, Johnson AL, Youngquist RS, Smith MF (1993) Apoptosis during luteal



regression in cattle. *Endocrinology* 132, 249-254.

Juengel JL, Smith GW, Smith MF, Youngquist RS, Garverick HA (1994) Pattern of protein production by bovine corpora lutea during luteolysis and characterization of expression of two major secretory products of regressing corpora lutea. *J.Reprod.Fertil.* 100, 515-520.

Karge WH, Schaefer EJ, Ordovas JM (1998) Quantification of mRNA by polymerase chain reaction (PCR) using an internal standard and a nonradioactive detection method. *Methods Mol.Biol.* 110, 43-61.

Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW (1991) Participation of p53 protein in the cellular response to DNA damage. *Cancer Res.* 51, 6304-6311.

Kayisli UA, Mahutte NG, Arici A (2002) Uterine chemokines in reproductive physiology and pathology. *Am.J Reprod.Immunol.* 47, 213-221.

Keller ML, Roberts AJ, Seidel GE, Jr. (1998) Characterization of insulin-like growth factor-binding proteins in the uterus and conceptus during early conceptus elongation in cattle. *Biol.Reprod.* 59, 632-642.

Khan KM, Falcone DJ (1997) Role of laminin in matrix induction of macrophage urokinase-type plasminogen activator and 92-kDa metalloproteinase expression. *J.Biol.Chem.* 272, 8270-8275.

Kilgore KS, Imlay MM, Szaflarski JP, Silverstein FS, Malani AN, Evans VM, Warren JS (1997) Neutrophils and reactive oxygen intermediates mediate glucan-induced pulmonary granuloma formation through the local induction of monocyte chemoattractant protein-1. *Lab Invest* 76, 191-201.

Kirchheimer JC, Nong YH, Remold HG (1988) IFN-gamma, tumor necrosis factor-alpha, and urokinase regulate the expression of urokinase receptors on human monocytes. *J.Immunol.* 141, 4229-4234.

Kiya T, Endo T, Henmi H, Goto T, Kitajima Y, Manase K, Takahashi S, Kudo R (1999) The effects of growth hormone on corpus luteum of superovulated rats. *Endocr.Res.* 25, 179-193.

Kobayashi T, Ruan S, Jabbur JR, Consoli U, Clodi K, Shiku H, Owen-Schaub LB, Andreeff M, Reed JC, Zhang W (1998) Differential p53 phosphorylation and activation of apoptosis-promoting genes Bax and Fas/APO-1 by irradiation and ara-C treatment. *Cell Death.Differ.* 5, 584-591.

Kolb C, Mauch S, Krawinkel U, Sedlacek R (1999) Matrix metalloproteinase-19 in capillary endothelial cells: expression in acutely, but not in chronically, inflamed synovium. *Exp.Cell Res.* 250, 122-130.

Kondo H, Maruo T, Peng X, Mochizuki M (1996) Immunological evidence for the expression of the Fas antigen in the infant and adult human ovary during follicular regression and atresia. *J Clin.Endocrinol.Metab* 81, 2702-2710.

Konishi A, Shimizu S, Hirota J, Takao T, Fan Y, Matsuoka Y, Zhang L, Yoneda Y, Fujii Y, Skoultchi AI, Tsujimoto Y (2003) Involvement of Histone H1.2 in apoptosis induced by DNA double-strand breaks. *Cell* 114, 673-688.

Koolmann J, Röhm K-H (1998) 'Taschenatlas der Biochemie.' (Georg Thieme: Stuttgart)

Kuranaga E, Kanuka H, Furuhashi Y, Yonezawa T, Suzuki M, Nishihara M, Takahashi M (2000) Requirement of the Fas ligand-expressing luteal immune cells for regression of corpus luteum.

---

*FEBS Lett.* 472, 137-142.

Kuzuya M, Iguchi A (2003) Role of matrix metalloproteinases in vascular remodeling. *J Atheroscler. Thromb.* 10, 275-282.

Lamoreaux WJ, Fitzgerald ME, Reiner A, Hasty KA, Charles ST (1998) Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. *Microvasc. Res.* 55, 29-42.

Leibovich SJ, Polverini PJ, Shepard HM, Wiseman DM, Shively V, Nuseir N (1987) Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha. *Nature* 329, 630-632.

Levine AJ (1997) p53, the cellular gatekeeper for growth and division. *Cell* 88, 323-331.

Lewis GS, Waterman RA (1983) Effects of endometrium on metabolism of arachidonic acid by bovine blastocysts in vitro. *Prostaglandins* 25, 881-889.

Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC (1998) Control of apoptosis and mitotic spindle checkpoint by survivin. *Nature* 396, 580-584.

Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X (1997) Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. *Cell* 91, 479-489.

Li PF, Dietz R, von Harsdorf R (1999) p53 regulates mitochondrial membrane potential through reactive oxygen species and induces cytochrome c-independent apoptosis blocked by Bcl-2. *EMBO J* 18, 6027-6036.

Lijnen HR, Silence J, Lemmens G, Frederix L, Collen D (1998) Regulation of gelatinase activity in mice with targeted inactivation of components of the plasminogen/plasmin system. *Thromb. Haemost.* 79, 1171-1176.

Liszewska E, Rekawiecki R, Kotwica J (2005) Effect of progesterone on the expression of Bax and bcl-2 and on caspase activity in bovine luteal cells. *Prostaglandins Other Lipid Mediat.* 78, 67-81.

Liu K, Brandstrom A, Liu YX, Ny T, Selstam G (1996) Coordinated expression of tissue-type plasminogen activator and plasminogen activator inhibitor type 1 during corpus luteum formation and luteolysis in the adult pseudopregnant rat. *Endocrinology* 137, 2126-2132.

Liu K, Feng Q, Gao HJ, Hu ZY, Zou RJ, Li YC, Liu YX (2003) Expression and regulation of plasminogen activators, plasminogen activator inhibitor type-1, and steroidogenic acute regulatory protein in the rhesus monkey corpus luteum. *Endocrinology* 144, 3611-3617.

Liu K, Liu YX, Hu ZY, Zou RY, Chen YJ, Mu XM, Ny T (1997) Temporal expression of urokinase type plasminogen activator, tissue type plasminogen activator, plasminogen activator inhibitor type 1 in rhesus monkey corpus luteum during the luteal maintenance and regression. *Mol. Cell Endocrinol.* 133, 109-116.

Liu K, Wahlberg P, Hagglund AC, Ny T (2003) Expression pattern and functional studies of matrix degrading proteases and their inhibitors in the mouse corpus luteum. *Mol. Cell Endocrinol.* 205, 131-140.

Liu YX, Chen YX, Shi FW, Feng Q (1995) Studies on the role of plasminogen activators and plasminogen activator inhibitor type-1 in rat corpus luteum of pregnancy. *Biol. Reprod.* 53, 1131-1138.

## Reference List

- Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* 25, 402-408.
- Luck MR (1994) The Gonadal Extracellular Matrix. *Oxford Reviews of Reproductive Biology* 16, 34-85.
- Luck MR, Zhao Y (1993) Identification and measurement of collagen in the bovine corpus luteum and its relationship with ascorbic acid and tissue development. *J.Reprod.Fertil.* 99, 647-652.
- MacKenzie SH, Roberts MP, Liu KH, Dore JJ, Godkin JD (1997) Bovine endometrial retinol-binding protein secretion, messenger ribonucleic acid expression, and cellular localization during the estrous cycle and early pregnancy. *Biol.Reprod.* 57, 1445-1450.
- Makowski GS, Ramsby ML (1998) Binding of latent matrix metalloproteinase 9 to fibrin: activation via a plasmin-dependent pathway. *Inflammation* 22, 287-305.
- Mandriota SJ, Pepper MS (1997) Vascular endothelial growth factor-induced in vitro angiogenesis and plasminogen activator expression are dependent on endogenous basic fibroblast growth factor. *J.Cell Sci.* 110 ( Pt 18), 2293-2302.
- Mansur NR, Meyer-Siegler K, Wurzer JC, Sirover MA (1993) Cell cycle regulation of the glyceraldehyde-3-phosphate dehydrogenase/uracil DNA glycosylase gene in normal human cells. *Nucleic Acids Res.* 21, 993-998.
- Marone M, Scambia G, Mozzetti S, Ferrandina G, Iacovella S, De Pasqua A, Benedetti-Panici P, Mancuso S (1998) bcl-2, Bax, bcl-XL, and bcl-XS expression in normal and neoplastic ovarian tissues. *Clin.Cancer Res.* 4, 517-524.
- Martin SJ, Green DR (1995) Protease activation during apoptosis: death by a thousand cuts? *Cell* 82, 349-352.
- Matikainen T, Perez GI, Zheng TS, Kluzak TR, Rueda BR, Flavell RA, Tilly JL (2001) Caspase-3 gene knockout defines cell lineage specificity for programmed cell death signaling in the ovary. *Endocrinology* 142, 2468-2480.
- McCawley LJ, Matrisian LM (2000) Matrix metalloproteinases: multifunctional contributors to tumor progression. *Mol.Med.Today* 6, 149-156.
- McCracken JA, Custer EE, Lamsa JC (1999) Luteolysis: a neuroendocrine-mediated event. *Physiol Rev.* 79, 263-323.
- McGuire WJ, Juengel JL, Niswender GD (1994) Protein kinase C second messenger system mediates the antisteroidogenic effects of prostaglandin F2 alpha in the ovine corpus luteum in vivo. *Biol.Reprod.* 51, 800-806.
- Meidan R, Milvae RA, Weiss S, Levy N, Friedman A (1999) Intraovarian regulation of luteolysis. *J Reprod.Fertil.Suppl* 54, 217-228.
- Meyer HH, Eisele K, Osaso J (1989) A biotin-streptavidin amplified enzymeimmunoassay for 13,14-dihydro-15-keto-PGF2 alpha. *Prostaglandins* 38, 375-383.
- Meyer HH, Mittermeier T, Schams D (1988) Dynamics of oxytocin, estrogen and progesterin receptors in the bovine endometrium during the estrous cycle. *Acta Endocrinol.(Copenh)* 118, 96-104.

## Reference List

- Meyer HH, Sauerwein H, Mutayoba BM (1990) Immunoaffinity chromatography and a biotin-streptavidin amplified enzymeimmunoassay for sensitive and specific estimation of estradiol-17 beta. *J Steroid Biochem.* 35, 263-269.
- Miller DK (1997) The role of the Caspase family of cysteine proteases in apoptosis. *Semin.Immunol.* 9, 35-49.
- Miyamoto A, Kobayashi S, Arata S, Ohtani M, Fukui Y, Schams D (1997) Prostaglandin F2 alpha promotes the inhibitory action of endothelin-1 on the bovine luteal function in vitro. *J Endocrinol.* 152, R7-11.
- Miyamoto A, von Lutzow H, Schams D (1993) Acute actions of prostaglandin F2 alpha, E2, and I2 in microdialyzed bovine corpus luteum in vitro. *Biol.Reprod.* 49, 423-430.
- Miyamoto Y, Sakumoto R, Sakabe Y, Miyake M, Okano A, Okuda K (2002) Tumour necrosis factor-alpha receptors are present in the corpus luteum throughout the oestrous cycle and during the early gestation period in pigs. *Reprod.Domest.Anim* 37, 105-110.
- Miyashita T, Harigai M, Hanada M, Reed JC (1994) Identification of a p53-dependent negative response element in the bcl-2 gene. *Cancer Res.* 54, 3131-3135.
- Miyashita T, Reed JC (1995) Tumor suppressor p53 is a direct transcriptional activator of the human Bax gene. *Cell* 80, 293-299.
- Modlich U, Kaup FJ, Augustin HG (1996) Cyclic angiogenesis and blood vessel regression in the ovary: blood vessel regression during luteolysis involves endothelial cell detachment and vessel occlusion. *Lab Invest* 74, 771-780.
- Monea S, Lehti K, Keski-Oja J, Mignatti P (2002) Plasmin activates pro-matrix metalloproteinase-2 with a membrane-type 1 matrix metalloproteinase-dependent mechanism. *J.Cell Physiol* 192, 160-170.
- Moses MA (1997) The regulation of neovascularization by matrix metalloproteinases and their inhibitors. *Stem Cells* 15, 180-189.
- Mueller O, Lightfoot S, Schroeder A (2004) 'RNA Integrity Number (RIN) - Standardisation of RNA Quality Control.'
- Mukaida N, Harada A, Yasumoto K, Matsushima K (1992) Properties of pro-inflammatory cell type-specific leukocyte chemotactic cytokines, interleukin 8 (IL-8) and monocyte chemotactic and activating factor (MCAF). *Microbiol.Immunol.* 36, 773-789.
- Mukhopadhyay A, Suttles J, Stout RD, Aggarwal BB (2001) Genetic deletion of the tumor necrosis factor receptor p60 or p80 abrogates ligand-mediated activation of nuclear factor-kappa B and of mitogen-activated protein kinases in macrophages. *J Biol.Chem.* 276, 31906-31912.
- Murdoch WJ (1987) Treatment of sheep with prostaglandin F2 alpha enhances production of a luteal chemoattractant for eosinophils. *Am.J Reprod.Immunol.Microbiol.* 15, 52-56.
- Murdoch WJ, Austin KA, Hansen TR (1996) PolyUbiquitin up-regulation in corpora lutea of prostaglandin-treated ewes. *Endocrinology* 137, 4526-4529.
- Murdoch WJ, Steadman LE (1991) Investigations concerning the relationship of ovarian eosinophilia to ovulation and luteal function in the sheep. *Am.J.Reprod.Immunol.* 25, 81-87.

## Reference List

- Murphy AN, Unsworth EJ, Stetler-Stevenson WG (1993) Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. *J Cell Physiol* 157, 351-358.
- Murphy G, Stanton H, Cowell S, Butler G, Knauper V, Atkinson S, Gavrilovic J (1999) Mechanisms for pro matrix metalloproteinase activation. *APMIS* 107, 38-44.
- Muzio M, Stockwell BR, Stennicke HR, Salvesen GS, Dixit VM (1998) An induced proximity model for caspase-8 activation. *J Biol.Chem.* 273, 2926-2930.
- Nagase H (1997) Activation mechanisms of matrix metalloproteinases. *Biol Chem.* 378, 151-160.
- Nagata S (1999) Fas ligand-induced apoptosis. *Annu Rev Genet.* 1999;33:29-55.
- Nagata S (1997) Apoptosis by death factor. *Cell* 88, 355-365.
- Nagata S, Golstein P (1995) The Fas death factor. *Science* 267, 1449-1456.
- Nakamura T, Sakamoto K (2001) Reactive oxygen species up-regulates cyclooxygenase-2, p53, and Bax mRNA expression in bovine luteal cells. *Biochem.Biophys.Res.Communic.* 284, 203-210.
- Nakayama M, Manabe N, Inoue N, Matsui T, Miyamoto H (2003) Changes in the expression of tumor necrosis factor (TNF) alpha, TNFalpha receptor (TNFR) 2, and TNFR-associated factor 2 in granulosa cells during atresia in pig ovaries. *Biol.Reprod.* 68, 530-535.
- Naora H, Naora H (1995) Differential expression patterns of beta-Actin mRNA in cells undergoing apoptosis. *Biochem.Biophys.Res.Communic.* 211, 491-496.
- Nehls V, Denzer K, Drenckhahn D (1992) Pericyte involvement in capillary sprouting during angiogenesis in situ. *Cell Tissue Res.* 270, 469-474.
- Neuvians T.P. (2003) Untersuchungen zu lokalen Regulationsfaktoren der Luteolyse des Rindes. 'Dissertation med. vet. München .
- Neuvians TP, Schams D, Berisha B, Pfaffl MW (2004) Involvement of pro-inflammatory cytokines, mediators of inflammation, and basic fibroblast growth factor in prostaglandin F2alpha-induced luteolysis in bovine corpus luteum. *Biol.Reprod.* 70, 473-480.
- Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA, . (1995) Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. *Nature* 376, 37-43.
- Nicholson DW, Thornberry NA (1997) Caspases: killer proteases. *Trends Biochem.Sci* 22, 299-306.
- Niswender GD, Juengel JL, McGuire WJ, Belfiore CJ, Wiltbank MC (1994) Luteal function: the estrous cycle and early pregnancy. *Biol.Reprod.* 50, 239-247.
- Nothnick WB (2003) Tissue inhibitor of metalloproteinase-1 (TIMP-1) deficient mice display reduced serum progesterone levels during corpus luteum development. *Endocrinology* 144, 5-8.
- Nothnick WB, Keeble SC, Curry TE, Jr. (1996) Collagenase, gelatinase, and proteoglycanase messenger ribonucleic acid expression and activity during luteal development, maintenance, and regression in the pseudopregnant rat ovary. *Biol.Reprod.* 54, 616-624.

## Reference List

- O'Connor DS, Schechner JS, Adida C, Mesri M, Rothermel AL, Li F, Nath AK, Pober JS, Altieri DC (2000) Control of apoptosis during angiogenesis by survivin expression in endothelial cells. *Am.J Pathol.* 156, 393-398.
- Okuda K, Korzekwa A, Shibaya M, Murakami S, Nishimura R, Tsubouchi M, Woclawek-Potocka I, Skarzynski DJ (2004) Progesterone is a suppressor of apoptosis in bovine luteal cells. *Biol.Reprod.* 71, 2065-2071.
- Okuda K, Sakumoto R, Uenoyama Y, Berisha B, Miyamoto A, Schams D (1999) Tumor necrosis factor alpha receptors in microvascular endothelial cells from bovine corpus luteum. *Biol.Reprod.* 61, 1017-1022.
- Okumura Y, Kamikubo Y, Curriden SA, Wang J, Kiwada T, Futaki S, Kitagawa K, Loskutoff DJ (2002) Kinetic analysis of the interaction between vitronectin and the urokinase receptor. *J.Biol.Chem.* 277, 9395-9404.
- Oppenheim JJ, Zachariae CO, Mukaida N, Matsushima K (1991) Properties of the novel proinflammatory supergene "intercrine" cytokine family. *Annu.Rev.Immunol.* 9, 617-648.
- Orlicky DJ, Fisher L, Dunscomb N, Miller GJ (1992) Immunohistochemical localization of PGF2 alpha receptor in the rat ovary. *Prostaglandins Leukot.Essent.Fatty Acids* 46, 223-229.
- Paavola LG (1979) The corpus luteum of the guinea pig. IV. Fine structure of macrophages during pregnancy and postpartum luteolysis, and the phagocytosis of luteal cells. *Am.J.Anat.* 154, 337-364.
- Pardo OE, Arcaro A, Salerno G, Raguz S, Downward J, Seckl MJ (2002) Fibroblast growth factor-2 induces translational regulation of Bcl-XL and Bcl-2 via a MEK-dependent pathway: correlation with resistance to etoposide-induced apoptosis. *J Biol.Chem.* 277, 12040-12046.
- Pardo OE, Lesay A, Arcaro A, Lopes R, Ng BL, Warne PH, McNeish IA, Tetley TD, Lemoine NR, Mehmet H, Seckl MJ, Downward J (2003) Fibroblast growth factor 2-mediated translational control of IAPs blocks mitochondrial release of Smac/DIABLO and apoptosis in small cell lung cancer cells. *Mol.Cell Biol.* 23, 7600-7610.
- Partridge CR, Hawker JR, Jr., Forough R (2000) Overexpression of a secretory form of FGF-1 promotes MMP-1-mediated endothelial cell migration. *J.Cell Biochem.* 78, 487-499.
- Pate JL (1995) Involvement of immune cells in regulation of ovarian function. *J Reprod.Fertil.Suppl* 49, 365-377.
- Pate JL, Landis KP (2001) Immune cells in the corpus luteum: friends or foes? *Reproduction.* 122, 665-676.
- Peluffo MC, Young KA, Stouffer RL (2005) Dynamic expression of caspase-2, -3, -8, and -9 proteins and enzyme activity, but not messenger ribonucleic acid, in the monkey corpus luteum during the menstrual cycle. *J Clin.Endocrinol.Metab* 90, 2327-2335.
- Penny LA (2000) Monocyte chemoattractant protein 1 in luteolysis. *Rev.Reprod.* 5, 63-66.
- Penny LA, Armstrong D, Bramley TA, Webb R, Collins RA, Watson ED (1999) Immune cells and cytokine production in the bovine corpus luteum throughout the oestrous cycle and after induced luteolysis. *J Reprod.Fertil.* 115, 87-96.
- Penny LA, Armstrong DG, Baxter G, Hogg C, Kindahl H, Bramley T, Watson ED, Webb R (1998)

Expression of monocyte chemoattractant protein-1 in the bovine corpus luteum around the time of natural luteolysis. *Biol.Reprod.* 59, 1464-1469.

Petroff MG, Petroff BK, Pate JL (2001) Mechanisms of cytokine-induced death of cultured bovine luteal cells. *Reproduction.* 121, 753-760.

Pfaffl M.W. (2005) Nucleic acids: mRNA identification and quantification. In 'Encyclopaedia of Analytical Science'. pp. 417-426.

Pfaffl MW, Tichopad A, Prgomet C, Neuvians TP (2004) Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: BestKeeper--Excel-based tool using pair-wise correlations. *Biotechnol.Lett.* 26, 509-515.

Pickart CM (2001) Ubiquitin enters the new millennium. *Mol.Cell* 8, 499-504.

Piquette GN, LaPolT PS, Oikawa M, Hsueh AJ (1991) Regulation of luteinizing hormone receptor messenger ribonucleic acid levels by gonadotropins, growth factors, and gonadotropin-releasing hormone in cultured rat granulosa cells. *Endocrinology* 128, 2449-2456.

Pitzel L, Ludemann S, Wuttke W (2000) Secretion and gene expression of metalloproteinases and gene expression of their inhibitors in porcine corpora lutea at different stages of the luteal phase. *Biol.Reprod.* 62, 1121-1127.

Plesner T, Behrendt N, Ploug M (1997) Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR. *Stem Cells* 15, 398-408.

Prakash BS, Meyer HH, Schallenberger E, van de Wiel DF (1987) Development of a sensitive enzymeimmunoassay (EIA) for progesterone determination in unextracted bovine plasma using the second antibody technique. *J Steroid Biochem.* 28, 623-627.

Pru JK, Lynch MP, Davis JS, Rueda BR (2003) Signaling mechanisms in tumor necrosis factor alpha-induced death of microvascular endothelial cells of the corpus luteum. *Reprod.Biol.Endocrinol.* 1, 17.

Pusarla RH, Bhargava P (2005) Histones in functional diversification. Core Histone variants. *FEBS J* 272, 5149-5168.

Qi L, Sit KH (2000a) Housekeeping genes commanded to commit suicide in CpG-cleavage commitment upstream of Bcl-2 inhibition in caspase-dependent and -independent pathways. *Mol.Cell Biol.Res.Commun.* 3, 319-327.

Qi L, Sit KH (2000b) Suicidal differential housekeeping gene activity in apoptosis induced by DCNP. *Apoptosis* 5, 379-388.

Quirk SM, Cowan RG, Joshi SG, Henrikson KP (1995) Fas antigen-mediated apoptosis in human granulosa/luteal cells. *Biol.Reprod.* 52, 279-287.

Quirk SM, Harman RM, Cowan RG (2000a) Regulation of Fas antigen (Fas, CD95)-mediated apoptosis of bovine granulosa cells by serum and growth factors. *Biol.Reprod.* 63, 1278-1284.

Quirk SM, Harman RM, Huber SC, Cowan RG (2000b) Responsiveness of mouse corpora luteal cells to Fas antigen (CD95)-mediated apoptosis. *Biol.Reprod.* 63, 49-56.

Rabbani ML, Rogers PA (2001) Role of vascular endothelial growth factor in endometrial vascular events before implantation in rats. *Reproduction.* 122, 85-90.

## Reference List

- Rasmussen R (2001) Quantification on the LightCycler. In 'Rapid Cycle Real-Time PCR, Methods and Applications'. (Ed. WCaNK Meuer S) pp. 21-34. (Springer Verlag: Berlin, Heidelberg, New York)
- Reibiger I, Spanel-Borowski K (2000) Difference in localization of eosinophils and mast cells in the bovine ovary. *J.Reprod.Fertil.* 118, 243-249.
- Reynolds LP, Grazul-Bilska AT, Killilea SD, Redmer DA (1994) Mitogenic factors of corpora lutea. *Prog.Growth Factor Res.* 5, 159-175.
- Rich T, Allen RL, Wyllie AH (2000) Defying death after DNA damage. *Nature* 407, 777-783.
- Ricke WA, Smith GW, Reynolds LP, Redmer DA, Smith MF (2002a) Matrix metalloproteinase (2, 9, and 14) expression, localization, and activity in ovine corpora lutea throughout the estrous cycle. *Biol.Reprod.* 66, 1083-1094.
- Ricke WA, Smith GW, Smith MF (2002b) Matrix metalloproteinase expression and activity following prostaglandin F(2 alpha)-induced luteolysis. *Biol.Reprod.* 66, 685-691.
- Riley JC, Behrman HR (1991) In vivo generation of hydrogen peroxide in the rat corpus luteum during luteolysis. *Endocrinology* 128, 1749-1753.
- Roche JF (1996) Control and regulation of folliculogenesis--a symposium in perspective. *Rev.Reprod.* 1, 19-27.
- Rodger FE, Fraser HM, Krajewski S, Illingworth PJ (1998) Production of the proto-oncogene BAX does not vary with changing in luteal function in women. *Mol.Hum.Reprod.* 4, 27-32.
- Roldan AL, Cubellis MV, Masucci MT, Behrendt N, Lund LR, Dano K, Appella E, Blasi F (1990) Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. *EMBO J* 9, 467-474.
- Rosen A, Casciola-Rosen L (1997) Macromolecular substrates for the ICE-like proteases during apoptosis. *J Cell Biochem.* 64, 50-54.
- Roughton SA, Lareu RR, Bittles AH, Dharmarajan AM (1999) Fas and Fas ligand messenger ribonucleic acid and protein expression in the rat corpus luteum during apoptosis-mediated luteolysis. *Biol.Reprod.* 60, 797-804.
- Rueda BR, Hendry IR, Hendry III WJ, Stormshak F, Slayden OD, Davis JS (2000a) Decreased progesterone levels and progesterone receptor antagonists promote apoptotic cell death in bovine luteal cells. *Biol.Reprod.* 62, 269-276.
- Rueda BR, Hendry IR, Ndjountche L, Suter J, Davis JS (2000b) Stress-induced mitogen-activated protein kinase signaling in the corpus luteum. *Mol.Cell Endocrinol.* 164, 59-67.
- Rueda BR, Hendry IR, Tilly JL, Hamernik DL (1999) Accumulation of caspase-3 messenger ribonucleic acid and induction of caspase activity in the ovine corpus luteum following prostaglandin F2alpha treatment in vivo. *Biol.Reprod.* 60, 1087-1092.
- Rueda BR, Tilly K.I., Hansen T.R., Hoyer P.B., Tilly J.L. (1995a) Expression of superoxide dismutase, catalase and glutathione peroxidase in the bovine corpus luteum: evidence supporting a role for oxidative stress in luteolysis. *Endocrine* 3, 227-232.
- Rueda BR, Tilly KI, Botros IW, Jolly PD, Hansen TR, Hoyer PB, Tilly JL (1997) Increased Bax and



interleukin-1beta-converting enzyme messenger ribonucleic acid levels coincide with apoptosis in the bovine corpus luteum during structural regression. *Biol.Reprod.* 56, 186-193.

Rueda BR, Wegner JA, Marion SL, Wahlen DD, Hoyer PB (1995) Internucleosomal DNA fragmentation in ovine luteal tissue associated with luteolysis: in vivo and in vitro analyses. *Biol.Reprod.* 52, 305-312.

Rüsse I, Sinowatz F (1994a) Follikulogenese und Differenzierung der Eizelle. In 'Lehrbuch der Embryologie der Haustiere'. pp. 74-82. (Parey):

Rüsse I, Sinowatz F (1994b) Rind: Frühgravidität. In 'Lehrbuch der Embryologie der Haustiere'. p. 159. (Parey):

Rüsse I, Sinowatz F (1994c) Rind: Implantation. In 'Lehrbuch der Embryologie der Haustiere'. pp. 159-161 (Parey).

Sakamaki K, Yoshida H, Nishimura Y, Nishikawa S, Manabe N, Yonehara S (1997) Involvement of Fas antigen in ovarian follicular atresia and luteolysis. *Mol.Reprod.Dev.* 47, 11-18.

Sakumoto R, Berisha B, Kawate N, Schams D, Okuda K (2000) Tumor necrosis factor-alpha and its receptor in bovine corpus luteum throughout the estrous cycle. *Biol.Reprod.* 62, 192-199.

Salvesen GS, Duckett CS (2002) IAP proteins: blocking the road to death's door. *Nat.Rev.Mol.Cell Biol.* 3, 401-410.

Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M (1994) A matrix metalloproteinase expressed on the surface of invasive tumour cells. *Nature* 370, 61-65.

Sato Y, Abe M, Tanaka K, Iwasaka C, Oda N, Kanno S, Oikawa M, Nakano T, Igarashi T (2000) Signal transduction and transcriptional regulation of angiogenesis. *Adv.Exp.Med.Biol.* 476, 109-115.

Satoh T, Kobayashi K, Yamashita S, Kikuchi M, Sendai Y, Hoshi H (1994) Tissue inhibitor of metalloproteinases (TIMP-1) produced by granulosa and oviduct cells enhances in vitro development of bovine embryo. *Biol.Reprod.* 50, 835-844.

Savio JD, Thatcher WW, Badinga L, de la Sota RL, Wolfenson D (1993) Regulation of dominant follicle turnover during the oestrous cycle in cows. *J.Reprod.Fertil.* 97, 197-203.

Sawada M, Carlson JC (1991) Rapid plasma membrane changes in superoxide radical formation, fluidity, and phospholipase A2 activity in the corpus luteum of the rat during induction of luteolysis. *Endocrinology* 128, 2992-2998.

Schams D, Schallenberger E, Meyer HH, Bullermann B, Breitingner H-J, Enzenhöfer G, Koll R, Kruij T.A.M., Walters D.L., Karg H (1985) Ovarian oxytocin during the estrous cycle in cattle. In 'Oxytocin - clinical and laboratory studies'. (Eds Amico J.A. and Robinson A.G.) pp. 317-334. (Elsevier Biochemical: Amsterdam)

Schams D, Berisha B, Neuvians T, Amselgruber W, Kraetzel WD. (2003) Real-time changes of the local vasoactive peptide systems (angiotensin, endothelin) in the bovine corpus luteum after induced luteal regression. *Mol.Reprod.Dev.* 65(1), 57-66.

Schams D, Berisha B (2002) Vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) family members in corpus luteum of farm animals. *Advances in Reproduction* VI.

## Reference List

- Schams D, Kosmann M, Berisha B, Amselgruber WM, Miyamoto A (2001) Stimulatory and synergistic effects of luteinising hormone and insulin like growth factor 1 on the secretion of vascular endothelial growth factor and progesterone of cultured bovine granulosa cells. *Exp.Clin.Endocrinol.Diabetes* 109, 155-162.
- Schams D, Amselgruber WM, Einspanier R, Sinowatz F, Gospodarowicz D (1994) Localization and tissue concentration of basic fibroblast growth factor in the bovine corpus luteum. *Endocrine* 2, 907-912.
- Schallenberger E, Schams D, Bullermann B, Walters DL (1984) Pulsatile secretion of gonadotrophins, ovarian steroids and ovarian oxytocin during prostaglandin-induced regression of the corpus luteum in the cow. *J of Reproduction and Fertility* 71, 493-501.
- Schorr K (1985) Prostaglandins, other eicosanoids and endothelial cells. *Basic Res.Cardiol.* 80, 502-514.
- Sedelnikova OA, Pilch DR, Redon C, Bonner WM (2003) Histone H2AX in DNA damage and repair. *Cancer Biol.Ther.* 2, 233-235.
- Senger DR, Perruzzi CA, Feder J, Dvorak HF (1986) A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. *Cancer Res.* 46, 5629-5632.
- Shapiro S.D., Kobayashi D.K., Pentland A.P., Welgus H.G. (1993) Induction of Macrophage Metalloproteinases by Extracellular Matrix. *The Journal of Biological Chemistry* 268 No. 11, 8170-8175.
- Shemesh M, Milaguir F, Ayalon N, Hansel W (1979) Steroidogenesis and prostaglandin synthesis by cultured bovine blastocysts. *J Reprod.Fertil.* 56, 181-185.
- Shi Y (2002a) A conserved tetrapeptide motif: potentiating apoptosis through IAP-binding. *Cell Death.Differ.* 9, 93-95.
- Shi Y (2002b) Mechanisms of caspase activation and inhibition during apoptosis. *Mol.Cell* 9, 459-470.
- Shikone T, Yamoto M, Kokawa K, Yamashita K, Nishimori K, Nakano R (1996) Apoptosis of human corpora lutea during cyclic luteal regression and early pregnancy. *J Clin.Endocrinol.Metab* 81, 2376-2380.
- Shimamura K, Sugino N, Yoshida Y, Nakamura Y, Ogino K, Kato H (1995) Changes in lipid peroxide and antioxidant enzyme activities in corpora lutea during pseudopregnancy in rats. *J Reprod.Fertil.* 105, 253-257.
- Shu HB, Takeuchi M, Goeddel DV (1996) The tumor necrosis factor receptor 2 signal transducers TRAF2 and c-IAP1 are components of the tumor necrosis factor receptor 1 signaling complex. *Proc.Natl.Acad.Sci U.S.A* 93, 13973-13978.
- Sitrin RG, Todd RF, Mizukami IF, Gross TJ, Shollenberger SB, Gyetko MR (1994) Cytokine-Specific Regulation of Urokinase Receptor (Cd87) Expression by U937 Mononuclear Phagocytes. *Blood* 84, 1268-1275.
- Skarzynski DJ, Bah MM, Deptula KM, Woclawek-Potocka I, Korzekwa A, Shibaya M, Pilawski W, Okuda K (2003) Roles of tumor necrosis factor-alpha of the estrous cycle in cattle: an in vivo study. *Biol.Reprod.* 69, 1907-1913.

## Reference List

- Skarzynski DJ, Miyamoto Y, Okuda K (2000) Production of prostaglandin f(2alpha) by cultured bovine endometrial cells in response to tumor necrosis factor alpha: cell type specificity and intracellular mechanisms. *Biol.Reprod.* 62, 1116-1120.
- Slee EA, Harte MT, Kluck RM, Wolf BB, Casiano CA, Newmeyer DD, Wang HG, Reed JC, Nicholson DW, Alnemri ES, Green DR, Martin SJ (1999) Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner. *J Cell Biol.* 144, 281-292.
- Smith GW, Goetz TL, Anthony RV, Smith MF (1994a) Molecular cloning of an ovine ovarian tissue inhibitor of metalloproteinases: ontogeny of messenger ribonucleic acid expression and in situ localization within preovulatory follicles and luteal tissue. *Endocrinology* 134, 344-352.
- Smith GW, Juengel JL, McIntush EW, Youngquist RS, Garverick HA, Smith MF (1996) Ontogenies of messenger RNA encoding tissue inhibitor of metalloproteinases 1 and 2 within bovine periovulatory follicles and luteal tissue. *Domest.Anim Endocrinol.* 13, 151-160.
- Smith MF, McIntush EW, Ricke WA, Kojima FN, Smith GW (1999) Regulation of ovarian extracellular matrix remodelling by metalloproteinases and their tissue inhibitors: effects on follicular development, ovulation and luteal function. *J Reprod Fertil.Suppl* 54, 367-381.
- Smith MF, McIntush EW, Smith GW (1994b) Mechanisms associated with corpus luteum development. *J.Anim Sci.* 72, 1857-1872.
- Somasundaram K (2000) Tumor suppressor p53: regulation and function. *Front Biosci.* 5, D424-D437.
- Song Z, Yao X, Wu M (2003) Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. *J Biol.Chem.* 278, 23130-23140.
- Srinivasula SM, Hegde R, Saleh A, Datta P, Shiozaki E, Chai J, Lee RA, Robbins PD, Fernandes-Alnemri T, Shi Y, Alnemri ES (2001) A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. *Nature* 410, 112-116.
- Standaert FE, Zamora CS, Chew BP (1991) Quantitative and qualitative changes in blood leukocytes in the porcine ovary. *Am.J.Reprod.Immunol.* 25, 163-168.
- Stanger BZ, Leder P, Lee TH, Kim E, Seed B (1995) RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death. *Cell* 81, 513-523.
- Stock AE, Fortune JE (1993) Ovarian follicular dominance in cattle: relationship between prolonged growth of the ovulatory follicle and endocrine parameters. *Endocrinology* 132, 1108-1114.
- Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI (1995) Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. *J Biol Chem.* 270, 5331-5338.
- Suarez-Huerta N, Mosselmans R, Dumont JE, Robaye B (2000) Actin depolymerization and polymerization are required during apoptosis in endothelial cells. *J Cell Physiol* 184, 239-245.
- Suda T, Takahashi T, Golstein P, Nagata S (1993) Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. *Cell* 75, 1169-1178.
- Sugino N, Nakamura Y, Okuno N, Ishimatu M, Teyama T, Kato H (1993) Effects of ovarian

- ischemia-reperfusion on luteal function in pregnant rats. *Biol.Reprod.* 49, 354-358.
- Sugino N, Shimamura K, Tamura H, Ono M, Nakamura Y, Ogino K, Kato H (1996) Progesterone inhibits superoxide radical production by mononuclear phagocytes in pseudopregnant rats. *Endocrinology* 137, 749-754.
- Sugino N, Suzuki T, Kashida S, Karube A, Takiguchi S, Kato H (2000) Expression of Bcl-2 and Bax in the human corpus luteum during the menstrual cycle and in early pregnancy: regulation by human chorionic gonadotropin. *J Clin.Endocrinol.Metab* 85, 4379-4386.
- Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN, Yancopoulos GD (1996) Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. *Cell* 87, 1171-1180.
- Suzuki K, Lees M, Newlands GF, Nagase H, Woolley DE (1995) Activation of precursors for matrix metalloproteinases 1 (interstitial collagenase) and 3 (stromelysin) by rat mast-cell proteinases I and II. *Biochem.J* 305 ( Pt 1), 301-306.
- Suzuki T, Higgins PJ, Crawford DR (2000) Control selection for RNA quantitation. *Biotechniques* 29, 332-337.
- Swartz JM, Bystrom J, Dyer KD, Nitto T, Wynn TA, Rosenberg HF (2004) Plasminogen activator inhibitor-2 (PAI-2) in eosinophilic leukocytes. *J.Leukoc.Biol.* 76, 812-819.
- Talhok RS, Bissell MJ, Werb Z (1992) Coordinated expression of extracellular matrix-degrading proteinases and their inhibitors regulates mammary epithelial function during involution. *J Cell Biol* 118, 1271-1282.
- Tanaka J, Acosta TJ, Berisha B, Tetsuka M, Matsui M, Kobayashi S, Schams D, Miyamoto A (2004) Relative changes in mRNA expression of angiopoietins and receptors tie in bovine corpus luteum during estrous cycle and prostaglandin F2alpha-induced luteolysis: a possible mechanism for the initiation of luteal regression. *J Reprod.Dev.* 50, 619-626.
- Taniguchi H, Yokomizo Y, Okuda K (2002) Fas-Fas ligand system mediates luteal cell death in bovine corpus luteum. *Biol.Reprod.* 66, 754-759.
- Teixeira MG, Austin KJ, Perry DJ, Dooley VD, Johnson GA, Francis BR, Hansen TR (1997) Bovine granulocyte chemotactic protein-2 is secreted by the endometrium in response to interferon-tau (IFN-tau). *Endocrine.* 6, 31-37.
- Thatcher WW, Staples CR, Danet-Desnoyers G, Oldick B, Schmitt E-P (1994) Embryo health and mortality in sheep and cattle. *J Anim Sci* 72 (Suppl), 16-30.
- Thellin O, Zorzi W, Lakaye B, De Borman B, Coumans B, Hennen G, Grisar T, Igout A, Heinen E (1999) Housekeeping genes as internal standards: use and limits. *J Biotechnol.* 75, 291-295.
- Thurston G, Rudge JS, Ioffe E, Zhou H, Ross L, Croll SD, Glazer N, Holash J, McDonald DM, Yancopoulos GD (2000) Angiopoietin-1 protects the adult vasculature against plasma leakage. *Nat.Med.* 6, 460-463.
- Tilly JL, Tilly KI, Kenton ML, Johnson AL (1995) Expression of members of the bcl-2 gene family in the immature rat ovary: equine chorionic gonadotropin-mediated inhibition of granulosa cell apoptosis is associated with decreased Bax and constitutive bcl-2 and bcl-xlong messenger ribonucleic acid levels. *Endocrinology* 136, 232-241.

## Reference List

- Towle TA, Tsang PC, Milvae RA, Newbury MK, McCracken JA (2002) Dynamic in vivo changes in tissue inhibitors of metalloproteinases 1 and 2, and matrix metalloproteinases 2 and 9, during prostaglandin F(2alpha)-induced luteolysis in sheep. *Biol.Reprod.* 66, 1515-1521.
- Townson DH, O'Connor CL, Pru JK (2002) Expression of monocyte chemoattractant protein-1 and distribution of immune cell populations in the bovine corpus luteum throughout the estrous cycle. *Biol.Reprod.* 66, 361-366.
- Townson DH, Warren JS, Flory CM, Naftalin DM, Keyes PL (1996) Expression of monocyte chemoattractant protein-1 in the corpus luteum of the rat. *Biol.Reprod.* 54, 513-520.
- Tran J, Rak J, Sheehan C, Saibil SD, LaCasse E, Korneluk RG, Kerbel RS (1999) Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. *Biochem.Biophys.Res.Commun.* 264, 781-788.
- Tsai SJ, Juengel JL, Wiltbank MC (1997) Hormonal regulation of monocyte chemoattractant protein-1 messenger ribonucleic acid expression in corpora lutea. *Endocrinology* 138, 4517-4520.
- Uberti D, Yavin E, Gil S, Ayasola KR, Goldfinger N, Rotter V (1999) Hydrogen peroxide induces nuclear translocation of p53 and apoptosis in cells of oligodendroglia origin. *Brain Res.Mol.Brain Res.* 65, 167-175.
- Unemori EN, Ferrara N, Bauer EA, Amento EP (1992) Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. *J.Cell Physiol* 153, 557-562.
- Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. *Genome Biol.* 3, RESEARCH0034.
- Vaskivuo TE, Ottander U, Oduwole O, Isomaa V, Vihko P, Olofsson JI, Tapanainen JS (2002) Role of apoptosis, apoptosis-related factors and 17beta-hydroxysteroid dehydrogenases in human corpus luteum regression. *Mol.Cell Endocrinol.* 194, 191-200.
- Vassalli JD, Wohlwend A, Belin D (1992) Urokinase-catalyzed plasminogen activation at the monocyte/macrophage cell surface: a localized and regulated proteolytic system. *Curr.Top.Microbiol.Immunol.* 181, 65-86.
- Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, Reid GE, Moritz RL, Simpson RJ, Vaux DL (2000) Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. *Cell* 102, 43-53.
- Visse R, Nagase H (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. *Circ.Res.* 92, 827-839.
- von Heijne G, Liljestrom P, Mikus P, Andersson H, Ny T (1991) The efficiency of the uncleaved secretion signal in the plasminogen activator inhibitor type 2 protein can be enhanced by point mutations that increase its hydrophobicity. *J.Biol.Chem.* 266, 15240-15243.
- Wajant H, Scheurich P (2001) Tumor necrosis factor receptor-associated factor (TRAF) 2 and its role in TNF signaling. *Int.J.Biochem.Cell Biol.* 33, 19-32.
- Wang L, Miura M, Bergeron L, Zhu H, Yuan J (1994) Ich-1, an Ice/ced-3-related gene, encodes both positive and negative regulators of programmed cell death. *Cell* 78, 739-750.
- Wang X (2001) The expanding role of mitochondria in apoptosis. *Genes Dev.* 15, 2922-2933.

- Wang Z, Juttermann R, Soloway PD (2000) TIMP-2 is required for efficient activation of proMMP-2 in vivo. *J Biol Chem.* 275, 26411-26415.
- Warrington JA, Nair A, Mahadevappa M, Tsyganskaya M (2000) Comparison of human adult and fetal expression and identification of 535 housekeeping/maintenance genes. *Physiol Genomics* 2, 143-147.
- Welgus HG, Campbell EJ, Cury JD, Eisen AZ, Senior RM, Wilhelm SM, Goldberg GI (1990) Neutral metalloproteinases produced by human mononuclear phagocytes. Enzyme profile, regulation, and expression during cellular development. *J.Clin.Invest* 86, 1496-1502.
- Wick M, Burger C, Brusselbach S, Lucibello FC, Muller R (1994) A novel member of human tissue inhibitor of metalloproteinases (TIMP) gene family is regulated during G1 progression, mitogenic stimulation, differentiation, and senescence. *J Biol Chem.* 269, 18953-18960.
- Wiltbank MC, Dysko RC, Gallagher KP, Keyes PL (1988) Relationship between blood flow and steroidogenesis in the rabbit corpus luteum. *J.Reprod.Fertil.* 84, 513-520.
- Winther H, Ahmed A, Dantzer V (1999) Immunohistochemical localization of vascular endothelial growth factor (VEGF) and its two specific receptors, Flt-1 and KDR, in the porcine placenta and non-pregnant uterus. *Placenta* 20, 35-43.
- Woessner JF, Jr. (2002) MMPs and TIMPs--an historical perspective. *Mol.Biotechnol.* 22, 33-49.
- Woods M, Mitchell JA, Wood EG, Barker S, Walcot NR, Rees GM, Warner TD (1999) Endothelin-1 is induced by cytokines in human vascular smooth muscle cells: evidence for intracellular endothelin-converting enzyme. *Mol.Pharmacol.* 55, 902-909.
- Wulff C, Wilson H, Dickson SE, Wiegand SJ, Fraser HM (2002) Hemochorial placentation in the primate: expression of vascular endothelial growth factor, angiopoietins, and their receptors throughout pregnancy. *Biol.Reprod.* 66, 802-812.
- Wulff C, Wilson H, Lague P, Duncan WC, Armstrong DG, Fraser HM (2000) Angiogenesis in the human corpus luteum: localization and changes in angiopoietins, tie-2, and vascular endothelial growth factor messenger ribonucleic acid. *J Clin.Endocrinol.Metab* 85, 4302-4309.
- Wuttke W, Pitzel L, Knoke I, Theiling K, Jarry H (1997) Immune-endocrine interactions affecting luteal function in pigs. *J Reprod.Fertil.Suppl* 52, 19-29.
- Xanthoudakis S, Nicholson DW (2000) Heat-shock proteins as death determinants. *Nat.Cell Biol.* 2, E163-E165.
- Xu Y, Rojkind M, Czaja MJ (1996) Regulation of monocyte chemoattractant protein 1 by cytokines and oxygen free radicals in rat hepatic fat-storing cells. *Gastroenterology* 110, 1870-1877.
- Yadav VK, Lakshmi G, Medhamurthy R (2005) Prostaglandin F<sub>2</sub>α-mediated activation of apoptotic signaling cascades in the corpus luteum during apoptosis: involvement of caspase-activated DNase. *J Biol.Chem.* 280, 10357-10367.
- Yadav VK, Sudhagar RR, Medhamurthy R (2002) Apoptosis during spontaneous and prostaglandin F<sub>2</sub>α-induced luteal regression in the buffalo cow (*Bubalus bubalis*): involvement of mitogen-activated protein kinases. *Biol.Reprod.* 67, 752-759.
- Yan Z, Hunter V, Weed J, Hutchison S, Lyles R, Terranova P (1993) Tumor necrosis factor-α alters steroidogenesis and stimulates proliferation of human ovarian granulosa cells in vitro.

---

*Fertil.Steril.* 59, 332-338.

Yeung MC, Lau AS (1998) Tumor suppressor p53 as a component of the tumor necrosis factor-induced, protein kinase PKR-mediated apoptotic pathway in human promonocytic U937 cells. *J.Biol.Chem.* 273, 25198-25202.

Young FM, Illingworth PJ, Fraser HM (1998) Ubiquitin and apoptosis in the corpus luteum of the marmoset monkey (*Callithrix jacchus*). *J Reprod.Fertil.* 114, 163-168.

Young KA, Hennebold JD, Stouffer RL (2002) Dynamic expression of mRNAs and proteins for matrix metalloproteinases and their tissue inhibitors in the primate corpus luteum during the menstrual cycle. *Mol.Hum.Reprod.* 8, 833-840.

Zhang B, Moses MA, Tsang PC (2003) Temporal and spatial expression of tissue inhibitors of metalloproteinases 1 and 2 (TIMP-1 and -2) in the bovine corpus luteum. *Reprod.Biol.Endocrinol.* 1, 85.

Zhang B, Yan L, Moses MA, Tsang PC (2002) Bovine membrane-type 1 matrix metalloproteinase: molecular cloning and expression in the corpus luteum. *Biol.Reprod.* 67, 99-106.

Zhang B, Yan L, Tsang PC, Moses MA (2005) Matrix metalloproteinase-2 (MMP-2) expression and regulation by tumor necrosis factor alpha (TNFalpha) in the bovine corpus luteum. *Mol.Reprod.Dev.* 70, 122-132.

Zhang L, Yu D, Hu M, Xiong S, Lang A, Ellis LM, Pollock RE (2000) Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. *Cancer Res.* 60, 3655-3661.

Zhang Y, McCluskey K, Fujii K, Wahl LM (1998) Differential regulation of monocyte matrix metalloproteinase and TIMP-1 production by TNF-alpha, granulocyte-macrophage CSF, and IL-1 beta through prostaglandin-dependent and -independent mechanisms. *J.Immunol.* 161, 3071-3076.

Zhao Y, Burbach JA, Roby KF, Terranova PF, Brannian JD (1998) Macrophages are the major source of tumor necrosis factor alpha in the porcine corpus luteum. *Biol.Reprod.* 59, 1385-1391.

Zheng J, Fricke PM, Reynolds LP, Redmer DA (1994) Evaluation of growth, cell proliferation, and cell death in bovine corpora lutea throughout the estrous cycle. *Biol.Reprod.* 51, 623-632.

Zhou M, Zhang Y, Ardans JA, Wahl LM (2003) Interferon-gamma differentially regulates monocyte matrix metalloproteinase-1 and -9 through tumor necrosis factor-alpha and caspase 8. *J.Biol.Chem.* 278, 45406-45413.

Zhou Z, Apte SS, Soininen R, Cao R, Baaklini GY, Rauser RW, Wang J, Cao Y, Tryggvason K (2000) Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. *Proc.Natl.Acad.Sci.U.S.A* 97, 4052-4057.

Zolti M, Meirom R, Shemesh M, Wollach D, Mashiach S, Shore L, Rafael ZB (1990) Granulosa cells as a source and target organ for tumor necrosis factor-alpha. *FEBS Lett.* 261, 253-255.

Zong WX (2004) Histone, H1.2: another housekeeping protein that kills. *Cancer Biol.Ther.* 3, 42-43.

## **10 Danksagung**

Herrn Prof. H.H.D. Meyer möchte ich für die Bereitstellung des Arbeitsplatzes und die hervorragenden Arbeitsbedingungen am Institut danken.

Herrn Prof. D. Schams und Dr. B. Berisha danke ich für die Überlassung des Themas und die immer offenen und freundlichen Diskussionen.

Dank gebührt auch Herrn Prof. F. Sinowatz für seine Bereitschaft, die Arbeit an der Tierärztlichen Fakultät der LMU München zu vertreten.

Mein besonderer Dank gilt Herrn Dr. W.-D. Kraetzel, Herrn Dr. H. Thenhuberg, Frau Ch. Fochtmann und Herrn M. Schmölz für Ihre stets konstruktiven Ratschläge, Mithilfe bei der Durchführung der Tierversuche, der Betreuung der Versuchstiere auf der Versuchstation Veitshof, sowie für die Gelegenheit zur Mitarbeit beim Embryotransfer.

Recht herzlich bedanken möchte ich mich auch bei Frau G. Schwentker und Frau M. Partsch für die Einarbeitung und Durchführung des Progesteron EIAs.

Außerdem möchte ich meinen Mit-Doktoranden Maria Kollmann, Vera Steinberg und Peter Reith für die Übernahme etlicher Blutentnahme Termine am Wochenende, Susanne Ulbrich für Ihre nie endende Geduld bei Fragen meinerseits, Harald Welter für die hervorragende Einarbeitung und allen anderen für die gute Zusammenarbeit, das nette Arbeitsklima und Diskussions- und Hilfsbereitschaft auf allen Ebenen danken.

Auch der Fa. Minitüb sei für die kostenlose Bereitstellung der Embryotransferkatheter gedankt.



---

## 11 Curriculum vitae

**Persönliche Daten** Heike Susanne Kliem  
geb. 12. Januar 1976 in Friedberg/Hessen  
ledig

### Schulbildung

9/82– 7/87 Grund- und Hauptschule Holzkirchen  
9/87 – 7/96 Gymnasium Bad Tölz

### Berufsausbildung

9/96 – 7/98 Ausbildung zur Bankkauffrau bei der Sparkasse Bad Tölz

### Studium der Veterinärmedizin

11/98 – 2/04 Ludwig-Maximilians-Universität München  
3/04 Approbation als Tierärztin

### Praktika

03/01 Tierärztliche Klinik Dres. Schmid, Borbe, Sauer, Steffen,  
Unterhaching  
08/02 Hygienekontrolle 3 Wochen, Veterinäramt München  
09/02 – 10/02 Schlachtier- und Fleischuntersuchung 3 Wochen, Schlachthof  
Lübeck  
02/03 04/03 Tierärztliche Klinik Dres. Erben, Fitz, und Partner, Gessertshausen  
04/03 – 06/03 Faculty of Veterinary Medicine, University of Pretoria,  
Onderstepoort, South Africa  
10/03 Überwachung und Untersuchung von Lebensmitteln 2 Wochen,  
Bay. Landesamt f. Gesundheit und Lebensmittelsicherheit,  
Oberschleißheim

### Berufstätigkeit

8/98 – 10/98 Sparkasse Bad Tölz  
seit 05/04 wissenschaftliche Mitarbeiterin / Doktorandin am Lehrstuhl für  
Physiologie der Technischen Universität München

## **12 Publications, Abstracts, Posters, Presentations**

### **Publications**

A.S.S. Abdoon, O.M. Kandil, B. Berisha, H. Kliem, D. Schams Morphology of dromedar camel oocytes and their ability to spontaneous and chemical parthenogenetic activation, *Reprod. Dom. Animal* (submitted)

H. Kliem, H. Welter, W.D. Kraetzl, H.H.D. Meyer, B. Berisha, D. Schams Expression of extracellular matrix degrading proteases and their inhibitors during oestrous cycle and induced luteolysis in the bovine CL (in progress)

### **Abstracts and Posters**

H. Kliem, W.D. Kraetzl, B. Berisha, D. Schams 2005 mRNA expression of apoptotic and anti-apoptotic factors during PGF<sub>2</sub> $\alpha$  induced luteolysis in the bovine corpus luteum, Poster presentation at the second qPCR symposium, Freising-Weihenstephan, 05. - 09. 2005

B. Berisha, R. Fürst, H. Kliem, H.H.D. Meyer, D. Schams 2005 Expression of mRNA of apoptotic and anti-apoptotic factors during oestrous cycle and pregnancy in the bovine corpus luteum, Poster presentation at the second qPCR symposium, Freising-Weihenstephan, 05. - 09. 2005

B. Berisha, H. Welter, H. Kliem, H.H.D. Meyer, D. Schams 2006 Changes in mRNA expression of angiopoitin and Tie receptors in bovine follicles before and after GnRH application and after ovulation, Abstract for the 39<sup>th</sup> annual conference of Physiology and Pathology of Reproduction and 31<sup>th</sup> mutual conference on veterinary and human reproductive medicine, Hannover, 16.-17.02.2006

H.H.D. Meyer, H. Kliem, D. Schams, B. Berisha 2006 Monitoring of gene expression (transcriptome) during reproduction via qRT-PCR mRNA expression of apoptotic and anti-apoptotic factors during induced luteolysis, Abstract for the 16<sup>th</sup> annual meeting of the Indian society for the study of reproduction and fertility (ISSRF), Karnal (Haryana), India, 23.-25.02.2006

D. Schams, H.Kliem, H. Welter, H.H.D. Meyer, B. Berisha 2006 Extracellular matrix degrading proteases and their inhibitors in corpus luteum during estrous cycle and induced luteolysis in cow, Abstract for the 39<sup>th</sup> annual meeting of the Society for the Study

### **Publications, Abstracts, Posters, Presentations**

of Reproduction, Omaha, USA, 29.07. – 01.08.2006 (accepted)

A.S.S. Abdoon, H. Kliem, O.M. Kandil, D. Schams, B. Berisha 2006 Expression of steroid receptors in corpus luteum and endometrium during different stages of pregnancy in dromedary camel, Abstract for the 10<sup>th</sup> annual conference of the European Society for Domestic Animals Reproduction, Portoroz-Lipiza, Slovenia, 07. - 09.09.2006 (accepted)

D. Schams, H. Kliem, W.D. Kraetzl, B. Berisha 2006 Expression of extracellular matrix degrading proteases and their inhibitors in the corpus luteum during induced luteolysis in cow, Abstract for the 10<sup>th</sup> annual conference of the European Society for Domestic Animals Reproduction, Portoroz-Lipiza, Slovenia, 07. - 09.09.2006 (accepted)

### **Presentations**

Expression of extracellular matrix proteases in the bovine CL during induced luteolysis, Montagsseminar 02/2005, Lehrstuhl für Physiologie, Technische Universität München

Expression of apoptotic and anti-apoptotic factors in the bovine CL during induced luteolysis, Montagsseminar 12/2005, , Technische Universität München

### **Gene sequence**

H. Kliem, H Welter, D. Schams and B. Berisha (2005) Bos taurus partial mRNA for second mitochondrial derived activator of caspases (SMAC gene), acc. no. of the EMBL database: AJ867847